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Abstract
Homo and heterodimerization of G-protein coupled receptors (GPCRs) is a 
concept which has gained credibility as another mechanism by which GPCR 
signalling can increase in complexity.
The generation of Flag and c-myc N-terminally tagged forms of the human 80R, 
with and without GFP fused to the C-terminus, has allowed identification of each 
receptor form after transient transfection in HEK293 cells. Stable cell lines 
expressing Flag-ôOR or Flag-ÔOR-GFP were generated in HEK293cells. High 
affinity [^H]antagonist binding and agonist stimulated inhibition of adenylyl 
cyclase activity was observed. Agonist stimulated internalization of Flag-ôOR- 
GFP was followed in live cells with a t% of < 10min.
Constitutively formed (mouse) ÔOR homodimers were identified using co- 
immunprecipitation techniques (Cvejic and Devi 1997). The human ÔOR is 
demonstrated here to also form constitutive homodimers using co~ 
immunoprécipitation techniques. Constitutive heterodimerization of human ôOR 
with the pOR, IP prostanoid receptor, IP prostaniod receptor-GFP, PiAR-GFP 
and P2AR-GFP was also observed. Further investigations of the lysis procedures 
and antibodies used for immunoprécipitation indicated that the heterodimers 
were not a reflection of the experimental conditions used.
Fluorescently labelled antibodies were used to specifically label N-terminally 
tagged GPCRs expressed at the cell-surface. The spectral overlap property of 
the fluorescent labels chosen allowed fluorescence resonance energy transfer 
(FRET) to be used to determine homo and heterodimerization of antibody-bound 
GPCRs. The fluorescent donor molecule, Europium, also has the property of 
long-lived fluorescence after excitation. Thus allowing the FRET to be time- 
resolved (TR-FRET) increasing the sensitivity of the developed assay.
Constitutively formed cell-surface 50R homodimers were identified using TR- 
FRET. The presence of agonist was unable to modulate this interaction.
Heterodimerization between the ôOR and P2AR-GFP, which had been observed 
using co-immunoprecipitation techniques, was not evident using the cell-surface 
TR-FRET in intact cells. The presence of agonist for each receptor within the 
dimer or the presence of both agonists together did not generate any 
heterodimerization between the ôOR and P2AR-GFP receptors. No significant 
level of heterodimers between the ôOR and pOR was observed using TR-FRET.
Optimisation of the TR-FRET assay has allowed the assay to be performed in a 
homogeneous format although this is less sensitive than the heterogeneous 
assay described.
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CHAPTER 1
INTRODUCTION
CHAPTER 1 INTRODUCTION
1.1 Opioid receptors -  a brief history
For centuries the pain relieving properties of the opium poppy Papaver 
somniferum  have been recognised. The alkaloid drug morphine and its closely 
related analogue etorphine have been shown to be responsible for the pain 
relief. These drugs were shown to also have the undesirable qualities of 
dependency and tolerance which result from their repeated use. This led to the 
development of new drugs, which it was hoped would have the desired pain 
relief qualities without any undesirable properties. One drug that was discovered 
during this search was heroin, a diacetylated form of morphine that was 
originally thought to be a safer form of morphine. The most potent drug of pain 
relief to date remains to be morphine and despite its undesirable properties, it is 
still in much use today. Morphine and other alkaloid drugs activate opioid 
receptors. These are important in the regulation of anaesthesia and analgesia 
and therefore have been widely studied. Investigation of the mechanisms of 
tolerance and dependency has especially been studied with a view to developing 
new drugs that do not have these qualities. Tolerance to morphine is thought to 
arise, in part, from desensitization of these receptors.
Opioid receptors have been identified in the central nervous system (CNS) 
where they inhibit the release of neurotransmitters from dorsal root ganglion 
projections in the dorsal horn of the spinal cord and also in the peripheral 
nervous system (PNS). The proposal of opioid receptor sub-types resulted from 
differential pharmacology observed in the guinea pig ileum assay when 
compared to that of the mouse vas deferens. Subsequently, this variation in 
pharmacology was attributed to there being a higher density of ô-opioid 
receptors in the mouse vas deferens and the guinea pig ileum having a higher 
density of the p.-opioid receptor (Quock et al., 1999). Opioid receptor density in 
different brain regions varies widely (Quock et al., 1999) However, all three 
opioid receptor subtypes have been shown to be present in some neurones (Ji 
et al., 1995). Knock-out mice with the absence of a single opioid receptor
subtype are fertile with no marked anatomical deficit indicating that full activity of 
the endogenous opioid system is not critical for development (Kieffer, 1999). 
Opioids are involved in diverse biological phenomena including gut motility and 
the immune response which results from interaction with endocrine and immune 
systems. The adverse effects of opiates include respiratory depression, 
decreased gastro-intestinal motility and sedation.
Opiate binding sites were found in the mammalian brain in 1973 (Pert and 
Snyder 1973; Simon et al., 1973) and the naturally occurring opiate peptide 
ligands identified as enkephalins, dynorphins and endorphins by Bradbury et al. 
(1976), Cox et al. (1976), Goldstein et al. (1981), Hughes et al. (1975) and 
Pasternak et al. (1976). They were found to be derived from the larger pre­
cursors, proenkephalin A (Noda et al., 1982), prodynorphin (Kakidani et al., 
1982), and opiomelanocortin (Nakanishi et al., 1979). Pharmacological studies 
using different ligands demonstrated the presence of three opioid receptor 
subtypes named after their respective agonists jiiOR (for morphine), kOR (for 
ketacyclazone) and ôOR (for [d]Ala^, [d]Leu®, enkephalin (DADLE)) (Chang and 
Cuatrecasas 1979; Lord et al., 1977). cDNAs encoding the p.OR, ôOR and kOR 
were isolated by Chen et al. (1993), Evans et al. (1992), Kieffer et al. (1992) 
and Yasuda et al. (1993). The availability of the cDNA for these receptors has 
allowed their study in vitro and has resulted in the identification of sub-type 
selective agonists, antagonists and inverse agonists. There is another receptor, 
ORL-1, which has been suggested to be another member of the opioid receptor 
family. However this receptor has its own specific ligand and does not exhibit 
significant binding of many opioid ligands identified to date. The ORL-1 receptor 
does have significant sequence similarities with the cloned opioid receptors and 
is reviewed along with them by Henderson and McKnight (1997).
1.2 G-protein coupled receptors
The opioid receptors have been classified as belonging to the large and varied 
family of G-protein coupled receptors (GPCRs) which, as for all cell-surface 
receptors, recognize specific extracellular signals, resulting in activation of 
intracellular effector molecules to generate an intracellular signal to elicit an
appropriate cellular response (Ji et al., 1998). GPCRs are the largest family of 
cell-surface receptors. They vary widely in their function and are involved in the 
control of many cellular processes including neurotransmission, cellular 
metabolism, secretion, cell differentiation and growth. A huge variety of ligands 
exist for these receptors, examples of which include, light, odorants, peptides 
and large glycoproteins. The importance of correct GPCR signalling is 
demonstrated in the many disease states that have been shown to result from a 
malfunctioning of their signalling. For example, mutant V2 vasopressin receptors 
cause X-linked nephrogenic diabetes insipidus. Other disease states resulting 
from defective GPCR signalling include cancer, diabetes and some neural 
disorders. Mutant receptors as well as naturally occurring polymorphic 
variations of receptors have been identified which either bind ligands incorrectly, 
are poorly trafficked to the cell surface, constitutively generate signals or are 
unable to signal. Some mutants, however, are beneficial. For example, a 
mutation in the chemokine receptor CCR5, which acts as a co-receptor for 
human immunodeficiency virus (FIIV), prevents binding of HIV to the target cells 
thus limiting viral infection for those who are homozygous for this mutation (Liu 
et al., 1996).
The GPCR family is the single largest known gene family in the human genome 
and greater than 1% of the genes of the human genome have been shown to 
code for GPCRs. Because of this the Human Genome Sequencing programme 
(HGS) has generated a huge interest in these receptors as the database 
contains many sequences that are thought to code for seven transmembrane 
receptors with unknown function. The pharmaceutical industry are therefore 
looking at the necessary techniques that would allow these receptors to be 
studied, identifying appropriate ligands and subsequently their function. There is 
a huge potential for new therapeutic drugs for these receptors as discussed by 
Stadel et al. (1997).
1.2.1 GPCR structural features
The first GPCRs to be purified and characterized were rhodopsin (Nathans and 
Hogness, 1983) and the P2AR (Dixon et al., 1986), since then a huge number of
GPCRs have been identified and many more predicted. GPCRs all have a 
similar structure consisting of an extracellular N-terminus with seven 
transmembrane domains that are linked by extracellular and intracellular loops 
and an intracellular C-terminal domain, see figure 1.1.
1.2.1.1 Extracellular N-terminus
The extracellular N-terminal domain varies in length from 7-595 amino acids (Ji 
et al., 1998) for different GPCRs. it is involved in the binding of large polypeptide 
ligands e.g. glucagon and glycoprotein hormones e.g. luteinizing hormone. The 
large extracellular N-terminus of family 3 GPCRs is involved in ligand binding 
and may also be involved in the dimerization of these receptors which is 
described in section 1.6.5. The N-terminal domain contains consensus 
sequences (Asp-X-Ser/Thr, where X is any amino acid except proline or 
aspartate) for N-linked glycosylation which is necessary to ensure correct 
trafficking of the GPCR to the plasma membrane.
1.2.1.2 Seven membrane spanning regions
GPCRs traverse the membrane seven times and are sometimes referred to as 
seven transmembrane (TM) receptors. The transmembrane regions are a  helical 
in structure, although the a helices can extend outside the membrane. The 
residues within the transmembrane domains are generally hydrophobic, typically 
consisting of 20-27 amino acids that are entropically driven into the membrane. 
The transmembrane domains are numbered 1 to 7 and they are arranged in a 
counter-clockwise direction within the membrane when viewed from the 
extracellular surface. In general, transmembrane domains 1, 4 and 7 are more 
hydrophobic than 2, 3, 5 and 6. Proline residues are frequently found in the 
transmembrane domains, resulting in a kink in the helix backbone by 26°. The 
angle of the a  helices influences how they interact with each other and with 
ligand molecules (Ji et al., 1998). Residues within the transmembrane domains 
are involved in ligand binding and receptor activation. The transmembrane 
domains form a rigid yet dynamic structure, which allows conformational 
changes to occur on ligand binding.
1.2.1.3 Ligand binding domains
There are 3 major families of GPCRs in mammals, the rhodopsin like (family 1), 
which is the largest and most studied family, the calcitonin like (family 2) and the 
metabotropic glutamate receptor (mGluR) like (family 3). These divisions are 
based on where ligands physically interact with the GPCR (Gether and Kobilka, 
1998). The rhodopsin-like family is further divided into subfamilies. These are the 
1a sub family which is activated by small molecular weight ligands e.g. 
catecholamines, that bind in a cavity formed by TM helices 3 to 6. The 1b 
subfamily which is activated by small peptides, including cytokine ligands and 
other peptides by interacting with the extracellular loops and N-terminal domain. 
The C-terminus of these peptides has been proposed to interact with the cavity 
within the transmembrane helices in a manner similar to that of the subfamily la . 
The 1c sub family are activated by glycoprotein hormones e.g. thyrotroph in 
stimulating hormone (TSH) which bind to the N-terminal region. Family 2 GPCRs 
include the calcitonin receptor that have ligand binding regions similar to that of 
type 1c although there is no sequence similarity between these and type 1c 
GPCRs. Family 3 GPCRs include the GABAb and glutamate receptors where the 
neurotransmitter ligands bind to the large extracellular N-terminal region 
(Bockaert and Pin, 1999).
Ligand interaction with receptors involves hydrogen bonds, ion pairs and 
hydrophobic contacts (Ji et al., 1998). Ligands have two main properties; affinity 
and efficacy. Affinity describes how well a drug binds to the receptor and efficacy 
describes the level of effect resulting from the ligand binding. Ligands range from 
agonists, which demonstrate positive efficacy, antagonists or neutral ligands, 
which demonstrate no efficacy and inverse agonists, which demonstrate a 
negative effect on efficacy. Ligands can demonstrate high affinity for a GPCR 
and have a neutral efficacy.
Ligand binding and receptor activation can be separated into two distinct 
mechanisms although these are difficult to separate. In the absence of ligand 
GPCRs are maintained in a certain conformation that changes upon ligand
binding. A high resolution structure of the bovine rhodopsin receptor was 
obtained recently by Palczewski et al. (2000) demonstrating the highly ordered 
structure of inactive receptor and the conformational changes on ligand 
activation. These conformational constraints are important in maintaining 
inactivity as a mutant P2AR which demonstrates constitutive activity in the 
absence of any ligand was more unstable and demonstrated enhanced 
conformational flexibility than the wild-type receptor (Gether et al., 1997).
Ligand binding of biogenic amines has been studied in great detail, 
demonstrating the involvement of several key residues in TMs 3, 5 and 7 and the 
side chains of these residues in determining the specificity of agonist binding. 
The amine of the ligand pairs with an aspartate residue in TM 3 and the catechol 
ring interacts with residues in TM’s 5 and 6. The interaction with TM 3 has been 
shown to be important for ligand binding, with residues in TM’s 5 and 6 being 
important for receptor activation (Ji et al., 1998). Ligand activation has been 
demonstrated to involve a change in conformation in the TMs resulting in a 
change in orientation of TM 3 to TM 7 as was shown by Barrens et al. (1996), for 
the rhodopsin receptor and by Javitch et al. (1997), for the P2AR receptor. This 
was confirmed recently by Ghanouni et al. (2001), for the P2AR using fluorescent 
labelling of the receptor.
1.2.1.4 Conserved DRY (aspartate, arginine, tyrosine) sequence
There is a highly conserved DRY sequence in all family 1 GPCRs at the 
interface of TM 3 and intracellular loop 2 which is important for receptor 
activation. These residues are not conserved in other GPCR famiiies. The 
conserved arginine has been hypothesised to be constrained in a hydrophilic 
pocket formed by conserved polar residues in TMs 1, 2 and 7. Receptor 
activation results in the protonation of the aspartate causing arginine to shift out 
of the polar pocket leading to cytoplasmic exposure of previously hidden 
sequences in the second and third intracellular loops. This has been indicated by 
computational studies and the generation of constitutively activated mutants by
mutation of the aspartate in the aib adrenergic receptor by Scheer et al. (1996) 
and the pgAR by Wess (1997).
1.2.1.5 Extracellular loops
The extracellular loops vary in size although not to the same extent as the N- 
terminal region or the intracellular loops. They can be involved in ligand binding 
e.g. of peptide ligands to opioid receptors. The majority of famiiy 1 receptors 
have two conserved cysteine residues in extracellular loops 1 and 2 that are 
thought to form a di-sulphide bond believed to be involved in maintaining the 
tertiary structure of the GPCR for ligand binding. There is some evidence that for 
opioid receptors this di-sulphide bond is broken upon ligand binding (Brandt et 
al., 1999).
1.2.1.6 Intracellular loops and intracellular C-terminal region
The intracellular loops of GPCRs vary in length from receptor to receptor, the 
largest variation being demonstrated by the third intracellular loop. Residues of 
the second and third intracellular loops have been shown by several groups to 
be involved in G-protein coupling especially the end of the intracellular loop 
near TM 6 (Bohm et al., 1997; Georgoussi et al., 1997; Merkouris et al., 1996). 
Sequences in the C-terminus are also involved in G-protein signalling. 
Phosphorylation sequences for G-protein coupled receptor kinases (GRKs) and 
second messenger activated kinases exist in both the third intracellular loop and 
the C-terminus. Receptor phosphorylation of the receptor occurs following 
activation by agonist and can result in receptor desensitization and 
internalization. This will be further described in section 1.4.5.
Palmitoylation is the reversible thioesterification by a palmitate group of one or 
more cysteine residues in the C-terminus. This results in the formation of a 
fourth intracellular loop. This has been shown for many GPCRs e.g. the PaAR 
receptor (Ng et al., 1994). Palmitoylation occurs post-translationally and can 
affect both the ligand binding and G-protein interaction of GPCRs.
Figure 1.1 Structure of a typical class 1 G-proteIn 
coupled receptor
Extracellular loops
Glycosylation/
COOH
Intracellular loops
1.3 Opioid receptor signalling
The opioid receptors are all predominantly linked to pertussis sensitive Gai/Gao 
G-proteins and thus their activation results in the inhibition of adenylyl cyclase 
leading to a decrease in intracellular cAMP. Other effectors include Ca^^ and 
channels. The ôOR has been shown to activate p42 and p44 mitogen-activated 
protein kinases on receptor activation (Burt et al., 1996). This activation has also 
been demonstrated for each of the opioid receptors (Fukuda et al., 1996). The 
structural features of the opioid receptors have been studied and shown to be 
consistent with GPCRs belonging to family 1. The ligand binding domains
Involve residues in the extracellular loops as well as the transmembrane
domains. The three extracellular and intracellular loops vary in size between the 
pOR, kOR and ÔOR as does the intracellular C-termlnus, which contains both 
palmitoylation and phosphorylation sites. (Guo et al., 2000; Wang et al., 1998; 
Kramer et al., 2000).
1.3.1 Opiold receptor sequence
The sequence of the human 6 0 R is shown in figure 1.2.. 65-70% homology
exists between the 3 opioid receptor types. The regions of highest similarity are 
those of the transmembrane regions and the intracellular loops and a small 
portion of the C-terminal tail near TM 7 domain. The regions with the most 
divergent residues are the second and third extracellular loops as well as the N- 
and C-terminal tails. Georgoussi et al. (1997) and Merkouris et al. (1996) 
identified at least two sites in the third intracellular loop and part of the carboxy 
terminal tail of the 6 0 R as being important for G-protein coupling. 6 0 R has been 
shown to activate different G-protein sub-sets in the presence of alkaloid 
compared to peptide opioid agonists (Allouche et al., 1999). This may be the 
result of different receptor conformations causing the activation of different sub­
families of G-proteins.
Figure 1.2 figure of human 50R
A R A S
E
L O F  a 
F A«'
F P S  A
M
E
P V P 
L L A
N
0  8  A
CAN
ASCS# W .C 'P  
■
A 8  S L A
I
G
IV
R
SP *
E T  H
I
I  
N 
T 
A
K t K T
i
Y I
AV
C H
V C HV
A
G
D
R
FQ
T
V 
A 
M
L 0
P V K A L
i
A 
P 
T 
R
D F
T ^  V D I  N R
W R
V D
%: A A ,W
p
G R D L F 0 «
L L B
M S
L R
L [] F B H c 1. ■
R K C
L E a  B 0  c  ■  A
R K 5
S V R L L S G 5 B B p  B ■ L
#
1 A » # # #
T
0  S #l  T B A 
G
F 0  0  0  A  *
Figure was reproduced from the web site XXXX (www.gpcr.or»/7tm/seq/). the 
white residues are those that are hyperlinked to a mutant database from that 
site.
Copyright F. Campagne (1), J.M. Bernassau (2), B. Maigret (1)
(1 ) Laboratoire de Chimie Théorique de Nancy
U.A. CNRS 510
B.P. 239 - 54506 Vandoeuvre-les-Nancy CEDEX 
France
(2) Sanofi Recherche
371, Rue du Pr. Blayac 
34184 Montpellier CEDEX 4 
France
10
1.3.2 Ligand binding of opioid receptors
The availability and use of many opioid ligands has led to proposals of several
further receptor sub-types although no cDNAs encoding these extra sub-types 
have been identified. Several splice variants of jnORs have been identified (Pan 
et al., 1999). A splice-variant of pOR, the M O RIb isoform has been identified. 
This differs by an 8 amino-acid deletion at the C-terminus, however, this does 
not alter the basic pharmacology of the receptor (Zimprich et al., 1995).
Investigations into ligand binding and the cloning of the opioid receptors has 
resulted in the isolation of several potent and selective opioid ligands which have 
been used to further study the pharmacology of these receptors. The use of 
chimeric receptors where regions of one receptor sub-type was replaced with 
that from another sub-type (Meng et al., 1995; Metzger and Ferguson 1995) and 
point mutations of the receptors has identified the ligand binding regions of the 
opioid receptors (Meng et al., 2000; Befort et al., 1996; Pepin et al., 1997).
Ligand binding to each opioid receptor has also been performed by computer 
modelling (Pogozheva et al., 1998). The many studies on opioid receptor ligand 
binding and receptor activation have been reviewed (Law et al., 1999; Jordan et 
al., 2000). A summary of the findings are described here.
Investigations into the ligand binding domains of the opioid receptors led to the 
conclusion that opiate ligands are bivalent molecules where one part is 
responsible for signal transduction and the other responsible for selectivity of the 
ligand (Meng et al., 1995). The extracellular loops act to sterically inhibit binding 
of some drugs to confer selectivity (Metzger and Ferguson, 1995). Their work 
also showed that pOR selective ligands bound to a ÔOR where the sixth 
transmembrane domain and the third extracellular loop were replaced with that 
from the p,OR. kOR and 50R chimeras demonstrated the importance of the TM 
domains 5-7 in ôOR selectivity. Point mutations have been used to determine the 
critical residues for agonist and antagonist binding. Aromatic residues in the 
transmembrane domains at positions 129 and 308 (Befort et al., 1996), as well 
as residues at positions 284, 296, 297 (Valiquette et al., 1996) and 95 (Kong et
11
al., 1993) are necessary for binding of ÔOR selective ligands. To identify 
residues involved in receptor activation has been more difficult, however for high 
affinity binding the common feature is a protonated nitrogen. This suggests the 
ligand binding pocket of opioid receptors is similar to that of the biogenic amines 
described in section 1.2.1.3. where an aspartate or glutamate has to be present 
within the receptor as a counter-ion for the ligand. Claude et al. (1996) mutated a 
serine residue at position 177 and antagonist molecules now acted as full 
agonists. Befort et al. (1999) generated a constitutively active mutant of ÔOR via 
point mutations in transmembrane 3 and 7 demonstrating the importance of key 
residues in receptor activation. Meng et al. (2 0 0 0 ) used point mutations of the 
6 0 R to identify residues in transmembrane domains that, when altered to the 
residues found in the ORL-1 receptor (Lys214 Ala (TM5), lle-277 -> Val ; 
His278 -^Gln ; He279 Val (TM6 ), He304 Thr (TM7)) demonstrated altered 
activation properties. These residues are thus involved in both ligand recognition 
and activation of the receptor.
Many GPCRs have been shown to have a di-sulphide bridge between cysteine 
residues in the 1®^ and 2 "^ extracellular loops, which is important in maintaining 
the correct receptor structure for ligand binding. This was also found to be true 
for opioid receptors as pre-treatment of membranes with the reducing agent 
dithiothreitol (DTT) prevented [^H]diprenorphine binding leading to the 
conclusion that dl-sulphide bonds are important for ligand binding to opioid 
receptors (Kamikubo, 1988). A study using point mutations of the 6 
transmembrane cysteines of the 6 0 R noted that these did not affect agonist or 
antagonist binding. However, mutagenesis of any of the two external cysteines 
abolished any agonist or antagonist binding (Ehrlich et al., 1998). DTT has been 
shown by Gioannini et al. (1989) to result in a decrease in receptor affinity for 
ligands without affecting receptor number.
1.4 GPGR signalling
Upon receptor activation by a corresponding ligand, a conformational change 
occurs within the receptor, facilitating its interaction with its G-protein. G-proteins 
are heterotrimeric proteins consisting of a, p and y subunits. The p and y sub
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units are tightly associated and act as a dimer. In the absence of agonist, 
heterotrimeric G-proteins normally exist in an inactive, trimeric form consisting of 
the a, p and y subunits. Receptor activation results in a decrease in the affinity of 
the Ga subunit for its bound GDP, which then dissociates and is replaced with 
GTP. Once GTP is bound, the a  subunit assumes its activated conformation and 
dissociates from both the receptor and the Py dimer. The py dimer promotes the 
association of the Ga subunit for its receptor possibly via isoprenylation of the Gy 
subunit at its carboxy terminus, localising the Gpy dimer to the plasma 
membrane (Higashijima et al., 1987). Both the Ga subunit and the Py dimer have 
been shown to regulate the activity of effector molecules (Rosomer et al., 1996; 
Zhu et al., 1996). The fate of the a subunit of the heterotrimeric G-protein after 
activation is a matter of debate. One model shows that the a subunit can be de- 
palmitoylated upon activation and then released into the cytoplasm. Another 
possibility is that the a  subunits cluster in sub-domains of the plasma membrane 
and are not released (Huang et al., 1999).
The Ga hydrolyses the GTP to GDP via its intrinsic GTPase activity and the aPy 
trimer reforms. This GTPase activity is of great importance as It acts as a rate- 
limiting turn-off switch for signalling (Hamm, 1998). The GTPase activities of G 
proteins can vary enormously (Vaughan, 1998). The efficiency of the receptor G- 
p rote in interaction depends on the absolute number and density of each within 
the membrane. To overcome the problem of varying stoichiometry GPCR-Ga 
fusions have been produced to study receptor activation as demonstrated for the 
ÔOR by Moon et al. (2001). The use of GPCR-Ga fusion proteins has been 
reviewed by Seifert et al. (1999).
Molecular cloning has identified many types of each G-protein subunit. These 
include 2 0  Ga subunits, 6  Gp subunits and 12  Gy subunits (Hamm, 1998), which 
can then generate a large number of possible heterotrimer combinations, 
although there are preferred combinations of these subunits which generates a 
more limited number of physiologically relevant G-proteins (Hamm and Gilchrist, 
1996).
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1.4.1 G-protein sub-groups
The G-protein to which each receptor preferentially couples, confers the second 
messenger response which occurs upon agonist stimulation. G-proteins are 
named according to their a-subunits, which are divided into four sub families that 
regulate distinct effectors. Gas activates adenylyl cyclase whereas Gai inhibits 
adenylyl cyclase. Gaq activates phospholipase C-p and G a l 2 /G al 3 are 
involved in stimulation of NaVH^ pumps, and have been shown to be involved in 
Rho mediated cytoskeletal effects (Offermanns et al., 1997). Each class of G- 
protein undergoes post-translational modifications e.g. myristoylation or 
palmitoylation. Palmitoylation is reversible, suggesting that the level of 
palmitoylation leads to variations in Ga membrane affinity and modulation of 
signalling. Palmitoylation, myristoylation and association with the Py subunits all 
contribute to membrane attachment. Receptor cross talk can be shown to be 
linked to Gpy exchange (Quitterer and Lohse, 1999) in some cases as activation 
of Gai-coupled receptors often leads to enhancement of inositol phosphate 
signalling triggered by Gaq receptors.
Two bacterial toxins, namely cholera and pertussis toxins, activate and inactivate 
certain G-proteins respectively by catalysing ADP-ribosylation of key amino 
acids. Cholera toxin catalyses the ADP-ribosylation of an arginine residue that is 
a key contributor to the GTPase activity of the Gas subunit of the G-protein. 
ADP-ribosylation by cholera toxin results in a continually active G-protein as the 
bound GTP is unable to be hydrolysed. Pertussis toxin ADP-ribosylates a 
cysteine residue which is four residues from the C-terminus of the Gai- sub­
family of G-proteins disrupting receptor-G-protein interaction. The effect of these 
toxins has been used to delineate the inhibition of adenylyl cyclase via Gai from 
its stimulation via Gas for the a2A adrenergic receptor (Milligan et al., 1991). 
These and other methods e.g. co-immunopreclpltation, have been developed to 
identify the G-protein involved in each receptor interaction.
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1.4.2 Desensitization, down-regulation and sequestration
Desensitization is the loss of responsiveness of GPCRs to an external stimulus 
after repeated or continuous stimulation. This involves many cellular proteins 
and the processes involved have been elucidated for several GPCRs e.g. P2AR 
(Zhang et al., 1996), vasopressin V2  receptor (Oakley et al., 1999) and the 
dopamine D2 receptor (Vickery and Von Zastrow, 1999). Desensitization is a 
multi-step process, first involving uncoupling of the receptor from the G-protein, 
causing the receptor function to be inhibited. Sequestration of the receptor into 
an intracellular compartment then occurs followed by possible down-regulation, if 
the stimulation is chronically present. Down-regulation involves a loss in receptor 
number due to degradation of the receptor protein and reduction of steady-state 
mRNA. Desensitization has been categorized as homologous (agonist-specific) 
or heterologous (agonist non-specific).
Homologous desensitization results from agonist activation of a specific receptor 
by G-protein receptor kinases (GRKs). Heterologous desensitization results from 
phosphorylation of receptors within a cell irrespective of the receptor being 
stimulated. In this case, receptor phosphorylation results from interaction with 
second messenger kinases e.g. protein kinase A and protein kinase 0  (Mullaney 
et al., 1995). Phosphorylation occurs on serine and threonine residues of the 
third intracellular loop and the C-terminal tail of GPCRs. The mammalian 
gonadotrophin-releasing hormone receptor lacks a C-termlnal tail and is 
resistant to agonist-dependent phosphorylation and consequent desensitization 
(Willars et al.. 1999).
1.4.3 Internalization
Soluble proteins called arrestins Interact with receptors immediately after 
phosphorylation by GRKs, as phosphorylation increases the affinity of the 
receptor for the arrestin molecule. This interaction has been shown for several 
different receptor types with a wide diversity of agonists and classes of G- 
proteins. It is apparent that arrestin binding terminates signalling by halting 
receptor interaction with G-proteins (Barak et al., 1997; Law et al., 2000). P-
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arrestin has been shown to function as an adapter protein that specifically 
targets GPCRs for dynamin-dependent endocytosis via clathrin-coated vesicles. 
(Zhang et al., 1996; Barak et al., 1997). The internalization process involves 
clathrin coated pits (Michaely et al., 1999) and the soluble protein dynamin which 
has GTPase activity and co-localises with clathrin. Dynamin contributes to the 
early stages of endocytosis by catalysing a GTP-dependent pinching off of 
endocytic vesicles from the plasma membrane. Other internalization 
mechanisms have been suggested e.g. the caveoIae-mediated pathway or a 
novel non-clathrin-coated vesicle pathway as the clathrin coated pit mechanism 
is not the mechanism used by all receptors (Zhang et al., 1996). The D1 
(postsynaptic) and D2 (presynaptic) dopamine GPCRs have been shown to 
internalize via distinct mechanisms which are dynamin dependent and 
independent and result in the receptors being delivered to different endocytotic 
vesicles (Vickery and von Zastrow, 1999).
1.4.4 Down-regulation
Down-regulation usually occurs after long term agonist exposure (Barritt and 
Gregory, 1997) where internalized receptors can be de-phosphorylated and re­
cycle back to the membrane or transported to lysosomes and degraded leading 
to a loss in receptor number. Signal attenuation mechanisms also include 
removal of the agonist from the extracellular fluid via dilution, uptake by 
transporters or enzymatic degradation (Bohm et ai., 1997). Downregulation may 
also result from reduced gene transcription and reduced de novo receptor 
synthesis (Li et al., 2000). For the P2AR it has been shown that internalization is 
not essential for down-regulation to occur (Jockers et al., 1999).
1.4.5 Desensitization, internalization and phosphorylation of opioid 
receptors
The mechanisms of desensitization, internalization via clathrin-coated pits and 
down-regulation have all been described for opioid receptors as a result of 
several studies aimed at understanding tolerance and dependency of opiates. 
Key findings are discussed by Jordan et al. (2000) and Whistler et al. (1999). A
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summary of the main features involved for ôOR desensitization, sequestration 
and down-regulation will be described here.
Agonist induced phosphorylation of serine and threonine residues of the C- 
terminal tail and in the third intracellular loop is produced by GRKs but not 
protein kinase 0  (Pei et al., 1995). Kramer et al. (2000) have also demonstrated 
tyrosine phosphorylation on activation of 50R and the involvement of both p- 
ARK and p-arrestin in homologous desensitization of the ôOR was demonstrated 
by Kovoor et al. (1997).
Phosphorylation is not the only process involved in desensitization as a mutant 
receptor, where serine 363 in the third intracellular loop was changed to alanine 
and therefore not phosphorylated, demonstrated unaltered desensitization 
compared to the wild type receptor (Kovoor et al., 1997). Only when clathrin- 
coated pit internalization was inhibited with 0.4M sucrose was the 
desensitization prevented.
Internalization has also been linked to the C-terminal tail as C-terminal deletions 
have resulted in impaired internalization. A ÔOR with a C-terminal deletion of 37 
amino acids did not internalize on agonist activation whereas a 15 amino-acid C- 
terminal truncated receptor did. A C-termlnally truncated mutant of ôOR, in which 
the last 15 residues had been removed and with point mutations at the putative 
phosphorylation sites T358A, and S363G was used to show the importance of 
these residues in receptor phosphorylation upon agonist stimulation. GRKs were 
shown to be the prominent kinases responsible for this phosphorylation (Kieffer 
et al., 1999; Guo et al., 2 0 0 0 ).
The processes of agonist-dependent activation and desensitization still occurred 
in a 8 0 R with a 31 amino acid C-terminal deletion although this was sensitive to 
a protein kinase inhibitor indicating the involvement of phosphorylation at other 
positions other than the C-terminal tail in 8 0 R desensitization (Wang et al., 
1998). A functional 8 0 R C-terminal truncation mutant (D344T) was not 
phosphorylated, and when expressed in CHO cells did not internalize, although
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this mutant did internalize in HEK293 cells. This is the first example of a GPCR 
that doesn’t require to be phosphorylated before it gets internalized (Murray et 
al., 1998).
The involvement of p-arrestin in the desensitization of 8 0 R has been 
demonstrated by Cheng et al. (1998) and Kovoor et al. (1999) who showed the 
C-terminus to be important for a successful interaction with both the kOR and 
the 80R. Expression of constitutively active p-arrestin with a C-terminally 
truncated 8 0 R restored the agonist-induced desensitization of that receptor 
(Kovoor et al., 1999). Point mutations between these two regions identified 
threonine 353 to be essential for down-regulation.
\xOR receptor internalization has been demonstrated for most agonists e.g. Tyr- 
D-Ala-Gly-NMe-Phe-Gly-o! (DAMGO) or etorphine, however, the agonist 
morphine does not produce effective receptor internalization (Keith et al., 1996). 
For the 80R, full agonists induced receptor down-regulation, whereas partial 
agonists did not (Remmers et al., 1998).
The process of down-regulation may involve other components as indicated by 
Li et al. (2000) who showed the down-regulation of human kORs to involve rab5 
and rab7 (involved in vesicle transport between intracellular compartments) as 
well as GRKs, arrestin and dynamin.
1.4.6 Pharmacology of 80R and ^ORs
It is possible that 8 0 R may be a better clinical target than the p-OR as its ligands 
provide greater relief from neuropathic pain, reduced respiratory depression, 
reduced constipation and a lower potential for developing dependency. Morphine 
has high affinity for both the pOR and the 8 0 R although in pOR knock-out mice 
no morphine-induced analgesia was found (Matthes et al., 1996). 80R-selective 
agonists did not require functional pOR to mediate antinociception (Matthes et 
al., 1998). A transgenic pOR knock-out mouse has been used by Sora et al. 
(1997) to study pOR and 8 0 R interactions. The results of various opioid knock­
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out mice have been discussed by Kieffer (1999). Ligand dependent results were 
demonstrated where the ôOR-selective agonist Tyr-DPen-Gly-Phe-DPen 
(DPDPE) gave a lower than expected antinociceptive effect In knock-out 
compared to control animals indicating that the presence of pOR may be 
necessary for the full effect of 8 0 R ligands. This was not the case though for 
Deltorphin II and (+)-4-[(aR)-a-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3- 
methoxybenzyl]-N,N-diethylbenzamide (SNC80), which gave normal GPCR 
activation, indicating that the 8 0 R was fully functional independently of the 
presence of the pOR. Sub-analgesic levels of 8 0 R ligands have been shown to 
decrease the amount of morphine required for analgesia, which is an important 
finding in respect to dependency. It has also been demonstrated that the 8 0 R 
does not have to be activated to potentiate pOR mediated analgesia. Evidence 
that activation of the 8 0 R could potentiate the agonist response of the pOR was 
demonstrated by Vaught and Takemori (1979) where administration of leucine- 
enkephalin (moderately 8 0 R selective) at a concentration unable to Induce 
analgesia, was able to produce a rightward shift in the ED50 dose-response 
curve to morphine. More selective 8 0 R ligands were also shown to have the 
same effect (Barrett and Vaught, 1982; Lee et al., 1980).
No synergy was detected between the 8 0 R inverse agonist N,N-diallyl-Tyr-Aib- 
Aib-Phe-Leu (ICI 174,864) and morphine, suggesting that the 8 0 R had to be 
activated for opioid receptor synergy to be observed (Heyman et al., 1989). The 
irreversible 8 0 R antagonist [D-Ala2 , Leu5, Cys6 ]enkephalin (DALCE) was 
observed to block 8 0 R mediated antinociception but could not block the 
potentiation of the morphine effect on pOR (Jiang et al., 1990; Porreca et al., 
1992). This led to the proposal that not all 8 0 R were involved in morphine 
analgesia.
Pharmacological evidence of opioid receptor synergy has made opioid receptors 
an interesting target for GPCR dimerization studies as non sub-type selective 
ligands could also result in the pharmacologies observed. The discovery of sub- 
type selective ligands and the existence of opioid receptor dimers have been
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utilized to elucidate the cause of the observed synergy. A mixed 50R 
antagonist/pOR agonist DiPP-NH2\|/ was able to potentiate morphine-induced 
analgesia indicating that the 8 0 R does not have to be activated to demonstrate 
this effect Schiller et al. (1999). Further evidence for pOR and 80R complexes 
was derived from evidence that DADLE bound with high and low affinity to 80R 
receptors non-complexed and complexed with pOR respectively. In vivo studies 
using compounds that are pOR antagonists /  8 0 R agonists show a better 
therapeutic profile than the pOR only agonists (Wells et al., 2001; Jordan et al.,
2000).
This pharmacology is consistent with potential receptor interactions which will be 
discussed in section 1.6.2. However, the pharmacological synergy, which has 
been described by Law and Loh (1999), may be the result of the effector 
pathways interacting synergistically and not the receptors themselves.
1.5 GPCR signalling diversity
GPGR signalling mechanisms are complex with many levels of control. Many 
signalling components and their substrates are anchored in the plasma 
membrane, which provides a unique mixture of proteins that can interact with 
each other. GPCRs interact with their extracellular ligands as well as intracellular 
effector molecules e.g. kinases and phosphatases, each of which have different 
sub-types, adding to the signalling complexity. The cytoskeleton provides 
compartmentalization and regional organization within cells and is involved in 
receptor movement from one compartment to another. Some neurotransmitter 
receptors have been shown to be targeted to specific membranes and anchored 
there by specific anchoring proteins e.g. in pre or postsynaptic membranes 
(Vickery and von Zastrow, 1999).
The stoichiometry of the individual signalling components within a cell can 
greatly affect signal generation resulting from GPCR activation within that cell. 
An agonist at a particular GPCR may have a different efficacy, depending on the 
level of G-proteins present within a cell as was demonstrated for the ag- 
adrenergic receptor by Yang and Lanier (1999).
20
GPCR diversity also results, partly, via sub-types being encoded by differential 
gene splicing, resulting in different receptor mRNAs encoding for different 
receptor isoforms (Kilpatrick et al., 1999).
1.6 Dimerization of GPCRs - introduction
One mechanism by which receptor signalling can diversify is if the receptors 
physically interact with each other to alter their ligand binding or signalling 
properties. There is evidence for GPCR homo- and heterodimerization and the 
varying effects this may have on ligand binding, cell signalling and cellular 
trafficking (Bouvier, 2001; Salahpour et al., 2000; Milligan and Rees, 2000; 
Milligan, 2001; Marshall, 2001).
1.6.1 Growth factor dimerization
It is not so suprising that protein-protein interactions between GPCRs may result 
in another mechanism of cell-signalling control as dimerization has been widely 
accepted as a control mechanism for single transmembrane helix growth factor 
receptors.
Growth factor receptors are members of a large family of single transmembrane 
species involved in apoptosis and differentiation as well as cell-growth. These 
receptors are structurally similar in having an extracellular N-termlnus, a single 
transmembrane domain and an intracellular C-terminus. Dimerization has been 
shown to be the process by which these receptors are switched on. Removal of 
the C-terminus of the epidermal growth factor (EGF) receptor results in a higher 
rate of dimerization on ligand activation indicating that the C-terminus hinders 
receptor dimerization (Tanner and Kyte, 1999). In the case of tumour necrosis 
factor (TNF) receptors ligand activation results in trimerization of the receptor 
(Heldin, 1995 and references therein).
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1.6.2 GPCR homo and hetero-oligomerization
There is increasing evidence for the existence of receptor oligomers from 
experiments performed in vitro. Constitutive homodimerization of the 
thyrotrophin releasing hormone receptor has been described by Kroeger et al. 
(2001). Dimerization of the histamine H2 receptor has been demonstrated via 
immunoprécipitation and immunoblotting (Fukushima et al., 1997). Moreover, 
receptor homodimers have also been identified in vivo as in the case of the D3 
dopamine receptor (Nimchinsky et al., 1997). Homodimers of muscarinic m3 
receptors have also been shown in brain and heart tissue (Avissar et al., 1983). 
Photoaffinity labelling revealed dimers, which were shown to correspond to the 
low affinity state of the receptor, and tetramers corresponding to the high affinity 
state of the receptor.
Interaction between different signalling systems, which may be a result of the 
GPCRs physically interacting with each other has also been indicated by 
alterations In receptor pharmacology. Adenosine A1 receptors have been shown 
to heterodimerize with dopamine D1 receptors (Gines et al., 2000). The 
vasopressor angiotensin II receptor heterodimerizes with the vasodepressor 
bradykinin B2 receptor although these two hormone systems have also been 
shown to be inter connected by angiotensin-converting enzyme (Abdalla et al.,
2000). The pgAR has been shown to dimerize with 8 0 R and kORs (Jordan et al.,
2001). Somatostatin receptors (SSTR) have been shown to form ligand-induced 
homo and heterodimers with other members of the SSTR family (Rocheville et 
al., 2000a; Pfeiffer et al., 2001). The somatostatin receptor SSTR5 and the 
dopamine D2 receptor have been shown to form heterodimers. Somatostatin is 
involved in modulating dopamine-mediated control of motor activity and 
dopamine has been shown to activate SSTRs. These two receptors are co­
localized in neuronal sub-groups. Interaction between the two receptors has 
been demonstrated via co-immunoprecipitation experiments and confirmed in 
live cells by photobleaching-fluorescence resonance energy transfer (pb-FRET) 
experiments (Rocheville et al., 2000b). The heterodimer showed a distinct 
pharmacology with higher ligand affinity for both dopamine and somatostatin
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agonists. Synergy of agonist binding was demonstrated where the binding 
affinity of the second agonist was increased by the presence of the first agonist.
Franco et al. (2000) have reported evidence of heterodimerization between 
adenosine Ai and dopamine Di receptors, where heterodimers between these 
receptors were found both in vivo and in vitro. pOR and 8 0 R receptors have also 
been shown to form heterodimers resulting in a distinct pharmacology. The 
potency of highly selective agonists for the individual receptors was reduced 
whereas binding of partial agonists increased, suggesting the heterodimers have 
a novel binding pocket. Co-immunoprecipitation also indicated the presence of 
the heterodimers in cells (George et al., 2000; Gomes et al., 2000).
1.6.3 Domain swapping theory
Evidence that GPCRs can physically interact was demonstrated by expressing 
chimeric receptors that were split in the third intracellular loop. Muscarinic m2 
and m3 receptor N-terminal and C-terminal fragments divided at the third 
intracellular loop could be expressed individually resulting in no ligand binding or 
signalling. Co-expression of the m3 N-terminal fragment and m3 C-terminal 
fragment resulted in ligand binding and activation of second messenger systems 
as did the co-expression of the m2 N-terminal fragment with the m2 C-terminal 
fragments (Maggie et al., 1993a). This led to the theory that GPCRs function as 
proteins with two Interacting subunits consisting of TM 1-5 and TM 6-7.
Further investigations into GPCRs interaction within the membrane were 
performed with chimeric GPCRs with the N-terminal fragment of the agc- 
adrenergic receptor fused to C-terminal fragment of the muscarinic m3 receptor 
and vice versa. Individual expression of the chimeras resulted in no ligand 
binding or signal transduction from either receptor whereas co-expression of the 
chimeras resulted in binding of adrenergic and muscarinic ligands and signalling 
via activation of each receptor (Maggio et al., 1993b). For the adrenergic and 
muscarinic receptors to interact to form a functional receptor the chimeric 
proteins must have interacted in such a way to allow the formation of native 
adrenergic and muscarinic receptors.
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Muscarinic m3 receptors have a large third intracellular loop in comparison with 
other GPCRs. Chimeric receptors between the a2c-adrenergic and muscarinic 
m3 receptors identical to those described above but with a 196 amino-acid 
deletion in the third intracellular loop, no longer formed functional receptors 
when co-expressed (Maggio et al.,1996). This indicated that the length and 
flexibility of the third intracellular loop is required for correct receptor-receptor 
interactions to occur. Jakubik and Wess (1999) developed an ELISA assay to 
examine interactions between m3 truncations and m3 C-terminal fragments and 
demonstrated that there are 3 proline residues in transmembrane regions 5, 6 
and 7 which are especially important for receptor assembly. Agonists and 
antagonists improved receptor assembly indicating that ligands anchor the two 
fragments together. Scarseli et al. (2000) reconstituted dopamine D2 receptors 
by co-expressing the N-terminal and C-terminal receptor fragments in the same 
cell. Further evidence of domain swapping was provided by Monnot et al. (1996) 
where reconstitution of the angiotensin II binding site occurred on co-expression 
of two deficient mutants. Computational studies have confirmed this domain 
swapping as a possible method for GPCR dimerization (Gouldson et al., 2000).
1.6.4 Lateral interaction and coiled-coil interactions
Domain swapping is not the only mechanism proposed for receptor-receptor 
interaction. Another mechanism is lateral interaction within the membrane which 
is the mechanism proposed for the V2 vasopressin receptor (Schulz et al., 
2000). Co-expression of mutant receptors did not demonstrate functional 
recovery which would have been expected if domain swapping occurred. 
Disruption of cysteine residues on the 1®^ and 2"^ extracellular loops by mutating 
the cysteine residues to alanine resulted in functional rescue of the receptor. 
Dopamine D2 receptors also appear to interact via lateral interaction as shown 
by co-expression of receptor point mutants (Lee et al., 2000a).
Coiled-coil conformation interaction is the mechanism by which the GABAb 
receptor isoforms have been proposed to interact, (Marshall et al., 1999; 
Margeta-Mitrovic et al., 2000) via the large C terminus of each receptor. Coiled-
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coil interactions have been shown previously to be involved in a range of protein- 
protein interactions (Lupas, 1996).
1.6.5 Family 3 GPCR dimerization
Family 3 GPCRs are unique in structure as they have a large N-terminal 
extension that can be up to half the total size of the protein. These receptors 
have been shown to dimerize via dl-sulphide bridges which occur in this N- 
terminal region. Mutants of the conserved cysteine residues of the calcium- 
sensing receptor (Fan et al., 1998) demonstrated effects on receptor expression 
at the cell surface, signal transduction, and dimerization. It was found that the 
majority of the mutant proteins were produced in an immature high mannose- 
linked glycosylated form and that only a few were fully mature with complex 
carbohydrates which allowed correct insertion in the membrane.
Another group of this family of GPCRs are the metabotropic glutamate receptors 
(mGluRs). The mGluR-5 dimerizes via the large N-terminal extension (Romano 
et al., 1996); again the dimerization was shown to be due to di-sulphide bonds. 
Crystal structures of the N-terminal extension of the mGluR-1 receptor have 
been produced in the presence and absence of glutamate. In each case the 
receptor exists in a di-sulphide (at cysteine 140) linked dimeric form (Kunishima 
et al., 2000). The importance of this cysteine in mGluR-1 dimerization was also 
shown by Ray and Hauschlld (2000).
A lot of work has been performed recently on the GABAb receptor which also 
belongs to this family. Activation of this receptor results in inhibition of neuronal 
responses in the mammalian central nervous system. The GABAb receptor has 
a large N-terminal extension responsible for ligand binding but as there are no 
cysteine residues within it a di-sulphide linked homodimer would not be possible. 
Using a yeast-two hybrid screen with the C-terminal domain of GABAbR I, the 
GABAbR2 was identified (Kaupmann et al., 1998; White et al., 1998). The 
individual receptors identified did not have the ligand binding capabilities or 
signal transduction properties anticipated for the wild type GABAb receptor. 
Heterodimerization of these receptors has been shown to result in cell-surface
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expression of the GABAbR I, ligand binding properties of the wild type receptor 
and signalling events consistent with the wild-type receptor. This was the first 
time that heterodimerization of a GPCR has been shown to be essential for 
correct receptor trafficking and signalling. The consequences of these findings 
for how we think of GPCR signalling have been reviewed (Mohler and Fritschy, 
1999; Marshall, 2001 ; Bouvier, 2001). A C-terminal motif arg-X-arg-(arg) which is 
responsible for the retention of the GABAbRI at the endoplasmic reticulum is 
thought to be masked by the GABAbR2 receptor as the receptors interact via the 
C-terminal coil-coil sequences (Margeta-Mitrovic et al., 2000).
1.6.6 Domains involved in GPCR dimerization
Considerable effort has been made to elucidate the structural determinants of 
the dimer interface and as is often found in signal transduction systems there 
appear to be several different possibilities. C terminal truncation mutants of the 
6 0 R were found to be dimerization deficient (Cvejic and Devi, 1997), indicating 
the C-terminus as being important for the dimer interface. As discussed above, 
the large N-terminal extension of the family 3 GPCRs has been shown to be 
important for dimerization of these receptors. Wild-type histamine H2 receptors 
were shown to dimerize with a truncated receptor form lacking the C-terminus 
demonstrating that for this receptor the C-terminus is not important for 
dimerization (Fukushima et al., 1997). For pg-AR the sixth transmembrane 
domain has been shown to be important. Hebert et al. (1996) showed that 
although peptides corresponding to the sixth transmembrane domain did not 
affect ligand binding they inhibited adenylyl cyclase activity upon agonist 
activation and dimerization of the receptors. Similarly, peptides corresponding to 
the 6^*^  and 7^ *^  transmembrane domain of the D2 dopamine receptors (Ng et al., 
1996) were shown to be inhibitors of dimerization. In contrast to this the 
dopamine DI receptor has been shown to dimerize and peptides corresponding 
to the 6*^  transmembrane domain inhibit dopamine binding and adenylyl cylase 
activity but there was no effect on dimerization (George et al., 1998). 
Vasopressin V2 receptors have been shown to interact within the TM domains. 
The first three transmembrane domains are required to allow interaction with the 
full length receptor (Schulz et al., 2000).
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B2 bradykinin receptors showed no dependence on the sixth transmembrane 
domain for receptor dimerization but peptides corresponding to the N-terminus of 
the receptor inhibited dimerization (Abdalla et al., 1999). The different regions of 
GPCRs identified may not be the only regions that are necessary for receptor 
dimerization. The differences may be explained in part because the dopamine Dg 
and p2-ARs belong to family 1 subtype a whereas B2 bradykinin receptors, whilst 
belonging to family 1, are in sub-type b. For the B2 bradykinin receptor agonists 
have been shown to induce dimerization whereas antagonists do not. A peptide 
corresponding to the N-terminus of this receptor has been shown to reduce 
dimerization but peptides corresponding to the other extracellular loops had no 
effect on dimerization (Abdalla et al., 1999).
It is clear that GPCR dimerization is not a simple process involving the same 
region for each GPCR. Clearly further work will have to be performed in this area 
to elucidate what is involved in receptor dimerization. Peptide inhibitors of 
dimerization could be used as novel inhibitors of GPCR signalling.
The evidence presented thus far shows the presence of GPCR dimers but does 
not present any evidence as to why receptor dimerization is necessary. The 
presence of some mutant receptors has shed some light on how receptor -  
receptor interaction can affect cell signalling.
1.6.7 Dominant negative effects of dimerization
Co-expression of wild-type receptors with mutant or truncated receptors can 
result in dominant negative effects of the defective receptors on the ligand 
binding or signalling of the co-expressed wild-type receptors. The level of cell- 
surface expression of the wild-type receptor has also been shown to decrease 
upon co-expression with mutant receptors where signalling from the wild-type 
receptor is also reduced as it is retained in an intracellular position.
D3 dopamine receptors have been shown to be present in dimeric and 
tetrameric forms in brain. A C-terminally truncated mutant of the D3 receptor.
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D3nf, is found to form heterodimers with the wild-type receptor and these 
receptor forms are found to be co-localised in cortical neurones. D3nf mutant 
receptors inhibit the cell-surface expression of the wild-type receptor as well as 
affecting ligand affinity (Nimchinsky et al., 1997). The presence of D3nf mutant 
receptors could be important biologically as there is increased expression of this 
form of the receptor in the brain tissue of patients suffering from schizophrenia 
(Karpa et al., 2000 and references therein) which may also result in decreased 
cell-surface expression of the wild-type receptor. Mutant dopamine D2 receptors 
have also been shown to reduce cell-surface expression of wild-type receptors 
when expressed in the same cells (Lee et al., 2000a).
Vasopressin V2 receptor truncation mutants have also been shown to be 
negative regulators of V2 activity by reducing cell-surface expression of the wild 
type receptor (Zhu and Wess, 1998) as well as reducing adenylyl cyclase activity 
and ligand binding. Dominant negative effects of mutant receptors may be useful 
as inhibitors of constitutively active receptors which can result in disease states. 
For example, missense mutations in the vasopressin V2 receptor have been 
linked to nephrogenic diabetes insipidus (Schulz et al., 2000) and the dopamine 
truncated receptor D3nf may be involved in schizophrenia (Karpa et al., 2000).
1.6.8 Dominant positive effect of dimerization
The converse of what is described above has also been shown where the wild- 
type receptor has a dominant positive effect on mutant receptors expressed. 
Hebert et al. (1998) showed that a palmitoylation deficient mutant P2AR, when 
expressed with wild-type P2AR resulted in cell surface expression of the mutant 
receptor and full adenylyl cyclase activity resulted. Expression of the mutant 
alone gave poor ligand binding and low functional activity. As this mutant is 
palmitoylation deficient the dimerization of these receptors is shown not to 
involve the palmitoylation state of the receptors. By using a phosphorylation 
deficient mutant phosphorylation was also shown not to be involved in 
dimerization.
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1.6.9 Effect of ligands on GPCR dimerization
Several studies have been performed to try to elucidate the effect of ligands on 
GPCR dimerization and again the answer is not a simple one. The effect of 
agonist activation on receptor dimerization has varied from no effect, as shown 
for the muscarinic m3 receptor (Zheng and Wess, 1999) the Ca^^ sensing 
receptor (Bai et al., 1998), the V2 vasopressin receptor (Schultz et al., 2000), the 
ÔOR (McVey et al., 2001) and the kOR (Jordan and Devi, 1999), to promotion of 
receptor dimerization as demonstrated for the PsAR (Hebert et al., 1996, Angers 
et al., 2000) and the B2 bradykinin receptor (Abdalla et al., 1999). A reduction in 
receptor dimerization on agonist activation has been reported for the ôOR 
(Cvejic and Devi, 1997) where agonists, with the exception of morphine, resulted 
in monomerization of the receptor before its internalization. Specific receptor 
antagonists did not effect the ratio of monomer to dimer.
For the chemokine receptors the stimulatory effect of agonist on dimerization 
appears universal. The chemokine receptor CCR2 dimerizes leading to its 
activation. Dimerization is produced by its ligand, monocyte chemoattractant 
protein-1 or by a receptor specific antibody. Monomeric antibody Fab fragments 
do not lead to dimerization of the receptor (Rodriguez-Frade et al., 1999). 
Activation of the CXCR4 chemokine receptor requires agonist-induced receptor 
dimerization (Vila-Coro et al., 1999). Certain chemokine receptors are co­
receptors for HIV, and receptor dimerization stimulated via an antibody raised to 
the extracellular domain of the CCR5 receptor impedes viral entry by inducing 
receptor dimerization. This occurs in the absence of chemokine, leading to 
activation and internalization of the receptor. There is a well studied chemokine 
CCR5 receptor polymorphism that renders homozygous individuals highly 
resistant to viral infection as the resultant mutant CCR5 receptor is not 
expressed on the cell surface thus impeding viral entry (Vila-Coro et al., 2000).
Further investigations will have to be performed to ascertain whether the 
differences in the effect of ligands on GPCR oligomerization for different 
receptors are real or are a function of how assays are performed.
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1.6.10 Kinetics of ligand interaction with dimers
The presence of GPCR dimers and ligand binding to them may alter the 
expected kinetics of the ligand binding and receptor activation profile. Indeed the 
presence of D2 oligomers was indicated before any dimeric receptor species 
were identified. In various tissues there appeared to be co-operativity of ligand 
binding, where the binding at one site leads to an increased binding at the other 
site in the dimer. Further investigations led to the conclusion that oligomers were 
present, The potential effects of GPCR dimerization on ligand efficacy and 
affinity are discussed by Onaran and GCirdal (1999).
1.6.11 Function of GPCR dimerization
GPCR dimerization leading to activation has been described above for many 
receptors. The study by Mijares et al. (2000) who showed that dimeric anti-ggAR 
antibodies acted as agonists whereas monomeric Fab fragments were 
antagonists provides more evidence for the dimer of the ggAR being the active 
form.
Correct trafficking of the GABAb receptor to the cellular membrane has been 
demonstrated only when both the GABAbR2 and the GABAbRI are co­
expressed (Margeta-Mitrovic et al., 2000). Hetero-dimer formation between the 
P2AR with opioid receptors has been shown to effect trafficking. P2AR-KOR 
dimerization leads to inhibition of receptor internalization on agonist activation, 
whereas P2AR -ÔOR dimerization does not inhibit agonist-induced internalization 
of either receptor (Jordan et al., 2001). Trafficking of mutant GPCRs to the cell- 
surface as a result of the addition of cell-permeable non-peptide antagonists has 
been demonstrated for eight out of fifteen mutant forms of the vasopressin V2 
receptor. This was a result of the promotion of correct receptor folding which 
resulted in trafficking of the GPCR to the cell-surface (Morello et al., 2000). 
Schôneberg et al. (1996) demonstrated functional rescue of vasopressin V2 
mutant receptors by co-expressing V2 receptor peptides which spanned the 
region of receptor that contained the mutation. Expression of several mutant 
forms of the vasopressin V2 receptor have been shown to cause nephrogenic
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diabetes insipidus. Co-expression of these receptor peptides could lead to a 
possible treatment of this disease. Other mutant receptors which are poorly 
trafficked to the cell surface include mutant dopamine D2 receptors (Lee et al., 
2 0 0 0 a) and the mutant D3nf receptors (Karpa et al., 2000). Intracellular retention 
has been shown in several cases to be the result of receptor dimerization within 
the endoplasmic reticulum (ER). Correct receptor folding and export from the ER 
were shown to be the key events for cell-surface expression of the ôOR (Petaja- 
Repo et ai., 2 0 0 0 ). The GABAbRI was retained intracellularly in the absence of 
GABAbR2 via its c-terminal ER retention motif RXR(R) (Margeta-Mitrovic et al., 
2000). CCR5 and the mutant CCR5A32 receptor dimerize in the ER (Benkirane 
et al., 1997) as do dimers of the vasopressin V2 receptors (Morello et al., 2000).
The consequence of dimerization of the protease activated receptor is unusual in 
that the protease activated receptor (PAR)3 acts as a co-factor for protease 
activated receptor 4 by presenting its agonist to the receptor. PAR4 resulted in 
thrombin activation when expressed alone but the EC50 for this was substantially 
decreased when the PAR3 receptor was co-expressed (Nakanishi-Matsui et al., 
2000). Thrombin interacts with PAR3, which then gets cleaved, leaving thrombin 
in close proximity of the co-expressed PAR4 leading to its cleavage. PAR3 is 
therefore functioning only to allow PAR4 activation.
1.7 GPCR interaction with other proteins
There are many proteins that have now been identified which interact with 
GPCRs both intracellularly and extracellularly. These have been demonstrated 
to affect the signalling as well as trafficking of GPCRs within the cell. Milligan 
and White (2001) have reviewed these other interactions and described their 
effect on GPCR signalling. Although many such interactions are known their 
pharmacological significance has not yet been fully elucidated.
1.8 Dimerization - conclusions
There is a lot of evidence for GPCR dimerization although much of the evidence 
derived from studies performed in vitro. Although GPCR dimerization is an 
attractive concept to explain cross-talk between different signalling systems
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more evidence will have to be provided for its functional significance in vivo. 
Functional rescue of mutant receptors is one area for which information on 
GPCR dimerization may be useful in developing new drugs. New technologies 
being developed which should allow receptor dimerization to be assessed in 
single cells should greatly improve our understanding of GPCR dimerization.
1.9 Properties of fluorescence
Fluorescent molecules are now widely used in biological assays and as I have 
used fluorescent molecules within this study a summary of fluorescent properties 
are described below. The phenomenon of fluorescence is depicted in figure 1.3 
where a molecule is excited by light of a particular wavelength resulting in the 
energy of that molecule increasing. As the energy returns to the resting level 
there is an emission of light at a longer wavelength and therefore lower energy, 
which is termed fluorescence. Fluorescent molecules lose some energy as 
internal vibrational energy which results in the emitted light being of lower energy 
and hence at a longer wavelength. Each fluorescent molecule has its own 
particular absorption or excitation (absorption and excitation describe the same 
thing) and emission wavelengths i.e. the wavelength of light necessary to excite 
the fluorescent molecule is its excitation wavelength and the light emitted from 
this molecule will be at its emission wavelength. Fluorescent light is emitted In all 
directions though detectors are usually set at 90° to the direction of the incident 
light. Non-fluorescent molecules lose energy as heat.
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Figure 1.3 Energy changes on excitation of a fluorescent molecule
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Fluorescent molecules are now being used in a variety of techniques to 
investigate molecular interactions and there are many properties that have to be 
considered when choosing a particular fluorophore for use in a specific assay 
format. These include:
Stokes shift, which is the wavelength distance between the absorption maxima 
and emission maxima. It is preferable for these to be far apart to ensure there is 
no direct interference of the excitation wavelength at the emission wavelength.
Quantum yield, which is a property of fluorescent molecules that refers to the 
amount of energy that is emitted, compared to that used to excite the fluorescent 
molecule. The maximal quantum yield is 1. (Fluorescein has a quantum yield of 
0.6).
Extinction co-efficient is a calculated value from the absorbance; it is the 
amount of light at a given wavelength that is absorbed by the fluorochrome. The
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molar extinction co-efficient is defined as the optical density of a one-molar 
solution of the fluorochrome through a one cm light path. To be useful in 
biological assays fluorescent molecules have to have an extinction co-efficient of 
tens of thousands (Fluorescein 70,000. Cy5 200,000). To calculate the 
concentration of a fluorescent compound the absorbance should be measured at 
a particular wavelength and the concentration calculated from the extinction co­
efficient.
Strongly fluorescent molecules have a high extinction co-efficient and a quantum 
yield close to one to allow the development of highly sensitive fluorescence 
based assays.
Quantum efficiency is the product of quantum yield and the extinction co­
efficient.
Fluorescent lifetime is the length of time the fluorescent molecule takes to 
decay back to its resting level. If the length of time for which the sample is 
excited is longer than the fluorescent lifetime of the fluorophore, the sample can 
undergo many excitation and decay cycles. The lifetime of the fluorescence 
molecule is important especially for time-resolved fluorescence resonance 
energy transfer (TR-FRET), which will be discussed in more detail later. 
Fluorescent lifetimes also have to be considered when designing fluorescence 
anisotropy assays (Pope et al., 1999).
The reduction of fluorescence emission can arise in several ways including: 
Photobleaching is the result of photodestruction of the fluorochrome as the 
excited state of a fluorophore is more chemically reactive than when it is in the 
ground state, giving decreased fluorescence. Different fluorophores have 
different susceptibility to photobleaching and the light intensity of the incident 
light, the length of time of illumination and the chemical environment affect the 
amount of photobleaching.
Quenching, which means a diminishing of the signal emitted due to the 
environment of the fluorophore. Quenching results from the energy that would
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have been emitted as light of a particular wavelength being absorbed or 
transferred to another molecule.
Light scattering, which results from the light from the excitation source 
"bouncing o f f  other molecules in solution resulting in a range of wavelengths 
which may interfere with the true emission reading. Light scattering is particularly 
relevant in solutions of high turbidity.
1.10 Fluorescent Assays
The use of fluorescent probes in the study of receptor interaction has increased 
recently as there are obvious advantages in using fluorescent ligands i.e. 
reduction in cost, increased safety over using radiolabelled ligands, as well as 
the ability to use live cell preparations.
Fluorescent labelling of ligands has previously been limited to the availability of 
suitable commercially available dyes where the fluorescent moiety has not 
altered the binding affinity for the receptors. As fluorescently labelled selective 
agonists become available for receptors, the ability to look at whole cell binding 
using a confocal microscope with appropriate quantitative software becomes 
possible. There are several different fluorescent assay formats that are used in 
the study of GPCRs including direct fluorescent intensity of the fluorescent 
molecule.
1.10.1 Fluorescence anisotropy
Fluorescence anisotropy is another assay that has been used to assay ligand 
binding to GPCRs (Pope et al., 1999). In this case there needs to be no 
separation of bound from free ligand as small fluorescent ligand molecules have 
little or no polarisation signal when rotating free in solution. A large polarisation 
signal is observed when bound to the receptor within a membrane.
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1.10.2 Fluorescence Resonance Energy Transfer
Fluorescent resonance energy transfer (FRET) involves the non-radlative energy 
transfer between two molecules. This Is a non-destructive quantifiable technique, 
which involves the use of two fluorescently labelled molecules whose excitation 
and emission spectra overlap i.e. the emitted light from one fluorophore excites 
the second fluorophore (figure 1.4). By measuring the output from the second 
fluorophore the amount of energy transfer can be calculated. For FRET to be 
able to take place the fluorescent moieties must be close together (10-100Â 
range) (Pope et al., 1999), therefore this technique measures molecular 
interactions by either the occurrence of FRET or its disruption. FRET has 
previously been used to produce a fluorescent indicator for Ca^^ (Romoser et al., 
1997, Miyawaki et al., 1997). It may be possible to use FRET to examine the 
interaction of receptors with G-proteins, arrestins and kinases. A related 
technique termed bioluminescence resonance energy transfer (BRET) has been 
used to demonstrate homodimerization of the P2AR receptor (Angers et al., 
2000). FRET and BRET are discussed further in Chapters 4 and 5.
Figure 1.4 A) Energy diagram of fluorescence resonance energy 
transfer between fluorescent donor and acceptor 
molecules
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Figure 1.4 B) Schematic representation of spectral overlap required for 
fluorescence resonance energy transfer
B)
co
CO
CO
E
LU
Spectral overlap
Donor fluorescence 
Acceptor absorption
Wavelength (nm)
1.10.3 Fluorescence Correlation Spectroscopy
To follow the kinetics of agonist association and dissociation, the sensitive 
technique known as Fluorescence Correlation Spectroscopy (FCS) can be used. 
This can be performed in an extremely small (femtolitre) volume and looks at the 
interactions of single molecules in solution and can be performed in individual 
cells, in real time (Eigen and Rigler, 1994). This technique employs a confocal 
microscope and measures the time for a fluorescent moiety to traverse the 
illuminated area. A highly sensitive single-photon detection device registers 
photons of fluorescent light.
Kinetics can also be performed using fluorescence correlation spectroscopy 
(FCS) which involves the measurement of molecular size by analysis of the 
diffusion time across the laser focus. This highly sensitive technique can
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measure single molecules and in femtolitre volumes. FCS has been used to 
measure binding for GPCRs achieving similar Kd values to that obtained from 
radiolabel ligand binding assays (Auer et al., 1998). Fluorescence Incidence 
Distribution Analysis (FIDA), is a related technique which has been adapted for 
confocal microscopy studies (Kask et al., 1999). Fluorescence correlation 
microscopy (FCM) combines the FCS technique with fluorescence imaging and 
has been used to localise a GFP-tagged epidermal growth factor receptor 
(EGFR) within live cells (Brock et al., 1999).
1.10.4 Fluorescence Recovery After Photobleaching
Fluorescence Recovery After Photobleaching (FRAP) is another technique 
which has been used to study receptor interactions. This involves exposing a 
small area of ceil membrane to a brief high intensity laser pulse to photolyse a 
fraction of the labelled protein. This results in a rapid decrease in the monitored 
fluorescence intensity. The recovery is shown by the rate of the diffusion of the 
non-photoiysed protein into the previously bleached area. Again this technique 
uses confocal microscopy and is performed on whole cells (Barak et al., 1997).
1.11 Green Fluorescent Protein (GFP)
The use of fluorescence in biology has been greatly influenced by the discovery 
of Green Fluorescent Protein (GFP). This is a 27kDa protein produced by the 
jellyfish Aequorea victoria where it is the acceptor of non-radiative energy 
transferred from aequorin. The fluorescent properties of GFP Include a large 
quantum yield and extinction co-efficient, the product of which results in the 
intrinsic brightness of the fluorophore. Many variants of GFP have now been 
produced with altered properties to allow its use in biological systems, which 
include its stability at 37°C, enhanced brightness at neutral pH and varying 
excitation and emission maxima (Tsien, 1998). GFP is strongly fluorescent and 
requires no co-factor as it is the correct folding of the protein that results in the 
formation of its chromophore (Tsien, 1998). GFP has been widely used in 
biology by fusing the GFP to the N or C-terminus of the protein of interest. It has
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been used to detect gene expression (Gervaix et a!., 1997) and to track 
enzymes (Fejes-Toth et al., 1996).
Having a fluorescent receptor protein overcomes the problems associated with 
selectively labelling a receptor molecule with fluorescent dyes. There are no 
problems with calculating labelling stoichiometry, or worries about labelling at 
essential residues generating a mis-functional protein. GFP has been coupled to 
the C-terminus of many different GPCRs allowing cellular trafficking to be 
studied by following the fluorescence. Barak et ai. (1997), Kallal et al. (1998) and 
Tarasova et al. (1997) demonstrated the trafficking of the cholecystokinin 
receptor type A (CCKAR) and that agonists induced internalization and 
antagonists inhibited spontaneous internalization of the receptor. Confocal 
microscopy was used to follow the trafficking in live cells demonstrating that the 
internalized receptor was present in endosomes before re-cycling back to the 
ceii-surface. Other molecules involved in GPCR trafficking have been labelled 
with GFP. Barak et al. (1997) used a GFP tagged |3-arrestin-2 molecule to follow 
its translocation to the cell-surface after activation and subsequent 
phosphorylation of the P2AR or the dopamine D1A receptors. This GFP tagged 
p-arrestin may be suitable for identification of agonists that activate orphan 
receptors. A further study of the substance P receptor which is a GPCR was 
performed using GFP fusions of protein kinase C, GRK2 and p-arrestin-2 (Barak 
et al., 1999).
1.11.1 FRET with GFP
Many new GFP variants have been produced which can be used in energy 
transfer assays or direct fluorescence in cells which have been reviewed by 
Billinton and Knight (2001). GFP mutants can be used in FRET as there are 
several variants with the necessary overlapping excitation and emission maxima. 
Rosomer et al. (1997) and Miyawaki et al. (1997) both describe an internal Ca^^ 
indicator that was designed using a calmodulin binding sequence with GFP 
variants at either end. The GFP variants used have overlapping excitation and 
emission spectra, Blue or Cyan FP as fluorescent donors with Green or Yellow 
FP as acceptor molecules. Upon Ca '^*' binding there is a change in direction and
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distance between the two GFP variants, which results in energy transfer 
between them when excited with the appropriate wavelength of light.
A study of the physiological role of the A kinase anchoring proteins with FRET 
allowed investigation of the specificity in signalling events controlled by 
compartmentalization and clustering of the signalling enzymes with their 
activators (Ruehr et al., 1999). A decrease in FRET signal was observed 
microscopically detecting synaptic excitation that resulted in an increase in post- 
synaptic Ca^^ with activation of the Ca^^ activated protease calpain. The 
substrate for the protease included a |u-calpain binding site; flanked by eYFP and 
eCFP which was present in the post-synaptic neurones. This protease substrate 
was attached to the postsynaptic dendrites via a PDZ domain present in the 
eCFP (Vanderklish et al., 1999).
1.12 Other fluorescent proteins
Other naturally occurring fluorescent molecules are being identified and tested 
for use in a similar manner to GFP, including DsRed, which is a 28kDa protein, 
expressed in a coral of the Discosoma species, described by Baird et al. (2000). 
DsRed has the advantage of emission at a longer wavelength greater than any 
of the mutant GFP molecules produced, making it possible to use DsRed in the 
presence of other fluorescent molecules to either study independently or using 
FRET. Further studies on this or other fluorescent protein molecules are likely to 
result in a brightly fluorescent protein molecule with longer wavelength emission 
than GFP and biological stability.
1.13 Research objectives
Currently, the evidence for GPCR homo and heterodimerization is increasing 
although some intriguing differences have been noted e.g. in the effect of 
agonist on the dimerization of GPCRs.
The primary aim of this study is to investigate 8 0 R homo and heterodimerization 
with other GPCRs. The pharmacology available for opioid receptors indicates 
complicated signalling mechanisms in which several different GPCR signalling
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systems are involved. Opioid receptor pharmacology indicates several opioid 
receptor sub types and as no cDNAs for these sub-types has been identified it is 
intriguing to speculate that homo and heterodimerization reactions between 
opioid receptors are responsible for this pharmacology.
The techniques involved to look at GPCR dimerization have involved disruption 
of the cells expressing the GPCRs of interest. Initially this study also involves 
disruption of the cells and subsequent co-imunoprecipitation of differentially 
tagged GPCRs.
A large portion of this work involves the development of a robust intact cell assay 
with a large signal to noise ratio for the study of 8 0 R homo and 
heterodimerization which can be applied to other GPCRs.
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CHAPTER 2
Materials
And
Methods
CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials
All reagents used in this study were of analytical or similar grade and were 
purchased from the following suppliers:
2.1.1 General Reagents
Alexis Corporation Ltd., Bingham, Nottingham, U.K.
DTT
Amersham Pharmacia biotech., Buckinghamshire, U.K.
Rainbow molecular weight markers 
FluoLink™ Mab Cy3 labelling kit
BDH
glycine, Na2HP0 4
Boerhinger Mannheim U.K. Ltd., Lewes, East Sussex, U.K.
Restriction enzymes, complete™,EDTA-free Protease Inhibitor Cocktail tablets 
and DNA molecular weight markers X (0.07-12.2kbp).
Calbiochem-Novabiochem Ltd., Beeston, Nottingham, U.K.
Geneticin (G418)
Fisher Scientific Equipment, Loughborough, U.K.
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Acetic acid, DMSO, EDTA, HEPES, hydrochloric acid, KCI, KH2PO4, K2HPO4, 
MgCl2, NaCl, Na2COs, NaHCOa, NaH2P0 4 , sucrose, SDS, trichloroacetic acid.
FMC Bioproducts, Rockland, USA
Agarose
Fuji Photo Film Co. Ltd., Tokyo, Japan 
X-ray film
Genosys, Cambridge, U.K.
Oligonucleotides
Gibco BRL Life Technologies Inc, Paisley, U.K.
Lipofectamine™, TRIS, 1 kb DNA ladder, oligonucleotides
Invitrogen, San Diego, CA, U.S.A
pcDNAS, pcDNA3(-)
Merck Ltd., Pole, Dorset, U.K.
Agar, NaOH
Novex , Germany 
7% Tris-acetate polyacylamide gels
Nunc, IL., U.S.A.
Black 96 and 384 well plates
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Oxoid Ltd., Hampshire, U.K.
Tryptone, yeast extract 
Premier Beverages, Stafford, U.K.
Marvel
Promega Ltd., Southampton U.K.
Restriction enzymes, DNA purification kits - Wizard™ Minipreps and Wizard™ 
Maxipreps systems
Prozyme® in c ., European distributor Europa Bioproducts Ltd., Cambridgeshire, 
UK.
Phycoiink™ SMCC-cross-iinked Allophycocyanin 
Qiagen Ltd., West Sussex, U.K.
QIAquick Gel Extraction Kit
RBI® Research Biochemicals International Natick MA, USA 
ICI-174,864
Sigma Chemical Company., Poole, Dorset, U.K.
Alumina (activity grade 1), ampicillin, DOWEX AG50 W-X4 (200-400 mesh), 
forskolin, imidazole, mineral oil, protein-G sepharose, TEMED, thimerosal,
Stratagene Ltd., Cambridge, U.K.
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PfuTurbo™ DNA polymerase
Whatman International Ltd., Maidstone, U.K.
GF/C Glassfibre filters
2.1.2 Radiochemicals
Amersham Pharmacia biotech., Buckinghamshire, U.K. 
[^HJadenine (specific activity: 20 Ci/mmol) 
pH]CGP-12177 (specific activity:41 Ci/mmoi) 
[^H]dihydroaiprenaiol (specific activity: 75Ci/mmol) 
[^Hjdiprenorphine (specific activity: 6 6 Ci/mmol)
Du Pont NEN Ltd., Stevenage, Hertfordshire, U.K. 
[Y^^P]GTP (specific activity: 30 Ci/mmol) 
pH]naitrindole (specific activity: 2 0 Ci mmol)
[^H]DADLE (specific activity: 50Ci/mmol)
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2.1.3 Tissue Culture
American Tissue Culture Collection, Rockville, U.S.A.
Human Embryonic Kidney (HEK293) cells 
Costar Scientific Corporation, Buckinghamshire, U.K.
Dishes 10cm and 6 cm diameter. Flasks 25cm^ and 75cm^, Plates 6 , 12  and 24 
wells, Disposable cell scraper
Gibco Life Technologies Inc, Paisley, U.K.
Glutamine (2 0 0 mM), Newborn calf serum, NaHCOs (7.5% % ), Optimem -1 
medium
Sarstedt, Numbrecht, Germany 
Cryovials
Sigma Chamical company, Poole, Dorset, U.K.
Dulbecco’s Modified Eagle’s Medium (DMEM)
Steriiin Bibby Ltd., Stone, Staffordshire, U.K.
Pipettes 5ml, 10ml and 25ml.
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2.1.4 Standard Buffers
Phosphate Buffered Saline (PBS)
Na2HP0 4  8.1 mM 
K2H PO 4 1.5mM 
NaCI 140mM
KCl 2.7mM
pH adjusted to 7.3
This was usually made up as a 10 x stock and diluted when required 
Phosphate Buffered Saline with Tween (PBS/T)
As for PBS but with Tween20 added (0.1%
Tris-EDTA Buffer (TE)
Tris/HCI lOmM 
EDTA 0.1 mM
pH adjusted to 7.5
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SDS-Page Sample Buffer
DTT 50mM
SDS 1.7%
Tris/HCI (pH6 .8 ) 58mM 
Bromophenol Blue 0 .0 0 2 %
Glycerol 6 %
This was stored in aliquots at -20°C  until required.
2.1.5 Antisera 
Anti- Flag antibody (M5)
Mouse monoclonal antibody that binds to N-terminal Flag proteins. 
Purchased from Sigma Chemical company, Poole, Dorset, U.K.
Anti-myc antibody (A-14)
Rabbit polyclonal antibody that binds to N-terminal c-myc proteins. 
Purchased from Santa Cruz™ biotechnology, Inc., CA, U.S.A.
Anti-myc 9E10-FITC antibody
Mouse monoclonal antibody labelled with Fluorescein Isothiocyanate (FITC). 
Purchased from Santa Cruz™ biotechnology,Inc.,CA, U.S.A.
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Anti-myc-EuK antibody
Mouse monoclonal 9E10 antibody raised against the 408-439 sequence of 
human c-myc protein, labelled with Europium cryptate ions.
Purchased from Packard Bioscience Ltd., Berkshire, U.K.
M2-XL665 anti- Fiag antibody
Mouse monoclonal antibody that binds to N-terminal methionine- Flag proteins, 
labelled with allophycocyanin.
Purchased from Packard Bioscience Ltd., Berkshire, U.K.
LANCE Eu-iabelled W1024-anti-myc antibody
Mouse monoclonal antibody which has been fluorescently labelled with Eu^^. 
Purchased from Wallac oy, Turku, Finland 
Anti-GFP antibody
Sheep antibody raised against GFP, produced by the Scottish Antibody 
Production Unit, Lanarkshire, U.K.
Anti-mouse IgG
Goat polyclonal antibody conjugated with horseradish peroxidase, purchased 
from Amersham Pharmacia biotech., Buckinghamshire, U.K.
Anti-rabbit IgG
Donkey polyclonal antibody conjugated with horseradish peroxidase, purchased 
from Amersham Pharmacia biotech., Buckinghamshire, U.K.
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Anti-Sheep IgG
Donkey polyclonal antibody conjucated with horseradish peroxidase, purchased 
from Jackson Immunoresearch. PA., U.S.A.
2.2 Cell Culture
All tissue culture manipulations were performed in a Laminar Flow Hood 
designed for this purpose. Aseptic techniques were used with all manipulations 
of ceils or preparation of plastics. Liquid waste was added to antiseptic before 
discarding. Solid waste was removed and autoclaved before being disposed.
2.2.1 Routine Cell Culture
Human Embryonic Kidney cells (HEK293) were grown in DMEM, supplemented 
with 10% Newborn Calf Serum and 2 mM L-Glutamine. The cells were grown as 
a monolayer on tissue culture treated plastic plates, dishes or flasks. Ceils were 
incubated in cell culture incubators (Jencons Nuaire) at 37°C in a humidified 
atmosphere with 95% air / 5 %C0 2 .
Cells were split when confluent by removing the medium followed by the addition 
of 1ml of trypsin solution (0.1% trypsin, 0.025% EDTA and lOmM 
Glucose). When the cells were detached 9ml of DMEM was then added to 
prevent further trypsinisation. The cells were then re-suspended in this medium 
and seeded into new flasks, plates or dishes containing DMEM.
2.2.2 Translent Transfections
Lipofectamine™ reagent (Gibco Life Technologies) was used to transfect the 
cells with the appropriate cDNA according to the manufacturers’ instructions. 
Briefly, DNA was diluted to 0.1 mg/ml with sterile water before the addition of 
Optimem. cDNA / Optimem for a lOcm^ dish being 600|uil containing Bjuig of DNA. 
To this an equal volume of Lipofectamine™ reagent which had also been diluted
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with Optimem was added, with there being 2 0 |4l of Optimem being added for a 
10cm^ dish. The DNA /  lipofectamine mixture was left for 30 - 45min at room 
temperature before the addition of 4.8ml Optimem (for a 1 0 cm^ dish), all of the 
mixture was then added drop-wise to the dish of cells which contained cells of 
approximately 80% confluency rinsed with Optimem. The dishes were then 
placed back in the tissue culture incubators for 4 h before the addition of Gml of 
DMEM. The cells were placed back in the incubators overnight before the entire 
medium on the dishes was replaced with fresh DMEM. Cells were routinely 
harvested 48 h after transfection.
2.2.3 Generation and maintenance of stable cell lines
Human Embryonic Kidney 293 cells were transfected using the method 
described in 2.2.2. 48 h after transfection, DMEM containing 1 mg/ml Geneticin 
(G-418) was added to select for antibiotic resistant clones. This medium was 
changed every 3 days and as non-resistant cells started to die discrete colonies 
of resistant clones were observed. Each clone was “picked” using a pipette, the 
cells and some medium were withdrawn and placed in an individual well of a 24 
well dish and allowed to grow. As the clones grew they were subsequently 
transferred to 6  well dishes, 25cm^ flasks and 75cm^ flasks. The clones were 
then split into 3 x 75cm^ flasks, one each for harvesting, freezing down and 
maintaining growth.
2.2.4 Preservation of cell lines
stable cell lines were preserved at a low passage, the ceils were grown to 
confluency before trypsinisation to remove them from the flask. The cells were 
then centrifuged for 5min at 3000 rpm in a bench top centrifuge. The pellet was 
then resuspended in 1ml of NBCS with 7.5% DMSO (as a cryoprotectant). The 
cells were then transferred into 1.5ml cryovials. These were frozen slowly in a - 
80°C freezer by wrapping the vials in cotton wool first. Long term storage was in 
liquid nitrogen tanks.
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These cells were resuscitated for use by thawing the cryovial at room 
temperature, before addition of the cells to 9ml of pre-warmed DMEM. The cells 
were then spun in a bench top centrifuge for 5min at 3000 rpm. The medium was 
removed and the cells resuspended in a further 10ml of DMEM, this removes the 
DMSO from the cells. The cell suspension was then added to a 75cm^ flask and 
routine cell-culture continued.
2.2.5 Cell harvesting
Cells were harvested by removing the medium and washing the cells with 2 x 
6 ml of ice-cold PBS. A disposable cell scraper was then used to remove the 
cells from the surface of the flask or dish in a small volume of PBS. The cell 
suspension was then centrifuged for 5min at 3000 rpm on a bench top centrifuge 
at 4°C. The PBS was removed and the cell pellets stored at -80°C before 
membrane preparation.
2.3 Molecular biology
Molecular biology manipulations were performed with materials which had been 
autoclaved, on a bench which had been swabbed with 70% alcohol. Disposable 
gloves were worn at all times to prevent contamination of the DNA.
2.3.1 Reagents for Molecular Biology
Gel loading buffer (6x)
Bromophenol Blue (2 %) 1.25ml
Sucrose 4g
These were dissolved in autoclaved water to give a final volume of 10ml. The 
buffer was stored in aliquots at -20°C.
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TAE buffer
Tris-acetate 40mM
EDTA Im M
This was prepared as a 50x stock solution by adding 242g of Tris / HCi, 57.1ml 
of glacial acetic acid and 100ml of lOmM EDTA (pH8 ) to deionised water in a 
final volume of 1 litre. This was diluted in deionised water when required.
Luria Bertani (LB) broth
Bacto-tryptone 10 g
Bacto-yeast extract 5g
NaCI lOg
These were dissolved in 1 litre of deionised water and sterilised by autoclaving. 
LB ampicillin agar plates
This has the same composition as the LB with the addition of bacto-agar (1.5% 
^/y). This was ieft to cool before ampicillin was added to a final concentration of 
50|ig/ml. The liquid agar was then poured into 10cm diameter petri dishes and 
allowed to solidify at room temperature before storing at 4°C.
2.3.2 Transformation
This is the transfer of DNA into E.cofi, which allows multiple copies of the DNA to 
be produced as the bacteria replicate. DH5a was the strain of E.coli used for
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transformation along with the vector pcDNA3.1(-), allowing a high copy number 
of the plasmid to be produced per bacteria.
Preparation of competent bacteria
E.Coli must first be “made competent" to allow the entry of foreign DNA. This 
involved treating the bacteria with various chemicals.
Solution 1
Potassium acetate 3mi
RbClg (1M) 1 0 ml
CaClg (1IVI) 1ml
MnCl2 (1M) 5ml
Glycerol (80% %) 18.75ml
The final volume was made up to 100ml with deionised water and the pH 
adjusted to 5.8 with lOOmM acetic acid. This was then fiiter-sterilised and stored 
at 4°C.
Solution 2
MOPS (lOOmM; pH6.5) 4ml
CaCl2 (1M) 3ml
RbCl2 (1M) 0.4ml
Glycerol (80% % ) 7.5ml
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The final volume was made up to 40ml with deionised water and the pH adjusted 
to 6.5 with HCI before filter sterilization, this was stored at 4°C.
A confluent 5ml culture of E.Coli DH5a cells, which had been grown overnight in 
LB broth was added to 250mi of sterile LB broth and incubated with shaking at 
37°C, for 4-5 h. When the optical density at 550nm was 0.48 the bacteria were 
pelleted by centrifugation at 3000 rpm, at 4°C for 5min. The bacteria were 
suspended in 100ml of solution 1 and incubated on ice for 5min. The bacteria 
were pelleted as before then resuspended in 15ml of solution 2 and incubated 
on ice for 15min. The DH5a bacteria were now suitable for transformation or 
were stored at -80°C in aliquots until required.
Transformation of DNA
10-50ng of each plasmid DNA was incubated with 50p,l of competent bacteria in 
a sterile tube for 15min on ice. The DNA / bacteria mix was then subjected to 
heat shock at 42°C for 90 s before being plunged back into ice for a further 2 min. 
450pl of LB broth was added and the bacteria allowed to recover in a shaking 
incubator at 37°C for 45 min. 2 Q0 pl of this mixture was then plated onto a LB 
ampicillin agar plate which was left on the bench for a short time to allow the 
agar to absorb the liquid before an overnight incubation at 30°C. Colonies picked 
from the plate can be cultured further in LB broth for DNA extraction. The plate 
was kept at 4°C for up to one month.
Transformed E.Coli LB broth cultures were also maintained as glycerol stocks by 
mixing 1 volume of culture with 1 volume of glycerol in a sterile eppendorf tube, 
and stored at -80°C. Cells kept as glycerol stocks are viable for up to 2 years.
2.3.3 DNA Preparation
DNA was purified using Promega Wizard™ Miniprep and Maxiprep kits 
according to the manufacturer’s instructions.
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2,3.4 Polymerase chain reaction (PCR)
PCR mix
Component volume
Template DNA(0.1 |ig/nl) 2yd
Primer 1 (25 pmol/jul) 1 jiil
Primer 2 (25 pmol/jil) I j i l
Deoxynucleotides triphosphate (2.5mM) 6yd 
Pfu polymerase buffer (lOx) 5pl
The volume was made up to 50pl with autoclaved water, the mix was added to 
thin-waiied PCR tubes, one drop of mineral oil was added on top. The mixture 
was heated to 95°C for lOmin, to denature the double stranded DNA and allow 
the primers to bind, before the addition of 0.5ml of Pfu turbo enzyme and the 
PCR cycles initiated in a Hybaid OmniGene temperature cycler.
PCR cycles
Dénaturation Annealing Extension Cycles
95°C; Im in 60°C; 1min* 72°C; 4min 35
95°C;1min 60°C; Im in* 72°C; lOmin 1
* The annealing temperature was determined empirically and was set at 55, 60 
or 65°C.
After the PCR cycles the aqueous lower layer was removed and transferred into 
another sterile tube.
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2.3.5 Agarose gel electrophoresis
Gel loading buffer (6 x) was added in the ratio of 1:5 with the DNA, which had 
been diluted with autoolaved water. Agarose gel was prepared by the addition of 
1% agarose in 40ml of TAE buffer and heating in the microwave oven until the 
agarose was dissolved. 5)^ 1 of ethidium bromide (lOmg/ml) was mixed with the 
liquid agarose before pouring into the chamber of the electrophoresis kit (Gibco 
Horizon 58 with Model 200 power pack). The appropriate combs were inserted 
to form the wells in the gel. After the gel had set, TAE buffer was added to cover 
the gel. The DNA in the gel loading buffer was loaded into the wells and the 
electrophoresis started. The gel was examined under UV light and an electronic 
image printed.
2.3.6 DNA purification from Agarose Gei
Purification of DNA fragments from agarose gel was performed using the 
QIAquick Gel Extraction kit (Qiagen, West Sussex, U.K.).
2.3.7 DNA sequencing
Sequencing of DNA was performed at the Protein and Nucleic Acid Chemistry 
Laboratory (PNACL) of Leicester University. An ABl Bigdye-terminator ready 
reaction kit was used for the PGR reaction, while a Perkin Elmer ABl 377 DNA 
sequencer was used for the electrophoresis and analysis of sequences.
2.3.8 Construction of Flag-50R and c-myc-50R
The DNA for human 6 opioid receptor (hôOR) in the piasmid pcDNA4 was a kind 
gift from Giaxo Pharmaceuticals.
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The set of PCR oligonucleotide primers used for the construction of Flag-ôOR 
were
Sense oligonucleotide 5’ -
AAAAAAGGGCCCGCCACCATGGACTACAAGGACGACGATGATAAGGAACC
GGCCGCCTCCGCC-3'
This primer introduced an Apa\ site (underlined) followed by the Flag epitope tag 
at the 5' end. The Kozak sequence is in bold.
Antisense oligonucleotide 5’ -  TGGTGTAGATGAGGGGGGAGGGGG-3'
This primer added an Xba\ site (underlined) at the 3’ end followed by a stop 
codon.
The set of PGR oligonucleotide primers used for the construction of c-myc-ôOR 
were
Sense oligonucleotide 5’ -
AAAAAAGGGGGGGCCACCATGGAAGAAAAAGTTATTTGTGAAGAAGATCTG
GAAGGGGGGGGGTGGGGG-3'
This primer introduced an Apa\ site (underlined) followed by the c-myc epitope 
tag at the 5‘ end. The Kozak sequence is in bold.
Antisense oligonucieotide 5’ -  TGGTGTAGATGAGGGGGGAGGGGG-3'.
This primer added an Xba\ site (underlined) at the 3' end followed by a stop 
codon.
The PGR amplified fragments were purified by agarose gel (1% %) 
electrophoresis followed by gel extraction. The fragments were digested with 
Apa\ and Xba\ before ligating to pcDNA3.1(-) (Stratagene) using these restriction 
sites. Both DNA constructs were fully sequenced.
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2.3.9 Construction of Flag-ôOR-GFP and c-myc-80R-GFP
The Flag-ôOR and c-myc-ÔOR cDNA was used as a template to which the GFP 
sequence was fused to the C-terminus. This necessitated the removal of the 
stop codon in the receptor cDNA and the introduction of a new restriction site so 
that the 5’ end of the GFP cDNA could be ligated in frame with the 3’ end of the 
FlagôOR and the c-myc-ôOR. Xba\ was chosen as the linker as a primer to 
generate the GFP with a 5’ Xba\ site was available.
PCR of the GFP cDNA was performed using the following primers:
Sense oligonucleotide 5’ -C TAG TGTAGAAGTAAAGGAGAAGAACTTTTCAC-3’
The underlined bases refer to the restriction site for Xba\ therefore this primer 
provides the generation of GFP with a 5’ Xba\ site.
Antisense oligonucieotide 5’-TGGTGTAGATTATTTGTATAGTTGATGGATGGG-
3’
The underlined bases refer to the restriction site for Xba\ therefore this primer 
provides the generation of GFP with a 3' Xbal site.
The sense primer used previously to generate a 5’ Xba\ site on the receptor was 
used again here, the following primer was used to remove the stop codon, 
replacing it with an Xba\ site.
Antisense oligonucleotide 5’ -  TGGTGTAGATGAGGGGGGAGGGGG-3'
The underlined bases refer to the restriction site for Xbal, therefore this primer 
provides the generation of an Xbal restiction site and the removal of the stop 
codon of the 6 0 R.
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The PCR fragments were purified by gel electrophoreses and extraction. 
Restriction enzymes Apa\ and Xba\ were used to digest the receptor fragment 
and Xba\ was used to digest the GFP fragment which was then ligated to 
pcDNA3.1(-) using the Apa\ and Xbai restriction sites. As the GFP generated 
contained Xba\ sites at both the 5’ and 3’ end the cDNA isolated from the 
successfully ligated clones was digested with Apa\ and EcoRV restriction 
enzymes, followed by gel electrophoresis and clones containing the GFP in the 
correct orientation were identified.
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2.4 Assays
2.4.1 Cell membrane radioligand binding
The expression of the ôOR in stable cell lines and in transiently transfected cells 
was assessed by [^H]diprenorphine or [^H]naltrindole binding studies. These 
were performed in triplicate in borosilicate glass tubes, containing the following 
mix:
Membrane protein (0.75mg/ml) 20|liI
Assay buffer (50mM Tris/HCI, pH7.5, 5mM MgCl2, 1 mM EDTA) 140]liI
[^H]diprenorphine or [^H]naltrindole (15nM or 50nM) 20\x\
Naloxone (3mM) or assay buffer 20p,l
Total volume 200|Lil
The reaction mix was incubated at 25°C for 45min. Binding was stopped by the 
addition of 2.5ml of ice-coid wash buffer (50mM Tris/HCI pH7.5, 0.25mM EDTA), 
followed by vacuum filtration through GF/C filters to remove the free radioligand 
from the membrane. The filters were washed 3 times with ice-cold wash buffer, 
and air-dried before adding to 5mi of liquid scintillant. The vials were counted 
after an overnight incubation In a Beckman LS6500 scintillation counter using 
the ^H counting channel. The specific binding was calculated by subtracting the 
counts in the presence of the competing antagonist naloxone from the total 
counts. Receptor expression level was expressed as fmol/mg, using the specific 
activity of the radiolabels ([^H]diprenorphine, 128.8 dpm/fmol or [^H]naltrindole, 
73.3 dpm/fmol).
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The binding affinity of the receptors was assayed similarly using increasing 
concentrations of f  H]naltrindole.
2.4.2 Intact cell radioligand binding
Intact cell binding was performed using two different methods, the first method 
being similar to that described above for the membrane binding with the addition 
of 2 X 10® cells in place of the membranes. In this case the assay buffer was 
Krebs Ringers Hepes (KRH) buffer.
KRH buffer
NaCI 20mM
KCI
M gS04
CaCl2
Hepes
N a 2 H P 0 4
Glucose
5mM
1.2mM
1.2mM
20mM
1.2mM
lOmM
Bovine Serum Albumin 0 .1%
The pH was 7.4.
This assay was also performed in the presence of 3nM anti-c-myc-Eu^^ and 
15nM anti-Flag-APC antibodies, the assay buffer used was 50% Newborn calf 
serum /  PBS and the incubation time was 2 h at room temperature. The
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radioligands used to determine the receptor expression levels were 
[®H]naltrindole (73dpm/fmol), pH]DADLE (123dpm/fmol), [^H]dihydroalprenolol 
(136dpm/fmol) and [®H]CGP 12177 (91 dpm/fmol).
The second method of intact cell binding was performed using cells that were 
attached onto the surface of 12 well dishes. The antagonist pH]naltrindole was 
used in this case and the assay mix was as described above with the assay 
buffer being the (KRH) buffer. On each 12 well plate 1 well was not used in the 
binding assay but the cells were detached from the surface of the well and 
counted. The mean value obtained for the cells per well was used, with the 
specific activity of [®H]naltrindole (73.3dpm/fmol) and Avogadro’s number to 
calculate the receptor number per cell.
2.4.3 Adenylate cyclase catalytic activity
The catalytic activity of adenylate cyclase was assayed in accordance with 
Wong (1994) based on the use of [^Hjadenine. Cells were split into 24 well 
dishes 24 h before the addition of [^H]adenine (0.5(xCi per well) in DMEM for an 
overnight incubation.
The cells were then washed in DMEM, 2mM L-glutamine, 20mM HEPES (pH7.4) 
containing IBMX, which is a non-selective inhibitor of phosphodiesterases. 
DADLE was added in this medium in the presence of 50p.M forskolin, at 37°C for 
30min. The reaction was stopped by the addition of 0.5ml of stop solution 
(5%TGA, 1mM ATP, Im M  cAMP). The plates were either stored at -20°C or 
incubated at 4°G before separating the nucleotides.
Separation of the cAMP from the other adenine nucleotides is based essentially 
on the method of Salomon et al. (1974). The dowex and alumina columns were 
set up according to Farndale et al. (1991). Columns were constructed from 5ml 
syringes with a glass wool plug to prevent loss of the resin. Racks containing the 
columns were aligned over each other while the assay took place. Before each 
use the columns were primed as follows: the dowex columns were washed with
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several volumes of water, 2  volumes of HCI (1M) followed by 5 further volumes 
of water. The alumina columns were washed with 5 volumes of imidazole (0.1 M). 
The column bed volumes were at least 1ml of the respective resin.
Separation of the [®H]cAMP from the other labelled components ([^H]ATP, 
[^H]ADP, [^H]AMP, [^HJadenine) begins with the dowex column, which is 
negatively charged and although no components bind to the dowex the cAMP is 
selectively retained which allows the other components to be removed by 
washing the dowex with water (Farndale et al., 1991). The alumina column binds 
cAMP with low affinity and this is competed off using imidazole.
The 0.5ml stop solution sample was added to the dowex column, followed by the 
addition of 3ml of deionised water. The eluant was collected in scintillation vials 
to which 5ml of scintillation fluid had previously been added. This contains 
predominantly the adenine nucleotides with the exception of fHJcAMP. The 
dowex columns were then placed on top of the alumina columns and 1 0 ml of 
deionised water added to the dowex columns. This passed through the dowex 
and onto the alumina, including the [^H]cAMP. The dowex columns were then 
removed and the alumina columns washed with 10ml of imidazole (0.1 M). The 
eluate was collected into scintillation vials containing 9ml of liquid scintillant. 
Both sets of vials were counted in the Beckman scintillation counter using the 
pH] channel. Results were expressed as the ratio of pHjcAMP to total 
pHjadenine nucleotides (xlOO) which was then expressed as a percentage 
inhibition of the forskolin stimulation in the absence of any agonist.
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2.4.4 High affinity GTPase activity assays
High affinity GTPase assay was performed essentially as described in Gierschik 
et al. (1994). An assay mix for 100 tubes was prepared as follows:
Creatine Phosphate (0.4M)
Volume (|Lil)
250
Creatine Phosphokinase (2.5U/ml) 200
ATP (0.04M; pH7.5) 
App(NH)p 
Ouabain (0.01 M)
NaCl (4M)
MgCl2 (1M)
DTT (0 .1M)
EDTA (0.02M; pH7.5) 
Tris/HCI (2 M; pH7.5) 
GTP (0.1 mM) 
[y®^P]GTP 5\iC\
250
25
1000
250
50
200
50
200
50
Final concentration 
20mM 
0 .1 U/ml 
2mM 
0.2mM 
2mM 
200mM 
10mM 
4mM 
0.2mM 
80mM 
1|4M 
50nCi
The volume was then made up to 5000^1 by the addition of deionised water.
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The assay mix was left on ice until it was added to the assay tubes.
1.5ml eppendorf tubes were used, containing:
Membrane protein (0.5mg/ml) 2Q\û
Agonist or water or GTP* 10p.1
Deionised water 20\i\
Assay m ix  5 0 |liI
Total volume 100p,l
*Each sample was assayed in the presence of each of these components. The 
addition of water estimates the basal activity, addition of agonist gives the 
stimulated activity and the GTP (100|aM final) gives the non-specific activity.
The assay tubes were set up in triplicate and were incubated at 37°C for 20min 
before the addition of 900jal of an ice-cold charcoal solution (5% activated 
charcoal in 10mM H3PO4) to each tube, which terminates the reaction. The tubes 
were then spun at 3000rpm for 5min in a bench top centrifuge at 4°G. The 
supernatant contains the free Pi and 500|il of this was removed and transferred 
into scintillation vials for Gerenkov radiation counting in a Beckman counter. 
High affinity GTP hydrolysis rate (pmol/min/mg) was obtained by subtracting the 
counts from GTP (100p,M final) control tubes, taking into consideration the 
specific activity of the [y^^P]GTP, the concentration of unlabelled GTP in the 
assay (0.5jiM), the membrane protein concentration and the incubation time. 
Results were presented as the percentage increase of the high affinity GTPase 
activity by agonist, over basal.
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2.4.5 Time-resolved fluorescence resonance energy transfer 
(TR-FRET) assays
Heterogeneous TR-FRET assay
Cells were transiently transfected at 80-90% confluency in 6 cm^ dishes. A total 
of Sfxg of DNA per dish was transfected using Lipofectamine™ reagent (Gibco 
Life Technologies).
The cells were harvested in PBS 48 h after transfection and a sample diluted in 
PBS/0.5mM EDTA before counting using a haemocytometer. 5x10® cells were 
incubated with 3nM anti-c-myc-Eu^^ antibody and 15nM anti-Flag-APC antibody 
(unless otherwise stated) for 2 h at room temperature in a 100|al volume. Mixing 
of samples was performed during the incubation on a rotating wheel. The 
incubation was performed in 50% Newborn calf serum /  PBS. After the 
incubation the cells were washed with 2 x 1 ml of PBS and re-suspended in 30ml 
PBS before being transferred to a well of a black 384 plate (Nunc). The TR- 
FRET measurement was performed using a Victor or a victor^ fluorescence plate 
reader. The TR-FRET signal being measured after a 50 j l i s  delay following 
excitation of the sample at 320nM for the victor^ and 340nm for the Victor 
fluorescence plate reader. Data were collected for 200jis with a cycle time of 1 s 
at both 615nm and 665nm, the emission maxima of Europium and ARC 
respectively.
Homogeneous TR-FRET assay
1-8 X 10® cells were incubated in a total volume of lOOpil containing 50% 
Newborn calf serum /  PBS and varying concentrations of anti-c-myc-Eu^^ and 
anti- Flag -APC in a 96 well, black maxisorb plate (Nunc). TR-FRET signals were 
read at 30min intervals for up to 3 h. The TR-FRET measurement was 
performed in a Victor^, with a 50jis delay after excitation of the sample at 320nM. 
Data were collected for 2 0 0 |is with a cycle time of Is  at both 615nm and 665nm.
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Between readings the piate was kept in the dark, at room temperature, with 
mixing on an orbital plate shaker.
2.5 Other Protocols
2.5.1 Preparation of cell membranes
Plasma membrane containing samples were prepared from frozen cell pastes, 
which had been stored at -80°C. The cell pellets were resuspended in TE buffer 
and then ruptured by homogenisation with a hand held Teflon-on-glass 
homogeniser, followed by passing the sample through a 25 gauge needle 10x. 
Any non-ruptured cells and cell nuclei were removed by centrifugation at 
1200rpm for 10min on a bench top centrifuge at 4°C. The supernatant fraction 
was removed and further centrifuged at 75,000 rpm for 30min in a Beckman 
Optima TLX Ultracentrifuge (Palo Alto, CA) with a TLA 100.2 rotor, to pellet the 
plasma-membranes. The membranes were resuspended in TE and the protein 
concentration determined after the membranes were passed through a 25 gauge 
needle lOx to ensure they were in a homogeneous mixture. The membranes 
were aliquoted and stored at -80°C until required.
2.5.2 Labelling anti-Flag (M5) antibody with cross-linked 
Allophycocyanin (APC)
1.5mg of anti-Flag (M5) antibody was reduced by the addition of 25 |liI of 1M DTT 
and incubating at room temperature for 30min. The reduced antibody was then 
desalted into 20mM Na3P0 4 , pH 7.5, using a Superdex 200 gel filtration column 
(Pharmacia) at a flow rate of 1.5ml / min using an FPLC system (Pharmacia). 
The protein was eluted in 9ml, to this lOjiM of SMCC x 1 APC was added and 
the reaction incubated overnight at 4°C during which the SMCC-APO reacts with 
the free sulfhydryl groups (-SH) generated by the reduction of the protein with 
DTT. Any un reacted sulphydryl groups on the antibody were blocked by the 
addition of 1Q0|xM N-ethyl maleimide one h at 4°C. Labelled antibody was
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separated from unlabelled antibody by gel filtration on a Superdex 200 column, 
run at 1.5ml / min with in PBS, 0.05% Tween20. The elution profile showed a 
good separation of the labelled antibody from the free SMCC-APC. The 
concentration and the labelling ratio were determined by the absorbance at 
650nm and 280nm and calculating the concentrations of APC and protein using 
their respective extinction co-efficients.
2.5.3 Electrophoresis of polyacrylamide gels
Approximately 10p,g of protein was loaded per lane of a 15 well 2-20% PAGE gel 
or 7% Tris-actetate gel (Novex). For the immunoprecipitates 8|il of the total GOjuil 
was run per lane. Tris-acetate running buffer (50mM Tris base, 50mM Tricine, 
0.1% SDS, pH8.24) was used for the NuPage Tris-Acetate gels. The samples 
were then run until the dye front was at the end of the gel, with running 
conditions of 200 constant volts, which took approximately one hour.
2.5.4 Protein transfer onto membrane
The proteins were then transferred to nitrocellulose using electroblotting. The 
nitrocellulose was placed next to the gel ensuring there were no air bubbles 
between them, this was then sandwiched between two pieces of filter paper 
which had been soaked in transfer buffer, again ensuring no air bubbles were 
present. This was placed with the nitrocellulose on the anode side of the gel 
transfer apparatus. The transfer tank was then filed with blotting buffer (20% 
methanol, 25mM Tris and 192mM Glycine). The protein transfer conditions were 
30 constant volts for 1 h.
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2.5.5 Incubation with antibodies
Following the transfer of the protein to the nitrocellulose the nitrocellulose was 
then blocked for one hour with 5% Marvel in PBS/0.1%Tween20. The 
nitrocellulose was then washed at room temperature for 30min with 3 changes of 
PBS/ 0.1% Tween20. The nitrocellulose was then incubated for at least 1 hour at 
room temperature (or overnight at 4°C), with the appropriate primary antibody 
diluted in 1% Marvel in PBS/ 0.1% Tween20. The nitrocellulose was then 
washed for 30min at room temperature with PBS/ 0.1% Tween20 for 1 hour to 
remove any unbound primary antibody with at least 3 changes of PBS/ 0.1% 
Tween20. The incubation with the peroxidase labelled secondary antibody 
(diluted 1:4000 in 1%Marvel in PBS/0.1 %Tween20), for one hour at room 
temperature. The excess secondary antibody was removed by washing the 
nitrocellulose with at ieast 3 changes of PBS/ 0.1% Tween20. During each wash 
or antibody incubation step the blot was agitated on an orbital shaker.
1° antibodv_____________ dilution 2° antibodv_______ dilution
Anti-Flag (M5) 1:2000 Anti-mouse 1:5,000
Anti-c-myc (9E10) 1:1000 Anti-rabbit 1:10,000
Anti-GFP 1:20,000 Anti-sheep 1:10,000
Anti-p2AR 1:1000 Anti-rabbit 1:10,000
2.5.6 Enhanced cheml-luminescence
Detection of the bound peroxidase labelled secondary antibody attached to the 
blot was achieved using an enhanced chemi-luminescence (ECL) kit from 
Pierce. The nitrocellulose was washed x 3 with PBS/ 0.1% Tween20 before 
placing on a plastic sheet and covering with a 1:1 mixture of the solutions of the 
kit, this was incubated for 5min at room temperature before blotting off the 
excess solution and placing the nitrocellulose between two plastic sheets. A
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signal was obtained when a piece of X-ray film was placed over the 
nitrocellulose for a length of time in the dark room. The film was then developed 
in an X-omat developer (Kodak).
2.5.7 Immunoprécipitation
To prepare cell lysates suitable for immunoprécipitation, transfected HEK293 
cells were washed 3x with PBS before harvesting and resuspending in 1x RIPA 
buffer (unless otherwise stated). The cell suspensions were then placed on a 
rotating wheel in eppendorfs for one h at 4°C. The 2 x RIPA buffer was made as 
a stock and stored at 4°C until required. On the day of the cell lysis the 1x RIPA 
buffer was prepared. The composition of the buffers was as follows:
2 X RIPA buffer
component concentration
Hepes pH7.5 lO O m M
NaCI
TX100
300mM
2% (% )
Na-deoxycholate 1 % (''''/v)
SDS 0.2% (% )
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1x RIPA buffer
2x RIPA
NaP (0.5M) 
EDTA(0.5M; pH 8)
Na phosphate (0.1M) 
ethylene glycol
Volume
25m!
1 ml 
0.5ml
5ml
2.5ml
protease inhibitor cocktail (25x) 800|ul
Final concentration 
1x
1GmM
5mM
lOmM
5%
1x
H2O 15.2ml
Total volume 50ml
immunoprécipitation
Any unlysed cells and large cell debris were removed by centrifugation on a 
bench top centrifuge at 13,000 rpm for 10min at 4°C. The supernatant was then 
taken and the protein concentration determined using the BCA assay. This 
supernatant was referred to as the cell lysate.
500|ig of protein of each sample was removed and the volume made to 800)41 
with 1x RIPA buffer. To this 20)41 of protein-G sepharose resin, (40)41 of a 1:1 
solution of resin : RIPA) which had been equilibrated in RIPA, was added. The 
assay tubes were then place this back on the rotating wheel at 4°C for one h, 
this was to remove any proteins that bound to the protein-G sepharose non- 
specificaily.
The protein-G sepharose was pelleted with a 15 s spin in a bench top centrifuge, 
the cell lysate was removed and added to a fresh eppendorf containing a further
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2 0 |jlI of protein-G sepharose which had been pre-equiiibrated with the antibody 
to be used for the immuno-precipitation. 2|ag of A14 anti-myc anti-body or anti- 
P2AR antibody or 8.6|4g of anti-Flag (M5) antibody was used per sample. The cell 
lysate / antibody / protein-G sepharose mixture was incubated overnight at 4°C 
on a rotating wheel.
The resin was pelleted with a 15 s spin in a bench top centrifuge and the 
supernatant was then removed and discarded. The protein-G sepharose was 
then washed 3 x 1ml of RIPA buffer before the addition of 60|4l of reducing 
sample buffer. The resin was agitated every 15 min to heip the dissociation of 
the proteins from the protein-G sepharose. After 1 h at room temperature the
sample was heated to 85°C for 4min before running on 7% Tris-acetate gels. 8fxl 
of the immunorecipitate was loaded into each well of the 15 well gels.
The other buffers used to generate cell lysates before immunoprécipitation were 
as follows:-
1%TX100 buffer
concentration
Tris-CI pH7.4 50mM
NaCI 300mM
TX-100 1% r/v)
Glycerol 1 0 % (%)
MgCl2 1 .5mM
CaCl2 Im M
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1% NP40 buffer
component 
Tris-CI pH8 
NaCI 
NaF
Na-pyrophosphate
EDTA
EGTA
NP40
concentration 
50mM 
120mM 
20mi\/l 
10mM 
1mM 
5mM 
1% (%)
0.5 % CHAPS buffer
component
Tris-CI pH7.4
NaCI
CHAPS
Glycerol
MgCL
CaCl2
concentration 
50mM 
SOOmM 
0.5% (%) 
10% (%) 
1.5mM 
1mM
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2%SDS buffer
component 
Tris-CI pH8 
2% SDS 
NaCI
concentration
50mM
2%  (7v)
SOOmM
Tween20 buffer
component
Tris-Ci pH7.4
NaCI
Tween20
Glycerol
MgCl2
CaCl2
concentration
50mM
SOOmM
1% (7v)
10% (7v)
1,5mM 
Im M
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2.5.8 Confocal Imaging
HEK293 cells which had been stably transfected with Flag-ÔOR-GFP were 
plated onto sterile glass covers lips 24 h before examination using a Zeiss 
Axiovert 100 laser scanning confocal microscope with a Zeiss Plan-apo 63 x 1.4 
NA oil immersion objective. Experiments were performed in a coversiip chamber 
in Krebs Ringers Hepes (KRH) buffer (pH7.4) at 37°C. Cells were excited at a 
wavelength of 488nm and detected with a 515 - 540nm band pass filter. Images 
were taken at various time-points following the addition of ^\xU DADLE.
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CHAPTER 3
Investigation of homo and heterodimerization of 
epitope tagged 50Rs using co- 
immunoprecipitation
CHAPTER 3
An investigation of homo and heterodimerization of 
epitope tagged ÔORs using co-immunoprecipitation
3.1 Introduction
By using SDS-PAGE, western blotting techniques and co-immunoprecipitation, 
G PCR monomers, dimers and oligomers in membranes of both native tissue and 
of heterologous cells transfected with GPCRs have been identified. Examples 
include the adenosine A1 receptor, which has been identified as homodimers in 
pig brain cortical membranes as well as from rat tissues and as heterodimers 
with the dopamine D1 receptor in co-transfected heterologous cells and in 
neuronal primary cultures (Franco et al., 2000). The dopamine D3 receptor 
forms dimers and tetramers in both brain and in transfected cells (Nimchinsky et 
al., 1997) as does the muscarinic m3 receptor in various brain regions as 
demonstrated by Avissar et al. (1983) using a photoaffinity agent.
SDS-PAGE, a technique described by Laemmli (1970), has been used to 
separate proteins according to their molecular mass. Generally proteins are 
resolved to their respective monomers however, some non-covalent interactions 
between proteins still remain allowing identification of higher molecular weight 
forms. The involvement of di-sulphide bonds in protein-protein interaction can be 
demonstrated by the addition of a reducing agent, usually dithiothreitol or 2- 
mercaptoethanol. A differential pattern of G PGR bands in the presence and 
absence of reducing agent indicates the importance of di-sulphide interaction 
between receptors for the kOR homodimers (Jordan and Devi, 1999) and the 
muscarinic m3 homodimers (Zeng and Wess, 1999). The family 3 receptors 
metabotropic glutamate receptor-1 (Romano et al., 1996) and the Ca^ "*" receptor 
(Fan et al., 1998) demonstrate the di-sulphide interaction to be vital for their 
dimerization.
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Di-sulphide bonds are not the only interaction responsible for GPCR dimerization 
as several studies have also shown the presence of dimeric and multimeric 
receptor species in the presence of reducing agents. Hebert et al. (1996) 
demonstrated P2AR homodimerization under non-reducing conditions but also 
stated that inclusion of reducing agents did not lead to monomerization of this 
receptor. The same was true for the dopamine D3 receptors from brain and in 
transfected cells (Nimchinsky et al., 1997).
Other possible protein-protein interactions are not easily determined by SDS- 
PAGE as shown by the somatostatin SST2A-SST3 heterodimers which were 
resistant to reducing agents but sensitive to high detergent concentrations. This 
suggests that dimerization involves non-covalent hydrophobic interactions 
between the receptors. Again this is not always the case as Hebert et al. (1996) 
stated that P2AR homodimers were stable at high (10%) concentrations of SDS. 
Protein dimers that are resistant to SDS are not only limited to GPCRs as other 
proteins e.g. the a  and p subunits of the major histocompatibility complex form 
an SDS-resistant dimer (Caplan et al., 2000).
As non-covalent interactions can be disrupted using SDS-PAGE the initial use of 
chemical cross-linkers to stabilize dimeric or oligomeric interactions present has 
been widely used. These cross-linkers are small molecules that will covalently 
interact with two molecules in close proximity. Hydrophilic cross-linkers exist 
e.g. 3,3’-Dithiobis[suifosuccinimidyl propionate], (DTSSP), which are membrane 
impermeable and cross-link via celi-surface residues only. Hydrophobic cross­
linkers e.g. Dithiobis[succinimidyl propionate], (DSP), can cross the lipid bilayer 
and cross-link via internal residues or with residues within the membrane itself. 
Cross-linkers can be useful to identify interactions between proteins and the 
different type of cross-linkers can indicate where these interactions take place 
although care has to be taken to ensure that the cross-linking is only between 
two interacting molecules and that spurious results do not occur (Fancy and 
Kodadek,1999).
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Chemical cross-linking has been employed to confirm the presence of P2AR 
(Hebert et a!., 1996), ÔOR (Cvejic and Devi, 1997), dopamine D2 (Ng et a!., 
1996) and chemokine receptor CXCR4 homodimers (Vila-coro et al., 1999) as 
well as ôOR-kOR heterodimers (Jordan and Devi, 1997). Chemokine receptor 
CCR2 dimerization on activation by its ligand was stabilized by chemical cross- 
linking (Rodriguez-Frade et al., 1999) as was the chemokine receptor CCR5 
dimerization induced by its agonist (Vila-Coro et al., 2000).
Co-immunoprecipitation is useful in the identification of GPCR homodimers 
which cannot be identified by investigation of their respective pharmacology. The 
use of specific antibodies for the individual receptors permitted identification of 
heterodimeric complexes between the wild-type dopamine D3 receptor and a 
mutant form of the receptor (D3nf), (Nimchinsky et al., 1997). As it is not 
possible to use specific antibodies to distinguish the respective partners in 
homodimeric receptors, co-expression of differentially tagged receptors has 
been used therefore to identify homodimers. This technique has been used to 
identfy ôOR homodimers (Cvejic and Devi, 1997), P2AR homodimers (Hebert et 
al., 1996) and SST2A and SST3 homodimers as well as heterodimers (Pfeiffer et 
al., 2001).
For ease of immunodetection and detection of homodimer and heterodimer 
species using co-immunoprecipitation the human ôOR was Flag- or c-myc- 
epitope tagged on the N-terminus by PCR. To assess the internalization of the 
Flag-ôOR receptor, GFP was fused to its C-terminus. Radiolabelled antagonist 
binding and high affinity GTPase assays were used to monitor expression and 
activation of these receptors following transient transfection. Cell lines that stably 
express the Flag-ôOR and Flag-ôOR-GFP were established and intact cell 
adenylyl cyclase assays used to determine their signalling capacity. Co- 
immunoprecipitation of Flag and c-myc-tagged receptors was used to investigate 
homodimerization. A variety of conditions were used to elucidate the specificity 
of interaction co-immunoprecipitation of the c-myc-tagged ôOR with other Flag- 
tagged GPCRs.
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3.2 Results
Construction and expression of human ÔOR with an N-terminal Flag or c- 
myc tag and N-termlnally Flag tagged ôOR with a C-terminal GFP.
A PCR strategy was used to incorporate the Flag epitope (Asp-Tyr-Lys-Asp-Asp- 
Asp-Asp-Lys) or the c-myc epitope (Glu-Gln-Lys-Leu-lle-Ser-Glu-GIu-Asp-Leu) 
at the N-terminus of the human ÔOR as described in section 2.3.4. A schematic 
representation of these constructs is shown in figure 3.1. Transient transfection 
of 10jig of each construct into HEK293 celis resulted In expression levels of 887 
± 262 fmol/mg and 731 ± 143 fmol/mg for the Flag-ÔOR and the c-myc-ôOR 
respectively (figure 3.2). Wild type ôOR resulted in an expression level of 3095 ± 
1470 fmol/mg after transient transfection of lOj^g of DNA into HEK293 cells.
Incorporation of a modified form of GFP from Aequorea victoria with enhanced 
autofluorescence properties (Zernicka-Goetz et al., 1997) onto the C-terminus of 
the cDNAs of both the Flag and c-myc-tagged forms of the human 6 0 R was also 
performed using a PCR-based strategy (section 2.3.4). These fusion proteins 
encode single open reading frames In which the C-terminus of the ÔOR was 
linked directly to the N-terminus of the GFP after removal of the stop codon of 
the receptor (figure 3.1). Transient transfection of 10|ig of each DNA was 
performed in HEK293 cells and resulted in expression levels of 530 ± 240 and 
469 ± 234 fmol/mg for the Flag-ôOR-GFP and the c-myc-ôOR-GFP respectively 
(figure 3.2).
Signalling capacity of N-terminally tagged ôOR receptors with and without 
a C-termlnal GFP
The signalling capacity of transiently expressed receptors was assessed by 
measurement of agonist stimulated high affinity GTPase activity. The level of 
GTPase activity over basal is shown in figure 3.3. Flag-ÔOR and c-myc-ÔOR 
demonstrated 17.5% ± 6.8% and 35.6% ± 8% increase respectively in GTPase
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activity over basal. Flag-ôOR-GFP and c-myc-ôOR-GFP showed 7.6% ± 6.1% 
and 9.6% ± 7% agonist induced increase in GTPase activity over the basal 
respectively. Wild type 6 0 R gave an increase over basal GTPase activity of 51% 
±6.
Production of HEK293 clones which stably express Flag-ôOR or Fiag-ÔOR- 
GFP and assessment of their expression and functionality
HEK293 cells were stably transfected with Flag-ÔOR or Flag-ôOR-GFP and 
receptor expression level was assessed using [^H]naltrindole binding at a single 
concentration (5nM) of the radiolabelled antagonist in intact cells. The receptor 
expression level of the clones was assessed and is shown in figure 3.4. The 
signalling capacity of the clones stably expressing the receptors was measured 
in the presence of IjiilVI of the 6 0 R agonist DADLE. Direct stimulation of the 
adenylyl cyclase was achieved by including SO i^M forskolin in the assay mix, 
which stimulated the adenylyl cyclase activity resulting in elevated cAMP levels. 
Inhibition of the cAMP levels was evident as the receptor was functioning via a 
Gai-family G-protein. The inhibition of the adenylyl cyclase activity for the stable 
clones tested is shown in figure 3.5.
Clone F28 expressing Flag-60R and clone FG6 expressing the Flag-60R-GFP 
were chosen and used in further work. Antagonist saturation binding studies 
were performed on clone F28 cells with up to 8nM [^H]naltrindole (figure 3.6A). 
The data were transformed and plotted as a Scatchard plot (figure 3.6 B). A 
dissociation constant (Kd) of 1.38 ± 0.47 nM for the Flag-60R was calculated and 
the maximum receptor level obtained (Bmax) for Flag-60R was 20.36 ± 3.87 
pmol/mg protein.
The signalling capacity of the stable clones was further assessed using a dose- 
response to DADLE and its effect on the forskolin stimulated levels of cAMP 
(figure 3.7). The EC50 for the Flag-ÔOR and Flag-60R-GFP was 0.02nM ± 0.009 
and 0.02nlVI ± 0.011 respectively. This demonstrated that the addition of the GFP 
to the 0  terminus of the receptor did not eliminate its ability to inhibit adenylyl
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cyclase, as there was no statistically significant difference in the ECso’s observed 
(p > 0.05).
Internalisation of the Flag-ÔOR-GFP was followed in real time using confocal 
microscopy, after the addition of lOOnM DADLE, to live cells. A punctate pattern 
of GFP fluorescence was observed within the cells 5 min after agonist 
stimulation (figure 3.8). This agrees with the internalisation rate observed by Chu 
et al. (1997) where the was shown to be <10 minutes. This demonstrated that 
the addition of GFP at the C terminus of this receptor did not prevent 
internalisation of the receptor.
Immunodetection of Flag and c-myc-tagged 60R with and without GFP
Immunodetection of Flag-ôOR and c-myc-ÔOR with and without the C-terminal 
GFP was performed and shown in figures 3.9A and B respectively. Membranes 
of transiently transfected HEK293 cells were resolved using SDS-PAGE and 
electro-blotted onto nitrocellulose before immunoblotting with anti-Flag and anti- 
c-myc-antibodies respectively. ÔOR receptor migrated at 60 kDa with another 
band running at 35kDa. ÔOR-GFP migrated at 100 kDa with another band at 
60kDa. Higher molecular weight species that may represent dimers and 
oligomers of the receptors were also observed (figures 3.9A and B).
Constitutive ôOR homodimers are detected by co-immunoprecipitation
Following transient expression of either form of the receptor in HEK293 cells 
these could be immunoprecipitated with appropriate anti-c-myc (figure 3.10A) or 
anti-Flag antibodies (figure 3.1 OB). No immunoprécipitation was observed, 
however, when the antibody/epitope-tagged GPCR combinations were reversed, 
confirming the specificity of immunoprécipitation (Figure 3.1 OA and 3.1 OB).
Immunoblotting of SDS-PAGE resolved membrane fractions expressing the c- 
myc-tagged 6-opioid receptor with the anti-c-myc antibody resulted in detection 
of a 60 kDa polypeptide (figure 3.1 OA). Such a polypeptide was not detected by
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the anti-c-myc antibody in membranes expressing the Flag-tagged form of the 
receptor (figure 3.10A) which confirmed the specificity of immunodetection with 
the anti-c-myc antibody. Similarly the anti-Flag antibody specifically recognised 
the Flag-ôOR when expressed in membrane fractions (figure 3.1 OB). Co­
expression of the c-myc and the Flag epitope-tagged forms of the ÔOR, followed 
by immunoprécipitation with the anti-Flag antibody and immunoblotting with the 
anti-c-myc antibody aiso resulted in detection of the 60 kDa c-myc-tagged 
Ô opioid receptor (Figure 3.10A). Equivalent results were obtained when the 
protocol was reversed and Immunoprécipitation of cells co-expressing the two 
epitope-tagged forms of the .Ôopioid receptor was performed with the anti-c-myc 
antibody followed by immunoblotting with the anti-Flag antibody (figure 3.1 OB). 
However, expression of either the c-myc or Flag-tagged ôOR alone failed to 
result in detection of the 60 kDa polypeptide using either of these two protocols 
(Figures 3.1 OA and 3.1 OB). Such results confirm previous data on the ability to 
detect homo-oligomers of co-expressed but differentially tagged forms the Ô- 
opioid receptor (Cvejic and Devi, 1997).
Separate expression of the c-myc and the Flag epitope-tagged forms of the 6- 
opioid receptor followed by physical mixing of cell lysates prior to 
immunoprécipitation with either antibody also failed to result in co- 
immunoprecipitation of the two forms of the receptor (figure 3.10c). 
Immunoprécipitation of ôOR resulted in the detection of co-transfected c-myc- 
ÔOR with GFP fused at its C-terminus (figure 3.10c).
Effect of ligands on co-immunoprecipitation of the ôOR
Cvejic and Devi (1997) demonstrated via cross-linking, that agonists decreased 
the level of ÔOR homodimerization whereas antagonists had no effect. An 
attempt to repeat these results was unsuccessful as after cross-linking with DSP 
the receptors did not resolve on SDS-PAGE or Tris-Borate gels (data not 
shown).
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The effect of ligands was then investigated using the co-immunoprecipitation 
technique described above in the absence of cross-linkers, in the presence of 
ligand. HEK293 cells transiently transfected with c-myc-ÔOR and Flag-ôOR were 
incubated with a final concentration of lOOnM of either the agonist DADLE 
(figure 3.11) or the antagonist naltrindole (figure 3.12) before production of the 
cell lysates prior to immunoprécipitation. Immunodetection was performed with 
anti-c-myc antibody after immunoprécipitation with anti-Flag antibody (figures 
3.11 and 3.12). No effect of either ligand was demonstrated on the monomeric 
and potential dimeric ôORs identified.
Heterodimerization between 60R and other GPCRs can be detected by co- 
immunoprecipitation
Heterodimerization between ÔOR and other GPCRs was investigated using the 
co-immunoprecipitation technique described above. Immunoprecipition was 
performed with anti-Flag antibody and immunodetection with anti-c-myc antibody 
(figure 3.14, lanes 1-5). Immunoprécipitation with anti-c-myc antibody and 
detection with anti-Flag antibody (figure 3.13, lanes 7-11) was also performed. In 
each case, equal amounts of DNA for each construct were transiently 
transfected into the HEK293 cells. The Flag-tagged receptors co-transfected 
were the IP prostanoid receptor-GFP (figure 3.13, lanes 5 and 11), the IP 
prostanoid receptor (figure 3.13, lanes 4 and 10), the piAR-GFP (lanes 3 and 9) 
and the P2AR-GFP (lanes 2 and 8). Co-immunoprecipitation between c-myc-ôOR 
and Flag-piAR-GFP, c-myc-ôOR and Flag-P2AR-GFP and between c-myc-ôOR 
and Flag-IP prostanoid receptor-GFP (figure 3.13) was observed. Co- 
immunoprecipitation of c-myc-ôOR with Flag-IP prostanoid receptor was not 
observed (figure 3.13). Immunoprécipitation with anti-c-myc antibody and 
detection with anti-Flag antibody revealed potential dimeric forms of Flag-ôOR 
receptor (figure 3.13).
Constitutive heterodimerization between the ôOR and the closely related ^OR 
was established on transient transfection of HEK293 cells with c-myc-ôOR and 
Flag-p,OR prior to co-immunoprecipitation experiments. Immunoprécipitation was
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performed with anti-Flag antibody and immunodetection with anti-c-myc- 
antibody. Monomeric and potential dimeric forms of the c-myc-ôOR were 
identified (figure 3.14). George et al., (2000) and Gomes et al., (2000) have 
since confirmed the interaction between these two opioid receptor subtypes.
When the c-myc-tagged 8-opioid receptor was co-expressed along with the 
human Ps-adrenoceptor, co-immunoprecipitation experiments akin to those 
described above but now using combinations of the anti-c-myc antibody and an 
anti-p2-adrenoceptor antibody, were able to provide evidence for the presence of 
hetero-interactions between these two GPCRs (figure 3.15). 
Immunoprécipitation of the P2-adrenoceptor resulted in the presence of the c- 
myc-tagged 8-opioid receptor in the precipitated sample, which could be 
detected by immunoblotting following resolution of the sample by SDS-PAGE. A 
second polypeptide with mobility consistent with a dimer containing the c-myc- 
tagged 8-opioid receptor was also detected (figure 3.15). Neither of these bands 
was detected when the human P2-adrenoceptor was expressed in the absence 
of the c-myc-tagged 8-opioid receptor and then immunoprecipitated (figure 3.15). 
Equivalent results were obtained when the c-myc-tagged 8-opioid receptor was 
co-expressed with a form of the p2-adrenoceptor that had been C-terminally 
tagged with enhanced yellow fluorescent protein (eYFP) or with a form of the P2- 
adrenoceptor tagged at the N-terminus with the Flag epitope and at the C- 
terminus with green fluorescent protein (GFP) (figure 3.15). Immunoprécipitation 
of either of these modified forms of the Pa-adrenoceptor resulted in co­
precipitation of the c-myc-tagged 8-opioid receptor and detection of both 
monomeric and potential dimeric species. These rather unexpected observations 
led us to consider whether such co-immunoprecipitation approaches following 
transient transfection of cells might produce artefactual resuits following 
solubilization of GPCRs from the membrane environment, a concept which was 
investigated further.
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Co-immunoprecipitation of human ôOR with P2AR
The solubilization conditions used to release the receptors from the membrane 
environment were investigated to ensure the lysis conditions used were not 
responsible for the homo and hetero-interactions found. Co-immunoprecipitation 
of the c-myc-ôOR with Flag-ÔOR or with the Flag-PaAR-GFP was performed on 
cell lysates that had been prepared using a range of solubilization buffers. 
Constitutive ôOR homodimerization was Indicated by immunoprecipitatation of 
the Flag-ôOR, immunodetecting with anti-c-myc-antibody as well as 
immunoprécipitation with anti-c-myc-antibody with detection by anti-Flag 
antibody (figure 3.16A and B). Constitutive heterodimerization of c-myc-ôOR with 
Flag-psAR-GFP was indicated under the same combination of 
immunoprécipitation and imunodetection conditions (figure 3.16A and B). The 
solubilization buffers which gave successful co-immunoprecipitations contained 
either 1% TX100, 1% NP40 or 0.5% CHAPS. The solubilization buffer containing 
1% Tween20 did not indicate the presence of any homo or heterodimers. 2% 
SDS showed heterodimerization of 60 R with Flag-p2AR-GFP when 
immunoprecipitating with anti-c-myc antibody and detecting with anti-Flag 
antibody (Figure 3.16A, lane 3). The 2% SDS solubilization buffer did not 
indicate corresponding heterodimerization when immunodetection was with anti- 
c-myc antibody after immunoprécipitation with anti-Flag antibody (figure 3.16B, 
lane 3) The 2% SDS containing solubilization buffer did not indicate the 
presence of any 6 0 R homodimers (figures 3.16A and B). The CHAPS containing 
solubilization buffer was able to indicate homodimers of ôORs. 
Heterodimerization between the c-myc-ôOR and Flag-p2AR-GFP (figure 3.16A) 
was also indicated. However, heterodimerization between c-myc-ÔOR and Flag- 
P2AR-GFP when immunoprecipitated with anti-Flag antibody did not reveal any 
c-myc-ôOR (Figure 3.16B).
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Figure 3.1 Schematic representation of Flag-ôOR, c-myc-ÔOR, Flag-ôOR- 
GFP and c-myc-ÔOR-GFP
Homologous primers allowed the introduction of A) Flag and B) c-myc epitopes 
at the N-terminus of the 6 0 R preceeded by an Apa\ restriction site and an Xba\ 
site at the C-terminus to permit sub-cloning into pcDNA3.1 (-). GFP was amplified 
using PCR to introduce an Xba\ site at either end permitting ligation to the C- 
terminus of the receptor constructs C). The orientation of the resulting DNA was 
determined by digestion of these constructs with Xba\ and E coR I.
Apal
As p-T y r- Lys-Asp-As p-As p-As p- Lys -
Xbal
ÔOR
B
Apal
Glu-Gln-Lys-Leu-lle-Ser-Glu-Glu-Asp-Leu -
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ÔOR
Apal Xbal Xbal
Flag or c-myc- ÔOR
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Figure 3.2 Estimation of 50R expression levels in membranes of 
HEK293 cells after transient transfection using a single 
concentration of [^H]dlprenorphlne
The specific binding of [^H]diprenorphine to membranes of HEK293 cells which 
had either been mock transfected or transiently transfected with ÔORs was 
assessed. Non-specific binding was determined in the presence of 300fjiM 
naloxone. The specific [^H]diprenorphine binding was obtained by subtraction of 
the non-specific binding from the total binding. The specific binding was 
expressed as fmol of [^H]diprenorphine bound per mg membrane protein. 
[^H]diprenorphine specific binding presented are the mean ± S.E.M. of three 
independent experiments performed in triplicate.
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Figure 3.3 High affinity GTPase activity of transiently transfected 60R 
constructs.
The DADLE-stimulated (1|4M) high affinity GTPase activity of membranes of 
HEK293 cells, which had been either mock transfected or transiently transfected 
with ÔOR constructs was assessed. Basal, non-specific and DADLE-stimulated 
GTPase were calculated. The percentage increase over basal is shown and is 
the mean ± S.E.M. for 5 independent experiments performed in triplicate.
II
0)I 20
oo
E
ccoCO
u.
cco
E
6
%
?
S’
Q.
LL
O
DC
0
1  £ 
Ô
CC
s
(Da>*
89
Figure 3.4 Intact cell [^H]naltrindole binding on stable cell lines 
expressing Flag-ôOR or Flag-ôOR-GFP.
Whole cell binding experiments were performed on the stable clones expressing 
Flag-ôOR or Flag-ôOR-GFP. The specific [^H]naltrindole binding was assessed 
by subtracting the non-specific binding (determined in the presence of 300pM 
naloxone) from the total binding. The specific binding is expressed as receptor 
number per cell x 1000). This graph is a typical representation of two 
independent experiments performed in triplicate.
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Figure 3.5 Intact cell adenylyl cyclase activity of ôOR stable cell lines In 
the presence of 1^M DADLE and SO^M forskolin
Stable clones expressing Flag-ôOR or Flag-ôOR-GFP were assessed for their 
ability to inhibit adenylyl cyclase activity after stimulation by 1pM DADLE. The 
inhibition was measured in the presence of 50pM forskolin, which stimulates 
adenylyl cyclase resulting in increased levels of cAMP. The data are the 
percentage decrease of the forskolin stimulation. This graph is a typical 
representation of two independent experiments performed in triplicate.
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Figure 3.6 Determination of Kd and Bmax of stabie cione F28 expressing 
Fiag-ÔOR in HEK293 ceiis
A) Saturation binding performed on membranes of clone F28 cells, with 
increasing concentrations of [^H]naltrindole. Non-specific binding was 
determined at each data point in the presence of SOOjuM naloxone. B) 
Transformation of the specific binding data to generate a Scatchard plot. The 
data shown here are a representative experiment, which was performed on two 
individual occasions.
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Figure 3.7 Adenylyl cyclase activity dose response to DADLE In stable 
cell lines after stimulation of the cells with forskolin.
HEK293 cells which were stably transfected with Flag-ôOR (clone 28) or Flag- 
ôOR-GFP (clone 6 ) were assessed for their ability to inhibit forskolin stimulated 
adenylyl cyclase activity in the presence of increasing concentrations of DADLE. 
The results are presented as the percentage of the forskolin stimulation. IC50 
was determined as 0.02nM ± 0.009 for Flag-ôOR and 0.02nM ± 0.011 for Flag- 
ôOR-GFP. Data are the mean ± S.E.M. of three independent experiments 
performed in triplicate. Statistical analysis has shown there to be no significant 
difference between these ICSO's (p > 0.05)
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Figure 3.8 Internalisation of Flag-ÔOR-GFP In real time after stimulation 
with lOOnM DADLE
Clone FG6 cells were plated onto glass coverslips 24 hours before examination 
using a Zeiss Axiovert 100 laser scanning confocal microscope with a Zeiss 
Plan-apo 63 x 1.4 NA oil immersion objective. Experiments were performed in a 
coverslip chamber in Krebs Ringers Hepes (KRH) buffer (pH7.4) at 37°C. Cells 
were excited at a wavelength of 488nm and detected with a 515-540nm band 
pass filter. Images were taken at A) 0, B) 5, C) 10 and D) 30min following the 
addition of lOOnM DADLE. The pictures shown are a representative sample of 
the experiment performed at least three times.
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Figure 3.9 Immunodetection of transiently transfected N-termlnally 
epitope tagged ôORs
SDS-PAGE resolved membrane proteins of HEK293 cells transiently transfected 
with N-terminally tagged ÔORs were electro-eluted onto nitrocellulose before 
immunodetection with A) anti-Flag and B) anti-c-myc antibodies. Flag-ôOR and 
c-myc-ÔOR bands were evident at 60kDa with another band evident at 35 kDa. 
Flag-ôOR-GFP and c-myc-ôOR-GFP were evident at lOOKda with another band 
running at 55kDa.
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Figure 3.10 Detection of constitutive ôOR homodimers by co-
immunopreclpltation.
500^g of cell lysate from HEK293 cells transfected with both Flag-ôOR and c- 
myc-ôOR (lane 3 in A and B, lane 1 in 0). Flag-ôOR only (lane A4 and B1) or c- 
myc-ôOR only (lane A5 and B2). In figure 0, lane 2 Flag-ôOR and c-myc-ÔOR- 
GFP receptors were co-expressed. In figure c, lane 3 a mixture of cell lysates 
from cells transfected with either Flag-ôOR or c-myc-ÔOR.
In A and 0  immunoprécipitation was performed with anti-Flag antibody and 
immunodetection with anti-c-myc-antibody, in B immunoprécipitation was with 
anti-c-myc-antibody and immunodetection with anti-Flag antibody.
Cell membranes of HEK293 cells transiently transfected with c-myc-ôOR (lanes 
A1 and B4) or Flag-ÔOR (lane A2 and B5). Immunodetection was performed with 
anti-c-myc-antibody. The blot shown here is representative of experiments which 
were performed at least three times.
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Figure 3.11 Lack of effect of DADLE on constitutive homodimerization of
ÔORs, detected by co-immunoprecipitation
HEK293 cells transiently transfected with both Flag-ôOR and c-myc-ôOR were 
incubated in the presence of lOOnM DADLE for the times indicated, SOOpg of 
cell lysate was then immunoprecipitated with anti-Flag antibody, followed by 
immunodetection with anti-c-myc antibody. The data presented here are a 
representative immunoblot of experiments that were performed three times.
Mr (10^)
105
75
50
Dimer
SOR
Mock 0 10 20 30 60
Time (min)
97
Figure 3.12 Lack of effect of naltrindole on constitutive
homodimerization of 50Rs, detected by co-
immunoprecipitation
HEK293 cells transiently transfected with both Flag-ôOR and c-myc-ôOR were 
incubated in the presence of lOOnM naltrindole for the times indicated, SOOpg of 
cell lysate was then immunoprecipitated with anti-Flag antibody, followed by 
immunodetection with anti-c-myc-antibody Molecular weight markers were run 
in lane M. The data presented here are a representative immunoblot of 
experiments that were performed three times.
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Figure 3.13 Evidence of constitutive heterodimers of ôORs with other
GPCRs using co-immunoprecipitation
Co-immunoprecipitation of 500pg of cell lysates of HEK293 cells transiently 
transfected with c-myc-ôOR and the following, Flag-ôOR (lanes 1 and 7), Flag- 
p2-AR-GFP (lanes 2 and 8) Flag-(3iAR-GFP (lanes 3 and 9), Flag-IP prostanoid 
receptor (lanes 4 and 10) or Flag-IP prostanoid receptor-GFP (lanes 5 and 11). 
Samples in lanes 1 - 5  were immunoprecipitated with anti-Flag antibody and 
immunodetection was with anti-c-myc antibody. Samples in lanes 7-11 were 
immunoprecipitated with anti-c-myc-ôOR and blotted with anti-Flag antibody 
Molecular weight markers were run in lane 6. The data shown here are a 
representative blot of the experiment which was performed at least three times.
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Figure 3.14 Constitutive heterodimerization between ÔOR and pORs,
detected by co-immunoprecipitation
Immunoprécipitation of SOOpg cell lysates of HEK293 cells transiently expressing 
both Flag-ôOR and c-myc-ôOR (lane 1), Flag-pOR only (lane 2), Flag-pOR and 
c-myc-ôOR (lane 4), was performed with anti-Flag-antibody and 
immunodetection with anti-c-myc antibody. In lane 3 HEK293 cells stably 
expressing Flag-ôOR (F28) were transiently transfected with c-myc-ôOR, 
immunoprécipitation was performed with anti-Flag antibody and 
immunodetection with anti-c-myc antibody. Immunoprécipitation of Flag-pOR 
resulted in the co-immunoprecipitation of the c-myc-ôOR. The data shown are a 
representative blot of experiments performed at least three times.
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Figure 3.15 Constitutive heterodimers between ôORs and PzARs are
detected by co-immunoprecipitation
Immunoprécipitation of SOOpg cell lysates of HEK293 cells transiently expressing 
the c-myc-ôOR (lanes 1, 3 and 4) in combination with wild type P2-AR (lane 1 ), 
Flag-P2-AR-GFP (lane 3) or P2-AR-eYFP (lane 4). In (lane 2) the wild type P2-AR 
was expressed alone. Immunoprécipitation was performed with an anti-P2- 
adrenoceptor antibody, and immunodetection with anti c-myc antibody. The non­
specific band present in all lanes represents detection of the anti-p2-AR antibody. 
The data shown are a representative blot of experiments performed at least 
three times.
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Figure 3.16 Constitutive heterodimerization between ôOR and P2AR-GFP 
is evident under various iysis conditions
Cell lysates of HEK293 cells transiently transfected with c-myc-ôOR and Flag- 
ÔOR or with c-myc-ôOR and Flag-P2AR-GFP were produced with lysis buffers 
(described fully in section 2.5.7) containing the following detergents 1) 1% 
TX100, 0.5% Na-deoxycholate, 2) 1% Tween20, 3) 2% SDS, 4) 0.5% CHAPS 5) 
1% NP40, 6) 1% TX-100. 500ju.g of each cell lysate was immunoprecipitated with 
either A) anti-c-myc antibody or B) anti-Flag-antibody. Immunodetection was 
performed with A) anti-Flag antibody or B) anti-c-myc antibody. The blot shown 
is representative of experiments which were performed at least three times.
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3.3 Discussion
The use of epitope tags allows proteins of interest to be identified easily, using 
commercially available antibodies without the need of the lengthy process of 
antibody generation for each protein to be studied. As epitope tags consist of a 
short sequence of amino acids they have only a limited potential to disrupt the 
activity of the protein to which they have been added. For GPCRs epitope tags 
have been widely used without detrimental effects to GPCR ligand binding or cell 
signalling. However, when using epitope tags care has to be taken to ensure that 
is the case.
The human ÔOR with N-terminal Flag or c-myc epitope tags (described in figure 
3.1) were constructed and used within this study. N-terminal epitope-tagging of 
GPCRs has previously been utilized, along with co-immunoprecipitation to 
demonstrate homodimeric ôORs (Cvejic and Devi, 1997) and PaARs (Hebert et 
al., 1996, Hebert et al., 1998). Heterodimeric ÔOR or kOR with PaARs have also 
been demonstrated using N-terminal epitope tags (Jordan et al., 2001), as have 
heterodimers between somatostatin receptor subtypes (Pfeiffer et al., 2001).
Transient expression of these constructs was assessed using a single 
concentration [^H]diprenorphine binding assay which is shown in figure 3.2. The 
expression level of the tagged constructs was found to be lower than that for the 
receptor alone.
The 0-opioid receptor on stimulation can activate the pertussis toxin sensitive G- 
proteins, Gai and Gao. The high affinity GTPase activity via activation of these 
G-proteins was examined to ensure that the addition of the N-terminal tag did 
prevent receptor functionality. The activity of the transiently expressed receptors 
is shown in figure 3.3. DADLE stimulated high affinity GTPase activity in cells 
transfected with the tagged receptors although the level of stimulation was lower 
than that observed for the wild-type receptor. The high affinity GTPase activity of 
the GFP-fusion constructs was particularly poor, therefore stable cell lines were 
set up to confirm that the receptor constructs were indeed functional and that the
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low level of high affinity GTPase measured was, in part, due to the low receptor 
expression level.
Immunoblots confirmed the transient expression of each receptor species in 
HEK 293 cells (figure 3.9). The predicted molecular masses from the amino-acid 
sequence for the Ô-OR and the ô-OR-GFP are 41 and 69 kDa respectively. 
Detection of Flag-ôOR with anti-Flag demonstrated bands at 35kDa and 60kDa 
(figures 3.9A) as well as unresolved material at the top of the gel which may be 
aggregated, or oligomeric receptor species. The membranes containing ÔOR- 
GFP showed bands at 55 and lOOkDa (figure 3.9A). The anti-c-myc detection of 
the corresponding c-myc-tagged constructs gave similar bands (figure 3.9B). 
The 60 kDa species likely represents the glycosylated monomeric Flag and c- 
myc-tagged ôOR with the other bands likely to represent multimeric and 
aggregated receptor species. In each immunoblot of membranes transfected 
with ÔOR alone there was a contaminating band running at approximately 35kDa 
and at 55Kda in the Immunoblot of membranes transfected with 60R-GFP. The 
nature of this polypeptide was not established although may be non-glycosylated 
receptor.
intact cell [^H]naltrindole binding studies on the Flag-ÔOR and Flag-ôOR-GFP 
stable cell lines were performed (figure 3.4) and single point adenylyl cyclase 
assays (figure 3.5) demonstrated the receptor expression level of the clones and 
confirmed their signalling capacity. The Kd determined from Scatchard plot of 
pH]naltrindole binding demonstrated its expected high affinity for the ÔOR. The 
inhibition of the adenylyl cyclase on stimulation with DADLE was in agreement to 
that found by Merkouris et al. (1997). DADLE gave a slightly lower amount of 
inhibition for the GFP-labelled receptor, although the IC50 (0.02nM ± 0.011) was 
equivalent to that found for the Flag-ôOR (0 .0 2  ± 0.009 nM) as shown by 
statistical analysis (p > 0.05).
Several stable clones of Flag-ôOR-GFP were identified as having the receptor 
mainly at the plasma membrane, as shown for clone FG6  in figure 3.8. The 
fusion of GFP to the G-terminus of GPCRs has been shown in several instances
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not to affect ligand binding, effector action or trafficking of GPCRs (Tarasova et 
al., 1997, Drmota et al., 1998, McLean et al., 1999).
This Flag-ôOR-GFP stable cell line was used to demonstrate agonist-activated 
internalisation of the receptor in real time, using confocal microscopy. Flag-00R- 
GFP was internalized to intracellular vesicles upon stimulation with agonist 
DADLE. Internalization was evident within 5 minutes of agonist stimulation. This 
agrees with the internalization rate observed by Chu et al. (1997) where the t% 
was shown to be <10 minutes thus demonstrating that the addition of GFP at the 
receptor C-terminus did not affect its rate of internalisation. The presence of 
some internal receptor at time zero was not unexpected as Petaja-Repo et al. 
(2000) demonstrated that a large proportion of transiently expressed ôOR was 
retained within the ER.
The aim of this project was to study possible homo and heterodimerization of 
ÔORs. Cvejic and Devi (1997) demonstrated that the mouse ôOR could form 
homodimers when transfected into a heterogeneous cell line. Initial experiments 
using co-immunoprecipitation to confirm these results were successful, as 
differentially tagged ÔORs could immunoprecipitate each other when expressed 
in the same cell (figure 3.10). Both monomeric receptor was identified as well as 
a potential dimeric receptor species migrating at 120kDa. In the co- 
immunoprecipitation experiments described here the immunoprecipitates were 
resuspended in sample buffer containing 50mM DTT and heated to 85°C before 
loading onto SDS-PAGE gels. This indicates that disulphide bonds alone are not 
responsible for the homo and heterodimeric interactions observed as potential 
dimeric species are detected after such treatment. However, it should be noted 
that disulphide bonds have been shown to be responsible for maintaining kOR 
homodimers, as well as ôOR ikOR heterodimers (Jordan and Devi 1999). 
ôOR:piOR heterodimers have also been shown to be disrupted by reducing 
agents (Gomes et al., 2000).
Ligand modulation of homo and heterodimerization has been studied for several 
GPCRs. The effects have varied from promoting dimerization of the P2AR
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(Hebert et al., 1996, Angers et al., 2000), no effect on dimerization as described 
for the muscarinic m3 receptor (Zeng and Wess, 1999) and the ôOR (McVey et 
al., 2001) or reduction of ôOR dimerization (Cvejic and Devi, 1997). This lack of 
consensus may arise, in part, from the different methods employed to study 
GPCR dimerization or may reflect true variation of GPCR dimerization. In this 
study, no effects of the agonist DADLE or the antagonist naltrindole were 
observed in co-immunoprecipitation studies. The variations in band intensity 
observed in figures 3.11 and 3.12 are likely to be due to variations in loading of 
the gel sample as they are not consistent with the time of incubation with the 
ligand. This is in contrast to the effect of ligands found by Cvejic and Devi (1997) 
where agonists showed a time and concentration-dependence for reduction of 
the level of receptor dimerization and a consequent increase in the monomeric 
component. The technique used to demonstrate this effect was also co- 
immunoprecipitation, but after cross-linking of the receptors with the hydrophobic 
cross-linker DSP. In this study replication of their data was not successful as 
SDS-PAGE of the immunoprecipitated samples after cross-linking resulted in a 
high molecular weight mass aggregate which did not resolve into the gel (data 
not shown).
Co-immunoprecipitation of ôOR with other receptors
To examine the specificity of the ÔOR interaction, and initially as potential 
negative controls for the homodimerization experiments, co-immunoprecipitation 
of ÔOR was performed with other co-expressed GPCRs.
Immunoprécipitation of the c-myc-ôOR with anti-c-myc antibody resulted in co- 
immunoprecipitation of each of a range of co-expressed Flag-tagged GPCRs. No 
co-immunoprecipitation was observed with the Flag-1 P prostanoid receptor 
(figure 3.13). Correspondingly immunoprécipitation of Flag-1 P prostanoid 
receptor did not result in the co-immunoprecipitation of the c-myc-ôOR (figure 
3.13). Each of the other Flag-tagged receptors were able to co- 
immunoprecipitate the c-myc-ôOR to some extent although the time required to
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detect an appropriate ECL signal was greater when the Flag-piAR-GFP (lane 2) 
and the Flag-^AR-GFP (lane 3) were co-expressed.
The varying levels of co-immunoprecipitated receptor may result from different 
expression levels of the individual receptors or as a result of differing affinities of 
the antibodies for the receptors at either the immunoprécipitation or 
immunodetection steps. It is possible that the lack of co-immunoprecipitation of 
Flag-1 P prostanoid receptor with the c-myc-ôOR could be due to poor receptor 
expression or possibly the lack of a C-terminal GFP. Flag-1 P prostanoid receptor- 
GFP did result in co-immunoprecipitation with the c-myc-ôOR therefore it may be 
possible that the C-terminal GFP is resulting in aggregation of the co-transfected 
receptors.
No direct receptor:receptor interaction has been demonstrated in the literature 
between the ÔOR and PiAR or IP prostanoid receptors although the opiate and 
adrenergic signalling systems have been shown to interact (Ammer and Schulz, 
1997, Stone et al., 1997). At which level of the signalling mechanisms interaction 
occurs is not clear. Interestingly, the prostanoid receptor EP3 has been shown to 
be involved in morphine tolerance (Nakagawa et al., 2000) as has the calcitonin 
gene-related peptide receptor (Powell et al., 2000). The opioid receptor system 
has also been shown to interact pharmacologically the cannabinoid receptor 
systems (Manzanares et al., 1999).
Clearly opiate signalling mechanisms are not simple as pharmacological 
interaction with several other GPCR signalling systems has been observed. 
Further investigation is needed to determine if the pharmacological interaction is 
a result of receptor:receptor interaction.
Co-expression of c-myc-ôOR and Flag-i^OR and immunoprécipitation of the 
lysate with anti-Flag (M5) antibody allowed the immunodetection of the c-myc- 
ÔOR, indicating that the 50R and p.OR receptors can form constitutive 
homodimers (figure 3.14). ô0R:|40R heterodimers could in part be responsible 
for the observed opiate subtype pharmacology for which no individual receptor
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cDNA has been identified. As the |jlOR used has no C-terminal GFP this co- 
immnoprecipitaion could not be attributed to GFP-induced receptor aggregation. 
George et al. (2000) and Gomes et al. (2000) have since confirmed the 
existence of ôOR:|liOR heterodimers.
To investigate the constitutive heterodimerization of GPCRs further the wild type 
P2 AR, Flag-P2AR-GFP, and p2AR-eYFP were co-transfected with c-myc-ôOR. 
Immunoprécipitation of the p2 -adrenoceptor with anti-P2AR resulted in the 
presence of the c-myc-tagged ô-opioid receptor in the precipitated sample that 
could be detected by immunoblotting following resolution of the sample by SDS- 
PAGE. Equivalent results were obtained when the c-myc-tagged ôOR was co­
expressed with a form of the p2 -adrenoceptor-eYFP or with Flag-P2AR-GFP 
(figure 3.15).
A second polypeptide with mobility consistent with a dimer containing the c-myc- 
tagged ÔOR was also detected (figure 3.15). Neither of these bands was 
detected when the human p2 -adrenoceptor was expressed in the absence of the 
c-myc-tagged ô-opioid receptor and then immunoprecipitated (figure 3.15). 
Immunoprécipitation of either of these modified forms of the p2 -adrenoceptor 
resulted in co-precipitation of the c-myc-tagged Ô-opioid receptor and detection 
of both monomeric and potential dimeric species.
These rather unexpected observations led us to consider whether such co- 
immunoprecipitation approaches following transient transfection of cells may 
produce artefactual results following solubilization of GPCRs from the membrane 
environment. However it should be noted that Jordan et al. (2001) have since 
published data demonstrating the existence of cell-surface hetero-dimers 
between the mouse ôOR and the human P2AR as well as the rat kOR with the 
human P2AR which alters the trafficking properties of the co-expressed 
receptors.
There is also the possiblity that heterodimeric interactions observed may result 
from a mass action effect resulting from overexpression of receptors. It must be
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acknowledged, therefore, that the interactions demonstrated may not be evident 
at lower expression levels or in vivo.
The possibility of these results being artefactual was thus further investigated 
using different detergents to solubilize the receptors from the membranes. Those 
used included the zwitterionic detergent CHAPS, the non-ionic detergents Trition 
X100, NP40, Tween20 and the ionic detergent SDS.
After transient transfection of c-myc-ôOR and Flag-paAR-GFP and solubilization 
in buffer containing the various detergents, co-immunoprecipitation was 
performed with the anti-Flag or anti-c-myc antibodies. Immunodetection of the 
precipitated samples, shown in figure 3.16 demonstrated that lysates produced 
with buffers containing 2% SDS or 1% Tween20 were unsuitable for subsequent 
co-immunoprecipitation of either receptor. SDS has denaturing properties and 
samples lysed In this buffer were extremely viscous and therefore difficult to load 
onto the SDS-PAGE gel which may explain the lack of any protein bands. The 
2% SDS containing solubilization buffer did however indicate heterodimerization 
between c-myc-ÔOR and Flag-|32AR-GFP on immunoprécipitation with anti-Flag 
antibody and immunodetection with anti-Flag antibody (Figure 3.16A, lane 3), 
indicating that the SDS containing buffer may be solubilizing the proteins from 
the membrane. Tween20 is an ionic detergent, which as previously been shown 
to solubilize membrane proteins (Chambers and Rickwood, 1993) The buffers 
containing TX100, CHAPS and NP40 did result in solubilization and subsequent 
co-immunoprecipitation of both receptors, (figures 3.16A and 3.16B). The result 
with CHAPS was not completely consistent even on repeating the experiment 
several times. In figure figure 3.16A, in lanes 4 both the ôOR and the P2AR-GFP 
receptors are evident but this is not the case in figure 3.16B where in lane 4 the 
c-myc-ôOR is identified on co-expression with Flag-ÔOR but not on co­
expression with Flag-P2AR-GFP. Successful co-immunoprecipitation was 
observed indicating the presence of both ôOR homodimers and ôORikAR-GFP 
heterodimers using the anti-c-myc antibody for immunoprécipitation and 
immunodetection by anti-Flag antibody (figure 3.16A), and vice versa (figure 
3.16B)
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As the detergents used have been shown to be suitable for solubilization of 
membrane proteins (Chambers and Rickwood, 1993) and differ in both micelle 
size and aggregation number it is less likely that the results obtained are 
artefactually introduced during detergent solubilization of the hydrophobic GPCR 
proteins. However, the inconsistent results obtained with the solubilization 
buffers containing CHAPS and SDS indicate the necessity for careful controls 
with these experiments.
Co-immunoprecipitation is a useful technique to demonstrate interactions 
between differentially tagged proteins. Careful controls have to be include to 
ensure the interactions demonstrated are not artefacts to the conditions used, 
especially when investigating interactions of the extremely hydrophobic GPCRs.
It may be possible to use the C-terminal ôOR-GFP fusion to examine receptor 
dimerization via FRET with a corresponding ôOR-Blue fluorescent protein (BFP) 
fusion as the enhanced GFP used in this study has good spectral overlap with 
BFP (Billinton and Knight, 2001). Development of such an assay to determine 
GPCR homo and heterodimerization that can be performed on live cells would 
be extremely advantageous to this study. The work performed to develop of such 
an assay is described in chapters 4 and 5.
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CHAPTER 4
Development of a time-resolved fluorescence 
resonance energy transfer assay to determine 
GPCR dimerization in live cells
CHAPTER 4
Development of a time-resolved fluorescence resonance 
energy transfer assay to determine GPCR dimerization 
in live cells
4.1 Introduction
When two molecules are in close proximity and have appropriate excitation and 
emission maxima, non-radiative energy transfer can occur, resulting in excitation 
of the acceptor molecule. This process is known as fluorescence resonance 
energy transfer (FRET) and has been used for a variety of purposes, including 
the measurement of enzyme activity (Zhang et al., 1999, Fattori et al., 2000), 
immunodetection (Oswald et al., 2000) and analytical chemistry (Blomberg et al., 
1999). Structural changes within macromolecules have also been measured 
using FRET, which is possible as the data are obtained in real time (Heyduk and 
Heyduk, 1997). Various fluorescently labelled biological components have been 
used in energy transfer assays including protein, DNA and RNA molecules. 
Assay formats include the use of intrinsic probes where, for example, the DNA or 
protein molecule itself is labelled with one or both fluorescent moieties. For some 
protein molecules, the fluorescence from internal tryptophan residues is utilised 
to measure a FRET signal with an external fluorescent acceptor molecule, which 
interacts with the protein. This is the approach used by Remmers (1998) who set 
up a homogeneous FRET assay for the detection and quantitation of G-proteins 
using an environmentally sensitive N-methyl-3’-0-anthranoyl (mant) guanine 
nucleotide analogue. The fluorescence increases as this mant guanine 
nucleotide binds to G-protein molecules, partly as a result of energy transfer 
from the tryptophan residues in the G-protein to the mant guanine nucleotide.
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As there are few intrinsic probes suitable for energy transfer available the 
majority of FRET assays have been developed with the use of extrinsic 
fluorescent probes which are covalently attached to the molecule to be studied. 
Care has to be taken though, to ensure that the label itself does not alter the 
properties of the molecule being studied. Extrinsic labelling with fluorescent 
molecules has been successfully performed on DNA, as Heyduk and Heyduk 
(1997) demonstrated an energy transfer signal with a 15bp double-stranded 
DNA molecule labelled at one end with a europium chelate and the acceptor 
label, Cy5, at the other.
Another method of fluorescently labelling molecules for FRET is via fluorescent 
antibodies. This does not require the protein or oligonucleotide to be purified 
before covalently labelling with its fluorophore. Suitably labelled specific 
antibodies, however, are not always available and may have to be produced 
specifically for the assay. Generic reagents have, however, been used 
successfully by Pope et al. (1999) in a ligand binding assay where a biotinylated 
ligand, which is fluorescently labelled via a streptavidin-APO molecule, binds to a 
receptor fusion protein-Fc to which protein-A-Eu^^ has labelled. Others have 
been unsuccessful with the use of such generic reagents (Stenroos et al., 1998). 
Specific antibodies labelled with fluorescent molecules have been used in 
several examples including antibodies labelled with FITC and Cy3 where the 
resultant energy transfer is not time-resolved (Damjanovich et al., 1997). Binding 
of an Eu^^-chelate labelled interleukin 2 (IL2) was measured in a time-resolved 
manner in the presence of an anti-IL2 receptor a  chain antibody labelled with 
Cy5 (Stenroos et al., 1998). A homogeneous TR-FRET assay, using terbium and 
tetramethylrhodamine labelled antibodies to measure the concentration of the (3 
subunit of human chorionic gonadotropin in serum, was described by Blomberg 
et al., (1999) where the antibodies used recognised different epitopes of the 
same protein.
FRET assays can be performed in a homogeneous format, which does not 
involve any separation of bound from free label. The main advantage over the 
heterogeneous assay is that no separation of the bound from the free label is
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required, providing a quick and simple assay format suitable for high throughput 
drug screening (Pope et al., 1999). The homogeneous assay format has allowed 
the development of assays, which use crude protein preparations where 
previously purified protein had to be used (Blomberg et al., 1999). Many of the 
assays described above have been in a homogeneous format. A comparison of 
a homogeneous assay format with terbium and tetramethylrhodamine was 
performed by Blomberg et al., (1999) comparing it to a heterogeneous Eu^^ 
separation assay. Although the homogeneous assay was not as sensitive the 
desired results were achieved.
FRET assays have been used successfully to look at the protein:protein 
interaction of receptor subunits. The IL-2 receptor is a multi subunit cytokine 
receptor found at the plasma membrane of cells. The pre-assembly of the 
subunits of the IL-2 receptor was investigated by Damjanovich et al., (1997) 
using flow cytometry FRET measurements with cells fluorescently labelled via 
antibodies to the receptor subunits. FITC or Cy3 labelled antibodies were used 
and the FRET signal measured to determine subunit interaction. Antibody- 
dependent subunit interaction was ruled out by performing the same 
experiments with labelled Fab fragments of these antibodies. The IL-2 receptor 
subunits were shown to be co-localized in resting T-cells and the effects of 
interleukin 2, 7 and 15 on the co-localized subunits described.
Farrar et al., (1999) by expressing combinations of the subunits where an 
individual subunit was tagged with c-myc, demonstrated the subunit 
stoichiometry of the cell-surface GABAa receptor. The fluorescence intensity 
level of the anti-c-myc, labelled with Europium cryptate, bound for each subunit 
was examined, and showed the stoichoimetry of the sub-units to be 2a, 2p and 
1y per receptor monomer. This was confirmed by binding the anti-c-myc labelled 
with europium cryptate, at sub-maximal levels, followed by removal of the excess 
antibody and replacing it with anti-c-myc-XL665. Energy transfer signals were 
only obtained when the a or p subunits were labelled, confirming the subunit 
stoichiometry of 2a, 2p and 1y.
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Interaction between receptor molecules can also be studied using energy 
transfer and a modified version of FRET, termed BRET, has been used to study 
the homodimerization of the P2AR (Angers et al., 2000). This relies on energy 
transfer between modified receptor proteins containing eYFP or Renilla 
luciferase fused in frame to the C-terminus of the receptor. When both these 
receptors were expressed in the same cell, after the addition of the luciferase 
substrate coelentrazine, a BRET signal was obtained. This demonstrated 
constitutive homodimerization of this receptor, which increased in the presence 
of agonist.
Immunodetection of receptors studied in vivo and in vitro indicates receptor 
homodimerization by the presence of high molecular weight bands 
corresponding to receptor dimers. Nimchinsky et al., (1997) demonstrated the 
dopamine D3 receptor in dimeric and trimeric forms in both brain tissue and in 
transfected cells. Similarly, Zeng and Wess (1999) showed muscarinic M3 
receptor dimers in brain tissue. Using FRET to study GPCR homodimerization 
allows the use of live cells whereas co-immunoprecipitation of differentially 
tagged receptors which has been used previously to demonstrate GPCR 
homodimerization (Cvejic and Devi 1997, Hebert et al., 1996), relies on 
disruption of the cells with detergents. The individual receptor contributions to 
the properties of a homodimer cannot be distinguished from that of the monomer 
which may limit pharmacological investigations into homodimers. Heterodimers, 
however may be studied pharmacologically by comparing the heterodimer 
pharmacology with that in the presence of selective antagonists of each 
receptor. The pharmacology of p,OR and 8 0 R heterodimers has been 
investigated using this method (Gomes et al., 2000, George et al., 2000). 
Rocheville et al., (2000b) demonstrated pharmacologically and by 
photobleaching FRET, the interaction between the somatostatin SSTR5 and the 
dopamine D2 receptor.
The ÔOR has been used in this study as differentially tagged ôOR receptors 
have been shown previously to co-immunoprecipitate (Cvejic and Devi 1997). 
This has also been described in Chapter 3 figure 3.10. This indicates the likely
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presence of constitutive ôOR homodimers. Heterodimers between 50R and 
kOR, but not between p.OR and kOR, were demonstrated using co- 
immunoprecipitation and ligand binding studies by Jordan and Devi (1999). 
Heterodimerization between ôOR and p,OR has been demonstrated by Gomes 
et al. (2000) and George et al. (2000). However data from co- 
immunoprecipitation studies cannot report where the homodimers are in the cell. 
Modification of the N-terminal region of the human 50R to contain either the Flag 
or c-myc epitope tag recognition sequences allows antibody detection of the 
receptors in live cells. Both FRET and TR-FRET have been used to investigate 
ÔOR cell-surface homodimerization. For FRET, antibodies labelled with FITC 
and Cy3 were used as these have been shown to be a suitable energy transfer 
pairing by Damjanovich et al., (1997). For TR-FRET, antibodies labelled with 
EuK and ARC were used as these were also shown by Farrar et al., (1999) to be 
an appropriate TR-FRET pairing. Homogeneous and heterogeneous assay 
formats were investigated.
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4.2 Results
Labelling of anti-Flag antibody with ARC makes it a suitable acceptor molecule in 
TR-FRET assays where Europium is used as the donor fluorophore. Anti-Flag 
(MS) antibody was labelled with RhycoLink® SMCC-xlARC as described in 
section 2.5.2. This cross-linked ARC molecule is stable and suitable for protein 
labelling. The sulfhydryl reactive (maleimide) groups, which have been 
introduced to the ARC, readily react with reduced cysteine groups of proteins.
In figure 4.1 A gel filtration of the reduced antibody to remove any excess DTT is 
shown. Only one peak was obtained, as the DTT does not have an absorbance 
at 280nm. The protein was eluted from the column after 22ml in a volume of 9ml. 
After an overnight incubation with the ARC the unbound ARC was removed from 
the labelled antibody, again by gel filtration using the Superdex 200 column. The 
separation of the ARC labelled antibody from the free ARC Is shown in figure 
4 .IB . The peak of labelled antibody did not return to the baseline before the 
excess ARC began to elute, this indicates that there is likely to be some unbound 
ARC eluted with the labelled antibody. To remove this unbound ARC the 
antibody mixture was concentrated using a Centricon® concentrator with a 
lOOkDa filter.
The absorbance of the labelled antibody was read at 280nm and 650nm and the 
labelling stoichiometry and antibody concentration was calculated as 0.63 
molecules of ARC bound per antibody molecule.
The specificity of the anti-Flag-ARC was assessed to ensure that the labelling of 
the antibody with the ARC did not inhibit its binding to the Flag sequence 
expressed on the N-terminus of receptors. The specificity of the anti-Flag-ARC 
antibody was retained after labelling (figure 4.2).
To ensure that the labelled antibody could be used for energy transfer with 
Europium labelled proteins in close vicinity, increasing concentrations of the 
ARC-labelled antibody were incubated in the presence of 5nM Europium chelate-
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protein A. This labelled protein A binds to the APC-labelled anti-Flag antibody 
generating an energy transfer signal shown in figure 4.3.
Cell lysates that had been used successfully to demonstrate co- 
immunoprecipitation of the differentially tagged ôORs (Chapter 3) were assessed 
in a homogeneous TR-FRET assay format. Equal amounts of protein (60|4g) 
were added to wells containing both 50nM anti-Flag-APC and 10nM anti-c-myc- 
EuK antibodies. The TR-FRET signal was monitored and is shown in figure 4.4. 
No energy transfer above background was observed (p > 0.05). The expression 
level of each tagged receptor could not be measured easily as this assay was 
performed in solution.
Development of TR-FRET on intact cells was then performed firstly in a 
homogeneous format. Transiently transfected cells were split 24 h after 
transfection into wells of a black 96 well plate, ensuring equal numbers of cells 
were added per well. After a further 24 h to allow the cells to adhere to the 
surface of the plate, fluorescently labelled antibodies were added. Each well was 
incubated in the presence of 50nM anti-Flag-APC and 10nM anti-c-myc-EuK. 
Again no energy transfer signal above background was observed (p > 0.05) 
(figure 4.5).
The fluorescence of the anti-c-myc-EuK antibody was assessed to determine if 
the level of TR-FRET observed could be resulting from anti-myc-EuK 
fluorescence alone. The A615nm and A665nm after excitation at 320nm of a 
standard curve of increasing amounts of anti-c-myc-Eu^^ in the presence of 5 x 
10^ HEK293 cells was measured. This demonstrated that the value of TR-FRET 
signal obtained from the whole cell heterogeneous assay was indeed from the 
anti-c-myc-EuK antibody alone.
A further experiment was performed in the same manner except that the TR- 
FRET signal was observed from the antibody associated with the cells. This 
included a wash step after the incubation with antibodies. The result from this
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experiment is shown in figure 4.6 where again no TR-FRET signal was obtained 
above background.
The lack of an energy transfer signal may simply reflect that the 6 0 R does not 
form constitutive homodimers at the cell-surface of these cells. The effect of the 
ÔOR agonist DADLE was also examined to determine whether agonist activation 
could result In cell-surface homo-dimerization of the 50R. In no case did DADLE 
alter the level of TR-FRET observed in these experiments (data not shown).
A further assessment of the assay conditions was then performed. The 
specificity of the commercially labelled anti-c-myc-EuK was assessed and is 
shown in figure 4.7. Where the anti-c-myc-EuK was incubated with cells which 
were either mock transfected or transfected with Flag-ÔOR or c-myc-ôOR, no 
specific binding was observed. To confirm that this lack of binding was not the 
result of very low expression of the c-myc-ôOR a comparison of the anti-c-myc- 
EuK binding with anti-c-myc-FITC binding was performed and is shown in figure 
4.8. The EuK and the FITC labels were both generated commercially on the 
rabbit polyclonal 9E10 antibody, therefore any difference in binding obtained 
must be the effect of the fluorescent label on the antibody. Figures 4.7 and 4.8 
show the levels of each antibody binding obtained. The anti-c-myc-FITC 
antibody binds specifically to cells expressing the c-myc-tagged receptors with 
high intensity values and the anti-myc-EuK did not. The fluorescent intensities 
obtained here could reflect the difference in the fluorescent intensity of each 
probe at the respective conditions used. A standard curve was therefore set up 
for each antibody to examine the corresponding fluorescence intensities at 
appropriate wavelengths (535nm after excitation at 490nm for FITC, 620nm after 
excitation at 320nm for EuK). The fluorescence intensity obtained for the 
equivalent amount of anti-c-myc-EuK was much higher than that for the anti-c- 
myc-FITC antibody (figure 4.9). Therefore if equivalent amounts of anti-c-myc- 
EuK and anti-c-myc-FITC bound to the receptors the fluorescence intensity from 
the anti-c-myc-EuK would be expected to be higher (at least 100 fold).
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These results indicate that either labelling of the anti-c-myc with the europium 
cryptate has inactivated the antibody or that the antibody was not stored under 
the appropriate conditions and had broken down in such a way to lose its 
fluorescent label or lose its specificity. Another batch of the same antibody was 
not available from the supplier to allow this to be tested.
As the fluorescent EuK donor molecule binding is at such a low level on cells 
expressing c-myc-tagged receptors, it could not be concluded from the 
experiments performed if the tagged ôOR receptors form constitutive or ligand 
dependent cell-surface homodimers.
The anti-c-myc-FITC antibody can be used as the fluorescent donor and Cy3 as 
an acceptor molecule, using FRET to determine the close proximities of the two. 
Anti-Flag antibody was then labelled according to the manufacturers instructions 
with Cy3. A labelling stoichiometry of 7.1 molecules of Cy3 per antibody was 
obtained.
Experiments were then performed in the presence of anti-c-myc-FITC and anti- 
Flag-Cy3 the results of which are shown in figure 4.10. In A, a FRET signal was 
achieved apparently demonstrating cell-surface constitutive dimerization of the 
ÔOR. However, when the fluorescence emission from the FITC alone was 
analysed as shown in figure B a large proportion of the apparent energy transfer 
signal arose from the high level of anti-myc-FITC antibody present and is not 
“real” energy transfer.
Another source of Europium tagged anti-c-myc antibody was then identified and 
assessed for specific binding to cells expressing receptors with N-terminal c-myc 
tag, this is shown in figure 4.11. This anti-c-myc-Eu^^ antibody bound specifically 
to cells that express N-terminal c-myc tags with low binding to cells that were 
either mock transfected or transfected with a N-terminally Flag-tagged receptor. 
The specificity of the anti-c-myc-Eu^'*' is shown in figure 4.12.
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Figure 4.1 Gel filtration of anti-Flag antibody labeüed with cross-linked 
aiiophycocyanln.
A280nm elution profiles of Superdex 200 gel filtration columns. A) After reduction 
with DTT the antibody was then desalted into 20mM NaP0 4 , pH 7.5. The protein 
was eluted after 22ml, in a volume of 9ml. A single protein peak was observed. 
B) Labelled antibody was separated from unlabelled antibody by gel filtration on 
a Superdex 200 column, run in PBS with 0.05% Tween20. The elution profile in 
B shows the first labelled antibody peak after 17ml which was collected up to 24 
ml where the unlabelled APC began to elute.
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Figure 4.2 Anti-Flag-APC antibody binds specificaiiy to ceiis expressing 
N-terminaily-tagged Flag receptors.
HEK293 cells were either mock transfected or transfected with Flag-ÔOR and 
harvested 48 h after transfection. 5 x 1 0 ® cells were then incubated with 50nM 
anti-Flag-APC for one hour at room temperature, before washing 2 x 1ml with 
PBS. The cells were then re-suspended in 70|xl of PBS and read in the Aquest™ 
fluorescence plate reader. The specific binding of the anti-Flag antibody is 
clearly demonstrated above the mock transfected cells. This graph is a typical 
representation of two independent experiments performed in triplicate.
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Figure 4.3 Time-resolved Fluorescence Resonance Energy Transfer 
with protein-A-Eu^^ and APC-iabelled M5 anti-Flag antibody
The capability of the anti-Flag-APC to interact with protein-A-Eu^^ to produce a 
TR-FRET signal was assessed. Increasing amounts of Anti-Flag-APC were 
added to 5nM protein-A-Eu^^ and the TR-FRET observed on a Victor 
fluorescence plate reader. The data represent the mean ± SEM. of 3 
independent experiments.
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Figure 4.4 No energy transfer signal Is obtained with cell lysates 
previously shown to co-lmmunopreclpltate Flag-ôOR and c- 
myc-ôOR
Cell lysates that had been previously used for co-immunoprecipitation 
experiments, indicating receptor dimerization, were taken and 60|aq of protein 
incubated with 50nM anti-Flag-APC and 10nM anti-c-myc-EuK for one hour at 
room temperature. The energy transfer signal was then read in a Victor. No 
significant energy transfer signal above background was obtained under any of 
the conditions used (p > 0.05). It was not possible to assess the individual 
antibody binding in this experiment as it was performed in solution. This graph is 
a typical representation of two Independent experiments performed in triplicate.
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Figure 4.5 No ÔOR homodimerization was observed in the 
homogeneous assay fomat in the presence of anti-c-myc- 
EuK and anti-Fiag-APC antibodies.
No TR-FRET was observed with HEK293 cells after transiently transfecting with 
Flag-ôOR or c-myc-ôOR alone or expressing both receptors. 24 h after 
transfection the cells were split into the wells of a 96 well plate with 2.01 ± 0.56 x 
10^ cells per well. No significant energy transfer signal above background was 
observed after a one hour, room temperature incubation with either 50nM anti- 
Flag-APC or lOnM anti-c-myc-EuK alone or together (p > 0.05).
This graph is a typical representation of two independent experiments performed 
in triplicate.
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Figure 4.6 No evidence of TR-FRET in ceiis expressing either Fiag-ÔOR 
aione or both Fiag-ÔOR and c-myc-ÔOR
Cells were transiently transfected with either Flag-ôOR alone or co-transfected 
with Flag-ôOR and c-myc-ôOR and incubated in the presence of 10nM anti-c- 
myc-EuK antibody and 50nM anti-Flag-APC antibody. The TR-FRET was 
observed after 1 h and after 14 h at room temperature. No energy transfer was 
observed above the background. It is likely that this level of background is 
resulting from fluorescent emission from the EuK alone. This graph is a typical 
representation of two independent experiments performed in triplicate.
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Figure 4.7 Lack of specific anti-c-myc-EuK binding to ceiis expressing 
an N-terminai c-myc tagged receptor
HEK293 cells were either mock transfected or transfected with either Flag-ôOR 
or c-myc-ÔOR. After a 2 h incubation at room temperature, unbound antibody 
was removed by washing with 2 x 1 ml of PBS. The cells were then re-suspended 
in a 30|il volume and placed in a black 384 well plate and fluorescence intensity 
read on a Victor^ fluorescence plate reader.
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Figure 4.8 Antl-c-myc-FITC antibody binds specifically to cells
expressing receptors with an N-termlnal c-myc-tag.
The rabbit polyclonal anti-c-myc antibody (9E10), which is commercially 
available labelled with FITC, was used to measure specific binding on live cells 
which were either mock transfected or transfected with Flag-ôOR or c-myc-ÔOR.
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Figure 4.9 Fluorescence intensity of anti-c-myc antibody labelled with 
Europium cryptate (EuK) and anti-c-myc antibody labelled 
with Fluorescein isothiocyanate (FITC).
Antibodies were diluted in PBS in the presence of 5 x 10^ HEK293 cells in a total 
volume of 30^1 and the respective fluorescence intensities measured. For EuK 
the excitation wavelength was 320nm, the emission being measured at 615nm. 
For FITC the excitation wavelength was 535nm, emission being measured at 
590nm. The fluorescence intensity of the EuK labelled antibody is much greater 
than that of the FITC labelled antibody at the conditions used (the results plotted 
for the EuK labelled antibody are divided by 100 to allow both sets of data to be 
plotted on the same graph).
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Figure 4.10 No energy transfer signal Is obtained from cells expressing 
both Flag-ôOR and c-myc-ÔOR In the presence of antl-Flag- 
Cy3 antibody and antl-c-myc-FITC antibody.
HEK293 cells were either mock transfected or transiently transfected with either 
Flag-ôOR alone or with both Flag-ôOR and c-myc-ôOR and incubated in the 
presence of 4nM anti-c-myc-FITC antibody and 20nM anti-Flag-Cy3 antibody. 
The energy transfer signal observed is shown in A. The corresponding FITC 
fluorescence emission at 535nm is shown in B. The results shown are the mean 
± S.E.M. of three independent experiments performed in duplicate.
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Figure 4.11 Fluorescence intensity of anti-c-myc-EuK aione at 665nm 
after excitation at 320nm
A standard curve of 0"40nM anti-c-myc-EuK was set-up in the presence and 
absence of 5 x 10® HEK293 cells in a total volume of 30p1 PBS. The samples 
were excited at 320nm and emission measured at 615 and 665nm.
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Figure 4.12 Antl-c-myc-Eu^* specifically binds to ceiis expressing
receptors with an N-terminai c-myc-tag.
5x10® HEK293 cells ware either mock transfected or transfected with Flag-ôOR 
or c-myc-ôOR, were incubated at room temperature with increasing amounts of 
anti-c-myc-Eu^^. The fluorescence intensity of the antibody associated with the 
cells was determined after a 2 hour room temperature incubation after removing 
the unbound antibody with 2 x 1ml washes with PBS. The fluorescence intensity 
at A 615nm and B. at 665nm are shown.
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4.3 Discussion
There are only a few methods available that allow p rote in-protein interactions to 
be examined within live cells. The yeast Two-Hybrid system has been used 
successfully to identify intracellular protein-protein interactions (Wang et al., 
1995). A drawback to this system is that the interaction has to occur within the 
yeast nucleus therefore interactions which involve secondary manipulation (e.g. 
palmitoylation) or compartmentalization are unlikely to be identified using this 
system. The technique of FRET was chosen here, a related technique known as 
BRET has previously been used to determine GPCR dimerization. Angers at al. 
(2000) demonstrated ggAR homodimerization using BRET, McVey et al. (2001) 
have also shown homodimerization of the ôOR using BRET. The FRET and 
BRET systems are much more suitable for identifying protein-protein interactions 
between or with transmembrane proteins such as GPCRs as they can be used in 
mammalian cells.
The co-immunoprecipitation technique used and described in chapter 3 along 
with BRET, does not provide any information on where the interaction between 
the receptors is occurring. Using antibodies which label cell-surface receptors 
allows the receptor interactions occurring at the cell-surface to be followed in 
isolation.
The availability of suitable reagents plays a major role in the assay format to be 
used. At the time when these experiments were performed there was not a 
commercially available, fluorescently labelled, pair of anti-Flag and anti-c-myc 
antibodies which could be used for TR-FRET. It was possible, however, to use a 
commercially available anti-c-myc antibody that was labelled with Europium 
cryptate ions as the fluorescent donor.
A fluorescent acceptor for Europium is APC and it was possible to obtain ARC in 
a stabilised form, which allowed it to be used to label an anti-Flag antibody. The 
labelling of the anti-Flag (M5) antibody gave a stoichiometry of 0.63 molecules of 
APC bound per antibody molecule. This indicates that there is some unlabelled
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antibody in this mixture. The value of 0.63 was not included in the calculations 
for the amount of anti-Flag antibody added to each preparation. Reduction of the 
antibody molecule results in exposure of free sulfhydryl groups allowing the APC 
to link covalently via its maleimide group. It is unusual to obtain more than one 
molecule of APC binding to antibody molecules due to steric hindrances as APC 
is a large molecule of approximately lOOkDa.
It was essential to ensure that the labelling procedure did not alter the binding 
properties of the anti-Flag antibody and this was shown to be the case (figure 
4.2) where specific antibody binding to cells expressing an N-terminally Flag 
tagged receptor is demonstrated. The specific antibody binding also indicates 
the sensitivity of the fluorescent antibody as the cells were transiently 
transfected, (see Chapter 3 about low expression levels with transient 
expression of opioid receptors).
Only a certain proportion of receptor homodimers can provide a signal using this 
method. They are those containing both a Flag-ôOR and a c-myc-ÔOR. There 
will, however, be monomeric receptors as well as homodimers containing the 
Flag-ôOR only and homodimers of the c-myc-ôOR only present in the cells. 
Neither of these combinations can give rise to an energy transfer signal. The 
proportion of the receptor monomers to dimers is not known.
For TR-FRET assays a homogeneous assay format would be preferred as there 
would be few manipulations of the cells and no separation of the bound from the 
free antibody would be necessary. However, the lack of an energy transfer signal 
in a homogeneous assay did not allow the assessment of individual antibody 
binding. The level of donor fluorescence used has to be carefully optimized to 
ensure the emission of the donor itself does not mask any true TR-FRET signal 
which may occur. A homogeneous assay format was tried using either cell- 
lysates, which had previously been successfully used in co-immunoprecipitation 
experiments (figure 3.10), or whole cells which were adhered to the surface of a 
96 well plate (figure 4.4). No useful information could be gained from these 
experiments, it was decided not to continue with this homogeneous assay and
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Using FRET to determine ÔOR homodimerization is shown in figure 4.10, and an 
energy transfer signal was detected for cells which express both Flag-ôOR and 
c-myc-ÔOR and in the presence of both antibodies. Further investigation into the 
level of the donor antibody binding and its associated fluorescence intensity at 
590nm indicated, however, that the energy transfer signal was a false one and 
that the energy transfer signal observed was the result of increased anti-c-myc- 
FITC binding only. It is possible with further assay development and the use of 
careful controls that this assay format may be used to measure receptor-receptor 
interaction using live cells. However as another source of anti-c-myc, Europium 
labelled antibody was identified further work was performed to try again to 
develop a TR-FRET assay for cell-surface homodimerization of the ôOR.
Anti-c-myc-Eu^^ binding specificity was assessed (figure 4.12) and specific anti- 
c-myc-Eu^^ binding to cells expressing only c-myc-ôOR was demonstrated. The 
fluorescence emission at 615nm and 665nm of the anti-c-myc-Eu^^, after 
excitation at 320nm, is shown in 4.12 B. The observed emission at 665nm from 
the Eu^'^-labelled anti-c-myc antibody, though only evident at high levels of 
antibody, should be considered in design of future assay conditions using this 
antibody. Further TR-FRET assays can be performed using this new source of 
anti-c-myc-Eu3+ as the donor and the previously labelled anti-Flag-APC. Such 
experiments were performed and are presented and discussed in chapter 5.
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CHAPTER 5
Investigation of opioid receptor homo- and 
heterodimerization in intact cells using time 
resolved fluorescence resonance energy
transfer
CHAPTER 5
Investigation of 5-OR homo and heterodimerization in 
intact cells using time-resoived fluorescence resonance 
energy transfer
5.1 Introduction
The existence of opioid receptor dimers in vivo was suggested by Hazum et al., 
(1982) by demonstrating that dimeric morphine and enkephalin agonists bound 
with higher affinity to the p.OR and 6 0 R in membranes. The dimeric forms of 
agonist also showed higher activity in a guinea-pig ileum assay than the 
monomeric agonist species. Physical interaction between the opioid receptor 
species was not demonstrated until much later. ôOR receptor homodimerization 
was demonstrated by Cvejic and Devi (1997) by co-immunoprecipitation of 
differentially tagged mouse ôORs in COS and CHO cell lines. Homodimers of the 
human ôOR have been confirmed in HEK293 cells and have been described in 
chapter 3. Homodimerization of the rat kOR was shown by Jordan and Devi 
(1999), who expressed the receptor in HEK293 or COS cells. Homodimerization 
of the rat p,OR was shown in HEK293 cells by George et al. (2000).
The pharmacology for the opioid receptors suggests a larger number of receptor 
subtypes that have been identified by molecular analysis. This could mean there 
are opioid receptors not yet identified. It could also indicate that the opioid 
receptors interact with each other in a functional manner, providing the different 
receptor pharmacologies. ôOR and p,OR have been identified in the dorsal root 
ganglia by Fields et al. (1980) and have been shown to exist in the same 
plasmalemma of these neurones by Cheng et al. (1997). The kOR has also been 
identified in similar regions of the brain as the other opioid receptors (Arvidsson 
et al.. 1995). The level of expression of each receptor sub-type and the level of 
interaction between them in vivo may then affect the observed pharmacology.
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The first demonstration of physical heterodimerization of the ôOR with the kOR 
was by Jordan and Devi (1999) using HEK293, COS or CHO cells. The 
heterodimer was shown by co-immunoprecipitation of differentially tagged 
receptors. The presence of [iORikOR heterodimers was looked for but no such 
heterodimer was found. Two independent studies have recently shown a 
heterodimeric ôORijaOR receptor species, using co-immunoprecipitation 
techniques (Gomes et al., 2000, George et al., 2000).
Receptor pharmacology of the 60R :k0 R  heterodimers was investigated in 
comparison with the individually expressed receptors. By using selective 
agonists and antagonists the pharmacology of each receptor present in the 
dimer was investigated. Highly selective 5 or k agonists or antagonists 
demonstrated poor binding affinity for the 50R :k0 R  heterodimer. However, 
partially selective ligands for the individual receptors demonstrated high affinity 
binding for the ôOR:kOR heterodimer. The rank order of ligand binding was also 
altered for the ôOR;iaOR heterodimer compared to the monomeric receptor 
species (Jordan and Devi, 1999). Ligand synergy, when the binding of a ligand 
to one receptor of the dimer is enhanced by the presence of a ligand to the other 
receptor, was observed for both the ôOR;kOR heterodimer (Jordan and Devi, 
1999). The observed synergy for the ôOR:p.OR heterodimer was ligand specific 
(Gomes et al., 2000, George et al., 2000). Ligand synergy was also 
demonstrated in the neuroblastoma cell line SKNSH which endogenously 
express both 50R and |iOR (Gomes et al., 2000). Synergy with two selective 
antagonists was demonstrated for ÔOR:kOR heterodimers, however no such 
synergy was observed when a combination of a kOR selective agonist and a 
ÔOR selective antagonist was used. These studies indicate that the opioid 
receptor heterodimers have a distinct binding site from the individual receptors. 
This results in the distinct pharmacology of the heterodimer, it has been 
suggested by Jordan and Devi (1999) that the 50R :k 0 R  heterodimer 
corresponds to the pharmacology of the k-2 receptor sub-type described by 
Zukin et al. (1988).
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A possible role for receptor dimerization in receptor trafficking also has been 
indicated by co-expression of mutant and wild type receptors in the same cell. 
The data on opioid receptor heterodimers complies with this suggestion in the 
following manner. ôOR is internalized by etorphine when expressed alone but no 
significant internalization of ÔOR is evident when it is expressed with kOR. 
Internalization of the kOR is not induced by etorphine either when expressed 
alone or with the ÔOR (Jordan and Devi, 1999) and the rate of internalization of 
the ôOR:jiOR heterodimer was different from that for receptors expressed alone 
(Gomes et al., 2000, George et al., 2000).
As discussed in Chapter 1 there is no consensus in the literature as to regions of 
receptor directly involved in dimerization. The C-terminus of the ÔOR was shown 
to be involved in homodimerization as a l 5-residue C-terminal truncated form of 
the receptor did not form homodimers and did not internalize on agonist 
stimulation (Cvejic and Devi, 1997). This is a further indication that dimerization 
and internalization may be linked. A heterodimer between ôOR and a c- 
terminally truncated p,OR, lacking the last 42 amino acids has been 
demonstrated by Gomes et al., (2000) suggesting that the C-terminus is not 
important in the interaction of these two opioid receptors. Clearly further work 
has to be done to elicudate the regions involved in dimerization of the opioid 
receptors.
In this chapter homodimerization of the ÔOR using TR-FRET with differentially 
tagged receptors and antibodies labelled with Eu^^ and APC has been studied. 
This is a heterogeneous format assay performed on transiently transfected 
HEK293 cells, unless otherwise stated. Cell-surface heterodimerization between 
ÔOR and other GPCRs has also been investigated as well as jiOR 
homodimerization. The development of this assay allows the interaction between 
N-terminally tagged GPCRs at the cell-surface only to be studied in live cells. 
Fluorescent antibodies have been utilized, which bind to the N-terminally tagged 
GPCRs. The time-resolved fluorescence resonance energy transfer signal 
observed indicates that this is a robust assay with a large signal to noise ratio. 
Some of these results have been published (McVey et al., 2001). Assay
138
optimization experiments as well as a description of the development of the TR- 
FRET assay into a homogeneous format have been included.
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5.2 Results
ÔOR : ÔOR cell surface homodimerization Is shown using Time Resolved -  
Fluorescence Resonance Energy transfer (TR-FRET)
HEK293 cells transiently transfected with ôOR with an N-terminal c-myc epitope 
tag and with ôOR with an N-terminal Flag epitope tag were assessed for 
homodimerization using TR-FRET as described in section 2.4.5. A statistically 
significant energy transfer signal (p < 0.05) was obtained when both receptors 
were expressed in the same cell (figure 5.1 A). Co-expression of appropriately 
tagged pairs of ôOR and P2AR was also performed, however, the TR-FRET 
signal obtained was not statistically significantly (p > 0.05) above the background 
signal from mock transfected cells. The signal observed when each form of the 
ÔOR was expressed alone was no different to mock transfected cells. Mixing 
cells that expressed the individual receptors also did not result in a statistically 
significant TR-FRET signal above background (p > 0.05). This demonstrated that 
the presence of both receptors is not enough to generate an energy transfer 
signal, as both receptors have to be expressed in the same cell and in close 
proximity to generate a TR-FRET signal.
Individual antibody binding to cells expressing each receptor individually or the 
combination of Flag-ôOR with c-myc-ôOR or Flag-P^AR with c-myc-ôOR was 
assessed via their respective fluorescence intensities (figures 5.1 B and 5.1C). 
The specificity of anti-c-myc-Eu^’*' binding in a statistically significant manner (p < 
0.05) was observed in cells expressing c-myc-ôOR alone or when co-expressed 
with Flag-ôOR or Flag-PgAR. Neither Fiag-ÔOR nor Flag-PgAR transfected cells 
showed any statistically significant anti-c-myc-Eu^^ binding over the level of 
mock transfected cells (p > 0.05). The level of anti-c-myc-Eu^^ binding in the 
presence of Flag-receptors is lower than that when expressed alone, although 
this difference was not statistically significant (p > 0.05). The anti-c-myc-Eu^"*" 
binding in the presence of c-myc-ôOR, co-expressed with Fiag-ÔOR is not 
significantly different (p < 0.05) to that when c-myc-ôOR is co-expressed with 
Flag-P2AR (figure 5.1 B).
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Anti-Flag-APC was also shown to bind specifically to cells expressing Flag- 
tagged receptors alone over mock transfected cells (figure 5.1 C). The level of 
anti-Flag-APC binding is not significantly different (p > 0.05) between the cells 
co-expressing c-myc-ÔOR with Flag-ôOR or c-myc-ÔOR with Flag-^AR.
Excitation of anti-c-myc-Eu^^, in the presence of 5 x 10® HEK293 cells resulted in 
a fluorescent emission at 665nm as well as 615nm (figure 5.2). To assess the 
level of fluorescence emission from the anti-c-myc-Eu^'*' alone at 665nm a 
standard curve of 0 - 40niVl anti-c-myc-Eu^'*' was produced. Excitation was at 
320nm with the fluorescence emission being measured at both 615nm and 
665nm. The emission signal at 665nm resulting from anti-c-myc-Eu^^ was no 
greater than 250 when concentrations of up to lOnM anti-c-myc-Eu^^ were 
present. This is within the TR-FRET signal obtained for the mock-transfected 
cells in the TR-FRET experiments (figure 5.1) i.e. background fluorescence. 
From these data it can be concluded that the emission signal obtained at 665nm 
is resulting from energy transfer. The emission signal from the anti-c-myc-Eu^^ at 
665nm for each experiment can be calculated using the graph in figure 5.1.
Effect of ligands on receptor:receptor interactions as measured by TR- 
FRET.
The effect of ligands on the homodimerization of ôOR:ôOR and lack of 
heterodimerization of ôORipaAR was investigated using TR-FRET. No 
statistically significant effect of lOOnM DADLE on the ôOR homodimerization 
level was observed (p>0.05). The inverse agonist IC1174,864 (Merkouris et al., 
1997) also did not affect the ôOR homodimerization level (figure 5.3A) (p>0.05). 
The level of each individual antibody binding was not influenced by the presence 
of ligand in the incubation mixture (figures 5.3B and 5.3C) in a statistically 
significant manner (p > 0.05).
To investigate whether ligand binding would demonstrate heterodimerization 
between the ôOR and P2AR a TR-FRET assay was performed. Again no 
statistically significant effect of DADLE, isoprenaline, or a combination of both
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was observed (p > 0.05), figure 5.4A. The ligands did not affect the level of each 
individual antibody binding (figures 5.4B and 5.4C).
Ligand binding can occur in the presence of the fluorescently labelled 
antibodies.
As the binding of fluorescently labelled antibodies to the N-terminal tag of the cell 
may obstruct ligand binding a pH] ligand binding assay was performed in the 
absence and presence of the fluorescent antibodies. The presence of the 
fluorescently labelled antibodies did not affect the specific binding of pHjDADLE, 
or pHjnaltrindole to the ôOR (figure 5.5), Binding of pHjdihydroalprenalol (DHA) 
and pH]GCP12,177 to the Flag-ggAR-GFP in the absence and presence of 
isoprenaline was also assessed and no affect of antibody on ligand binding was 
observed (figure 5.6). This confirmed that the ligands can bind to the receptors in 
the presence of the fluorescently labelled antibodies. Agonist-stimulated 
inhibition of adenylyl cyclase was also not significantly disrupted by the presence 
of the fluorescently labelled antibodies (p > 0.05) (Table 5.1).
ÔOR : [.lOR heterodimerization
Interaction between ÔOR and piOR receptors was investigated using transiently 
transfected HEK293 cells. Although there was a clear indication of 
heterodimerization with this TR-FRET assay on cells co-transfected with Flag- 
ôOR and c-myc-jAGR or with Flag-fxQR and c-myc-ÔOR, this did not achieve 
statistical significance. The i^OR homodimerization signal obtained again was 
not significantly greater (p > 0.05) than that for cells transfected with the 
individual receptors (figure 5.7).
The level of individual antibody binding was assessed for these experiments and 
the level of anti-c-myc-Eu^^ binding to cells expressing c-myc-fiGR and Flag 
tagged ôGR or jiGR was not significantly different (p > 0.05) to that found for c- 
myc-ôGR co-transfected with Flag tagged ôGR or juiGR (figure 5.7B). The anti-c- 
myc-Eu^^ binding achieved for cells transfected with c-myc-jiGR alone was
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significantly lower (p<0.05) than that for cells transfected with c-myc-ÔOR alone 
(figure 5.7B).
The anti-Flag-APC binding in cells expressing Flag-piOR in the presence of c- 
myc tagged 50R or jiOR was not significantly different (p > 0.05) from anti-Flag- 
APC binding to cells expressing Flag-ôOR in the presence of c-myc tagged ôOR 
or jiOR (figure 5.7C). However, again when the Flag-piOR was expressed alone 
there was significantly less (p < 0.05) anti-Flag-APC binding observed 
compared to that for cells expressing Fiag-ÔOR alone (figure 5.7C).
Optimization of the TR-FRET signal obtained from this assay was studied by 
both transfecting varying levels of each epitope tagged receptor into cells and by 
varying the levels of labelled antibody included In the incubation (figure 5.8). An 
increase in anti-c-myc-Eu^"^ binding was observed with increasing levels of c- 
myc-ôOR (figure 5.8B). The energy transfer increased with the level of c-myc- 
ÔOR transfected and with the concentration of fluorescent antibody used (figure 
5.8A). As the level of anti-c-myc-Eu^^ was also increased a larger proportion of 
this signal would arise from emission directly from the anti-c-myc-Eu^"^, taking 
this into consideration and using the data shown in figure 5.2, the TR-FRET 
signal was greater when increasing amounts of transfected c-myc-ÔOR. There 
was no significant increase in anti-Flag antibody binding when 3nM or 9nM 
antibody was present in the incubation (figure 5.80).
A homogeneous format of this assay was set up to avoid the lengthy process of 
harvesting the cells, washing and then adding to the 384 well plate. This assay 
was performed in a 96 well format varying the number of cells added per well. 
The concentrations of antibodies used were 0.5nM anti-c-myc-Eu^^ and 5nM 
anti-Flag-APC (figure 5.9A) or 1nM anti-c-myc-Eu^^ and 3nM anti-Flag-APC 
(figure 5.9B). The TR-FRET signal was measured each hour up to 3 hours after 
the addition of antibody. ôOR homodimerization was evident at each of the 
conditions used. The TR-FRET signal was greater with the higher concentration 
of antibodies was used and increased with the number of cells used. No levels of 
individual antibody binding were obtained using this assay format.
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Figure 5.1 ôOR homodimerization is demonstrated on live cells via TR- 
FRET
HEK293 cells were transiently transfected with Flag-ôOR, Flag-P2AR-GFP or c- 
myc-ôOR alone or transfected with both Fiag-ÔOR and c-myc-ôOR or Flag-ôOR 
and Flag-p2AR-GFP. A mix of cells expressing Flag-ôOR alone with cells 
expressing c-myc-ôOR alone was also used. 5x10® cells were incubated for 2 h 
at room temperature in the presence of 3nM anti-c-myc-Eu^'*' and 15nM anti- 
Flag-APC antibody. After washing with 2 x 1ml of PBS the cells were re­
suspended in 30|il PBS and the TR-FRET signal read on a Victor^ fluorescence 
plate reader.
A) The energy transfer signal presented are mean ± S.E.M. of four 
independent experiments. Co-expression of Flag-ôOR with c-myc-ôOR 
resulted in a statistically significant level of energy transfer (p < 0.05). No 
such signal was observed when c-myc-ôOR was co-expressed with 
Flag-pgAR-GFP (p > 0.05).
B) Specific binding of anti-c-myc-Eu^^ to cells expressing an N-terminal c- 
myc-tag was statistically significant (p < 0.05). Data are mean 
fluorescence intensity ± S.E.M. for four independent experiments.
C) Specific binding of anti-Flag-APC to cells expressing an N-terminal Flag- 
tag was statistically significant (p < 0.05). Data presented are mean 
fluorescent intensity ± S.E.M. of four independent experiments.
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Figure 5.2 Fluorescence intensity of anti-c-myc-Eu^^ at 615nm vs 665nm
A dilution curve of anti-c-myc-Eu^^ antibody was set up in a total volume of 30|il 
in the presence of 5 x 10^ HEK293 ceils. Excitation at 320nm was followed by a 
50p.s delay and reading for 2 0 0 |lis at both 615 and 665nm. A linear relationship 
between the emissions at each wavelength exists. This can be used to 
determine what fraction of the energy transfer signal obtained is from excitation 
of the Eu '^*' itself. This value can then be subtracted to give the true energy 
transfer signal. The data is plotted on a linear scale to show the relationship of 
the emission at the two wavelengths and on a logarithmic scale to show more 
clearly the level of anti-c-myc-Eu^"*" antibody binding needed to give an energy 
transfer signal of 1000-2000 units under the conditions used.
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Figure 5.3 Lack of ligand effect on 50R homo-dimerization
5 x 1 0 ^  HEK293 cells transiently expressing Flag-ôOR and c-myc-ôOR were 
incubated for 2 h at room temperature in the presence of anti-Flag-APC 
antibodies and anti-c-myc-Eu^^ antibodies. The effect of ligands was investigated 
by inclusion in the 2 h incubation of the ôOR peptide agonist DADLE, the ÔOR 
inverse agonist ICI 174,864 or the PaAR agonist isoprenaline. Each agonist was 
used at a final concentration of lOOnM.
No effect of ligand was demonstrated on :
A) The energy transfer signal, resulting from ôOR homodimerization (p >
0.05). The data are the mean energy transfer signal ± S.E.M. of three 
independent experiments performed in triplicate.
B) The anti-c-myc-Eu^^ binding to the cells (p > 0.05). The data are the
mean fluorescence intensity ± S.E.M of three independent experiments 
performed in triplicate.
0) The anti-Flag-APC antibody binding to the cells (p > 0.05). The data are
the mean fluorescence intensity ± S.E.M. of three independent 
experiments performed in triplicate.
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Figure 5.4 Lack of ligand effect on ÔOR : P2AR hetero-dimerization
5  X 10^ HEK293 cells transiently expressing Flag-P2AR and c-myc-ôOR were 
incubated for 2 h at room temperature in the presence of anti-Flag-APC 
antibodies and anti-c-myc-Eu^^ antibodies. The effect of ligands was investigated 
by inclusion in the 2 h incubation of the ôOR peptide agonist DADLE, or the 
P2AR agonist isoprenaline, or a combination of both DADLE and isoprenaline. 
Each agonist was used at a final concentration of lOOnM.
No effect of ligand was demonstrated on :
A) The energy transfer signal (p > 0 .0 5 ) .  The data are the mean energy
transfer signal ± S.E.M. of three independent experiments performed in 
triplicate.
B) The anti-c-myc-Eu^^ bindng to the cells (p > 0 .0 5 ) .  The data are the
mean fluorescence intensity ± S.E.M. of three independent experiments 
performed in triplicate.
C) The anti-Flag-APC antibody binding to the cells (p > 0 .0 5 ) .  The data are
the fluorescence intensity ± S.E.M. of three independent experiments 
performed in triplicate.
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Figure 5.5 Effect of antibodies on [^H]iigand binding to cells expressing 
50Rs
Binding experiments with a single high concentration of the agonist pH]DADLE 
(5nM) or the antagonist [^H]naltrindole (5nM) were performed under conditions 
used for the TR-FRET assay to determine whether the presence of antibodies 
affected ligand binding. 300nM naloxone was used to determine non-specific 
binding. The antibodies did not have any significant effect on the level of 
radioligand binding (p >0.05).
The data shown are the mean ± S.E.M. for three independent experiments.
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Figure 5.6 Effect of antibodies on [^H] iigand binding to ceiis
expressing ôOR and P2 AR-GFP
Saturation binding experiments for the antagonist [^H] CGP12177 (10nM) and 
[^H] dihydroalprenolol (2nM) were performed under conditions used for the TR- 
FRET assay to determine whether the presence of antibodies affected ligand 
binding. CGP12177 being hydrophillic can only label cell surface receptors 
(McLean and Milligan, 1999) whereas dihydroalprenolol, being hydrophobic can 
pass through the plasma membrane and therefore can label both internal and 
ce 11-surface receptors. The data shown below are the mean ± S.E.M for three 
independent experiments. The antibodies had no significant effect (p > 0.05) on 
either ligand binding.
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Figure 5.7 jaOR homodimerization and heterodimerizatlon with ôOR 
shown via TR-FRET
5x10® HEK293 cells transiently transfected with Flag- or c-myc-tagged 50R and 
Flag- or c-myc-tagged p,OR, were incubated in the presence of anti-Flag-APC 
and anti-myc-Eu®"^. After a 2 h room temperature incubation, the cells were 
washed and re-suspended in PBS before reading the TR-FRET signal and the 
fluorescence intensity of each bound antibody on a Victor^. The data are mean ± 
S.E.M. of three independent experiments performed in triplicate, the exceptions 
being the Flag-|4,0R/c-myc-p,0R and Flag-00R/c-myc-|a0R which are from two 
independent experiments performed in triplicate.
A) No significant TR-FRET signal (p > 0.05) was observed in the presence 
of co-expressed Flag-|.iOR with c-myc-p.OR, c-myc-ÔOR with Flag-|iOR 
or Flag-ÔOR with c-myc-piOR.
B) Anti-c-myc-Eu®^ binding to cells expressing c-myc-jiOR and Flag tagged 
ÔOR or jiOR was not significantly different (p > 0.05) to that found for c- 
myc-ÔOR co-transfected with Flag tagged ôOR or jiOR. The anti-c- myc- 
Eu®'*' binding achieved for cells transfected with c-myc-p.OR alone was 
significantly lower (p < 0.05) than that for cells transfected with c-myc- 
ÔOR alone.
0) Anti-Flag-APC binding in cells expressing Flag-|xOR in the presence of
c-myc tagged ÔOR or piOR was not significantly different (p > 0.05) from 
anti-Flag-APC binding to cells expressing Flag-ôOR in the presence of c- 
myc tagged 50R or |xOR. When Flag-jjtOR was expressed alone there 
was significantly less (p < 0.05) anti-Flag-APC binding observed 
compared to that for cells expressing Flag-ôOR alone.
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Table 5.1 Fluorescently labelled antibodies do not disrupt agonist 
mediated inhibition of adenylyl cyclase by the ÔOR.
Intact cell adenylyl cyclase assays as described in section 2.4.3 were performed 
on HEK293 cells expressing both Flag-ôOR and c-myc-ôOR.
The effect of 1|llM DADLE on the forskolin stimulation of basal cAMP levels was 
demonstrated in the presence and absence of anti-Flag-APC and anti-c-myc- 
Eu®’*'. The results presented are the % of the cAMP levels produced by 50|aM 
forskolin In the absence of antibodies. Results are mean ± S.D. for two 
independent experiments performed in triplicate. The presence of antibodies did 
not significantly alter the effect of DADLE (p > 0.05).
No antibody Plus antibodies
Basal 1.0 ±0.6 0.9 ±0.6
Forskolin (50jaM) 100 132 ± 1 9
Forskolin (50jaM) 
plus DADLE (lOOnM)
29 ± 2 45 ± 14
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Figure 5.8 Optimization of TR-FRET assays
5x10® HEK293 cells transiently transfected with 0.2 -  1.5jLig of c-myc-ôOR and 
1.5|ig Flag-ôOR and incubated in the presence of anti-Flag-APC and anti-c-myc- 
Eu®’*'. Concentrations of either 3nM of each antibody, 3nM anti-c-myc-Eu3+ and 
9nM anti-Flag-APC, 9nM of both antibodies or 15nM of both antibodies were 
used. After a 2 hour room temperature incubation, the ceils were washed and 
resuspended in PBS before reading the TR-FRET and the fluorescence intensity 
of each bound antibody on a Victor® fluorescence plate reader. This graph is a 
typical representation of two independent experiments performed in triplicate.
A) TR-FRET signal
B) Fluorescent intensity of anti-c-myc-Eu®^ bound to cells
C) Fluorescent intensity of anti-Flag-APC bound to cells
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Figure 5.9 Development of a homogenous assay format for the TR- 
FRET assay to determine ôOR homodimerization
1 -  8 X 10^ celts transiently transfected with equal amounts of Flag-ôOR and c- 
myc-ÔOR were incubated in the presence of A) 0.5nM anti-c-myc-Eu^^ and 
2.5nM anti-Flag-APC or B) 0.5nM anti-c-myc-Eu^^ and 5nM anti-c-myc-APC. The 
TR-FRET signal was measured over a 3 hour time-period on a Victor^. This 
graph is a typical representation of two independent experiments performed in 
triplicate.
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5.3 Discussion
Determination of ôOR homodimerization and heterodimerization using live cells 
was a main aim of this project. Using N-terminal differentially tagged opioid 
receptors and the fluorescent antibodies described in Chapter 4 has resulted in 
the development of a heterogeneous cell-surface TR-FRET assay for receptor 
dimerization which should be applicable to a wide range of GPCRs.
Immunocytochemistry of live or fixed cells as well as flow cytometry has been 
performed using fluorescently tagged antibodies. These techniques were used to 
show agonist-stimulated internalization of both the 50R and p,OR receptors 
(Whistler and Von Zastrow, 1999). The lack of suitably labelled specific 
antibodies led to the in-house generation of an anti-Flag-APC molecule which 
was described in Chapter 4, however it would be equally feasible to fluorescently 
label an antibody which had been raised to an external epitope of the receptor. 
The energy transfer between Eu^’^  and APC is 50% at a distance of 9.5nm 
making this pairing suitable to look at protein-protein interactions. (Farrar et al., 
1999).
Care has to be taken to ensure that the antibody binding does not directly disrupt 
or cause receptor dimerization. As Cvejic and Devi (1997) showed that the C- 
terminus of the ÔOR is important for dimerization it is unlikely that an antibody to 
an N-terminal tag would disrupt dimerization of these receptors. Antibodies are 
bivalent and have been shown to cause aggregation of receptors at the cell 
surface (Mijares et al., 2000). This is unlikely in this case because if the anti-Flag 
antibody caused aggregation of receptors it would be of Flag-tagged receptors 
only. Homodimers of Flag-tagged receptors will not generate an energy transfer 
signal in this system. Similarly for c-myc-tagged receptors, homodimers of 
receptors both containing c-myc do not generate an energy transfer signal in this 
system. Furthermore, Whistler and von Zastrow (1999) used antibodies to N- 
terminal tags and no receptor aggregation was observed.
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A specific fluorescence intensity signal of anti-c-myc-Eu^^ and anti-Flag-APC 
binding over mock transfected cells is demonstrated in figures 4.12 and 4.2 
respectively. The level of donor antibody chosen was 3nM to maintain a high 
level of specific antibody binding over mock transfected cells. The incubation 
time was set at two hours to ensure the cells were alive and healthy when the 
TR-FRET signal was measured. Cost was also considered in determining the 
assay conditions, as the commercially available anti-myc-Eu^"^ is very expensive. 
At 3nM, with a 100|4l incubation volume, the cost of the anti-c-myc-Eu^^ alone is 
60p per individual data point, therefore increasing the concentration of the anti-c- 
myc-Eu^^ would substantially increase the cost of these assays. Measuring the 
fluorescence intensity of the incubation mixture after the removal of the cells 
showed that there was an excess of anti-c-myc-Eu^'*' antibody in the incubation 
mixture. This fluorescent intensity was approximately ten times the level of 
antibody bound to the cells.
This assay in its present format cannot be fully quantitative as monomeric 
receptor species and some homodimeric interactions, which do not generate a 
signal i.e. between Flag-receptor with Flag-receptor and c-myc-receptor with c- 
myc-receptor, will be present. With this assay an estimation of the level of 
receptors in each form is not possible. Saturation of all the receptors with 
antibody was therefore not considered an absolute requirement to observe an 
informative TR-FRET signal.
Optimisation of cell number, antibody concentration and antibody incubation time 
used are all necessary to provide a robust assay giving the maximal energy 
transfer signal at an appropriate cost.
ÔOR homodimerization is demonstrated using TR-FRET
The TR-FRET signal was measured with cells expressing Flag-tagged or c-myc- 
tagged receptors alone and cells expressing both receptors. An energy transfer 
signal was only obtained with cells expressing both receptors (figure 5.1 A). 
These observations demonstrate that constitutive homodimers of 60R are
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present on the cell-surface as the antibodies do not have access to receptors 
present inside the cell. Mixing cells expressing Flag-ôOR or c-myc-ÔOR 
individually gave no TR-FRET signal (figure 5.1 A). This demonstrates that the 
presence of both receptors and both antibodies in the same mixture is not 
enough to generate a signal, as both receptors have to be expressed in the 
same cell to be in sufficiently close proximity. As both antibodies were present in 
each incubation the possibility of a false positive resulting from non-specific 
interactions between the antibodies or their respective fluorophores was 
eliminated.
The co-immunoprecipitation studies described in Chapter 3, generated an 
unexpected result indicating a possible interaction between the ôOR and P2AR. 
As the paAR-GFP construct also contains an N-terminal Flag tag it was used to 
look for cell-surface heterodimerization using TR-FRET. No TR-FRET signal was 
obtained (figure 5.1 A) indicating that these receptors do not form a significant 
level of cell surface heterodimer, this contradicts the co-immunoprecipitation 
data. The levels of each antibody binding were similar to those observed in the 
ÔOR homodimerization experiments (figures 5.1 B and 5.10) therefore the lack of 
a signal does not represent reduced receptor expression or reduced antibody 
binding to the Flag-PgAR.
It is possible that the ÔOR and P2AR receptors interact but not at the cell-surface, 
which would agree with both sets of results found. Indeed recent BRET studies 
have detected such an Interaction (McVey et al., 2001). Cell-surface 
heterodimers between the 6 0 R and the P2AR using a co-immunoprecipitation 
technique have since been demonstrated (Devi et al., 2001). It could be possible 
that the 00R:p2AR may interact via an intermediate molecule which hold the 
receptors in a conformation which is unfavourable for a FRET signal to be 
observed whereas the co-immunoprecipitation may not be affected by such an 
interaction.
To confirm that the TR-FRET signal observed from these experiments was not 
the result of fluorescent “carry-over” from the Eu^ "^ , a standard curve with
156
increasing amounts of anti-c-myc-Eu^^ in the presence of 5 x 10® HEK293 cells 
was set up. It can be seen that the level of anti-c-myc-Eu®^ antibody binding 
necessary to generate the energy transfer that was observed in figure 4.11 
would be in the region of 300,000 counts. The fluorescence intensity associated 
with the cells which were co-transfected with c-myc-ÔOR and Flag-ôOR, for 
example, shown in figure 5.1 B is only approximately one tenth of that value. This 
confirms that the signal observed is energy transfer to the anti-Flag-APC and not 
an emission signal from anti-c-myc-Eu®^.
Incubation with ôOR ligands does not effect the ôOR homodimerization 
signai.
(Cvejic and Devi, 1997) showed via chemical cross-linking and co- 
immunoprecipitation that the ôOR forms constitutive dimers and that agonist 
activation leads to monomerization and subsequent internalization of the 
receptor. It was postulated that if an agonist ligand resulted in monomerisation of 
the ÔOR homodimer then an inverse agonist might increase the level of the 
homodimer. The ôOR peptide agonist DADLE and the ôOR selective inverse 
agonist ICI 174,864 were used to look for effects on the TR-FRET signal. As 
shown in figure 5.3 there was no effect of these ligands or the P2AR agonist 
isoprenaline on the ÔOR homodimerization level. This is consistent with the data 
described in Chapter 3. As the TR-FRET signal is dependent on the antibody 
binding to the cells it is vital that ligand binding is not disrupted upon antibody 
binding. This is shown in figures 5.38 and 5.3C.
The effect of ligands on the lack of heterodimerization between the ôOR and the 
P2AR was also studied as the lack of significant levels of a constitutive 
heterodimer does not exclude the possibility that ligand interaction could result in 
heterodimer formation between ôOR and P2AR. Hebert et al. (1998) 
demonstrated, via cross-linking and co-immunoprecipitation and Angers et al., 
(2000) subsequently showed via BRET that agonist activation of the P2AR leads 
to increased homodimerization of the receptor. No such demonstration of 
ôOR:p2AR heterodimerization upon ligand interaction was shown for either the
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ÔOR agonist DADLE, the P2AR selective agonist isoprenaiine or a combination of 
the two agonists (figure 5.4). Again agonists did not alter the level of antibody 
binding to the receptors (figures 5.4B and 5.4C). The TR-FRET signal obtained 
here can only result from interaction between receptors at the cell surface and 
any internal or internalised receptor will not contribute to the signal obtained. 
This may explain the differences obtained from the two types of experimental 
approaches, however, a BRET assay which has been developed for the ôOR 
which can measure ÔOR interaction within the cell, also showed receptor 
homodimerization which was not affected by ligands (McVey et al., 2001). 
Interestingly, a small but significant BRET signal was also found indicative of the 
formation of 00R:p2AR heterodimers. Addition of an agonist to either receptor 
resulted in a further small increase in signal.
The lack of ligand effect on ÔOR homodimerization is not a result of the 
antibodies preventing the ligand binding to the receptors as shown in figures 5.5 
and 5.6 as ligand binding is not affected by the presence of the antibody. It was 
also possible that the antibodies used for TR-FRET could modulate receptor 
function. Thus, the effect of the labelled antibodies on forskolin stimulated 
increases in cAMP was investigated using an intact cell adenylyl cyclase assay. 
Activation of the ôOR by the agonist DADLE was also tested in the absence and 
presence of the antibodies as shown in table 5.1. No significant effect of the 
labelled antibodies on either forskolin stimulation or receptor-mediated inhibition 
of adenylyl cyclase activity was observed.
HOR homo- and heterodimerization
Statistically significant i^OR homodimerization was not demonstrated in this 
assay (figure 5.7). This conflicts with the results of Gomes et al., (2000) and 
George et al., (2000) produced via co-immunoprecipitation studies. 14.OR and 
ÔOR are two closely related receptor species have been shown to interact via 
co-immunoprecipitation (Chapter 3) and by detailed kinetic investigation of the 
binding of various ligands (Gomes et al., 2000. George et al., 2000).
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Although no significant heterodimers between Flag-fxOR and c-myc-ôOR were 
observed (figure 5.7) demonstrated by statistical analysis of these data (p > 
0.05) there was some evidence that at least some heterodimerization was 
occurring. The level of individual antibody binding shown in figures 5.7B and 
5.7C were not significantly lower for the |4,0R than the ôOR or the P2AR 
constructs on co-expression, (p > 0.05). Further Investigations into |iOR:ôOR 
heterodimerization may require an increase in receptor expression level and 
further optimization of assay conditions to detect any cell-surface heterodimer. 
These results indicate that there is little cell-surface fxOR:ôOR heterodimer 
present in the cells transiently transfected with these epitope tagged receptors. 
The lack of cell-surface expression of this |xOR has recently been demonstrated 
on expression of this receptor with GFP fused to its G-terminus where a 
significant amount of the receptor was found to present inside the cells, this 
would explain the lack of a significant TR-FRET signal.
It would be interesting to produce stable cell lines expressing both the p,OR and 
ÔOR at different ratios and determine the level of heterodimerization and even 
more interesting if levels of homo and heterodimers could be assessed 
simultaneously. If appropriate fluorescent labelling of selective antibodies for 
each receptor and not to an epitope tag it may be possible to use this assay to 
determine homo and heterodimerization within primary cell lines.
Optimization of TR-FRET signal
For an efficient FRET signal, limiting amounts of fluorescent donor molecule in 
the presence of excess acceptor is preferred as the energy transfer is dependent 
on the level of donor molecule. If there is excess acceptor molecule the maximal 
energy transfer signal will be obtained. To control the levels of donor and 
acceptor molecule in such experiments is extremely difficult, as this is dependent 
on the ratio of the c-myc and Flag-tagged receptors and the levels in monomeric 
and homodimeric forms. To try to optimize the TR-FRET signal obtained two 
approaches were used. In transient transfections with increasing the level of c-
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myc-ÔOR cDNA transfected, TR-FRET signal was measured at 3 different 
concentration combinations of anti-c-myc-Eu^^ and anti-Flag-APC (figure 5.8). 
An increase in the overall energy transfer was obtained with increasing amounts 
of anti-c-myc-Eu^^ antibody. No significant difference (p > 0.05) in TR-FRET was 
observed when 3nM, 9nM or 15nM anti-Flag antibody was present in the 
incubation indicating that 3nM anti-Flag antibody may be saturating in these 
experiments. The level of energy transfer present with 1.25 and 1.5^ig of c-myc- 
8 0 R transfected when incubating with 9nM of each fluorescent antibody was 
higher than the other treatments studied. This higher signal is likely to arise from 
the increased anti-c-myc-Eu^"*" binding found with these cells (figure 5.8B). The 
TR-FRET signal was dependent on the level of c-myc-ôOR present in the cells. 
For complete optimization of these TR-FRET experiments cells a stably 
transfected cell line would be necessary to ensure a consistent level of each 
receptor was present in each experiment.
Homogenous assay format
Development of a homogeneous TR-FRET assay format to monitor cell-surface 
receptor homodimerization was an initial aim of this project. A homogeneous 
assay does not require any washing procedures to remove the unbound 
antibody and optimisation of the TR-FRET signal should be achieved quickly as 
many samples can be assayed under varying conditions simultaneously.
As was shown in Chapter 4 and in figure 5.2 the level of the fluorescent donor 
has to be decided carefully and empirically as the TR-FRET signal in a 
homogenous assay format has to be determined in the presence of the donor 
molecule. High levels of fluorescent donor could easily mask any TR-FRET 
signal that may occur. Homogenous TR-FRET assays were described in 
Chapter 4 where cells were plated down onto the surface of the wells of a 96 
well plate. To allow a comparison with the heterogeneous system and the results 
shown in figure 5.10, 1-8x10® cells were added per well in a volume of 100^1. 
The energy transfer signal was monitored over 3 h as is shown in figure 5.9. This 
demonstrated that a homogenous assay format can be developed to determine
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TR-FRET. The best conditions determined here were with addition of 0.5 nM 
donor and 5nM acceptor antibodies with 8 x 10® cells in the lOOjiil volume. 
Although this assay could demonstrate receptor homodimerization the signal to 
noise was much less than the heterogeneous assay. A similar loss in sensitivity 
was found by Blomberg et al., (1999) in the development of a TR-FRET assay 
when compared to a heterogenous assay format. The homogeneous assay 
format, however, was much easier to perform as no time-consuming wash steps 
were involved, and there was no possibility of loss of any cells during washing or 
transfer into the plate for analysis.
Opioid receptors are very similar, sharing a 65-70% homology (Jordan and Devi, 
1998) therefore it is not suprising if they can form homodimers that heterodimers 
can also be found. The main region of variability between these receptors is at 
the C-terminus which has been indicated to be important for homodimerization of 
the 8 0 R (Cvejic and Devi, 1997) but not for heterodimerization between the 8 0 R 
and a C-terminally truncated |xOR (Gomes et al., 2000). The C-terminus of the 
8 0 R has been shown to be involved in receptor internalisation as well as 
dimerizatlon (Cvejic et al. 1996). This is unlikely to be a simple issue because 
Murray et al., (1998) demonstrated that a mutant 8 0 R which lacks 
phosphorylation sites In its C-terminus, does not internalize when expressed in 
CHO cells but does when expressed in HEK293 cells. It would be interesting to 
assess the level of homo and heterodimerization of mutant opioid receptors 
lacking the C-terminus via this TR-FRET assay.
Fluorescent techniques, alongside the development of new highly sensitive 
fluorescent probes, will allow many cell signalling mechanisms to be assayed in 
a live cell format. This can only be advantageous for the further understanding of 
these mechanisms.
The lack of suitable antibodies has hindered the development of this assay and 
the results gained from it. The levels of homodimer versus heterodimer cannot 
be addressed in this particular assay format. However, using appropriate 
fluorescently labelled antibodies it may be possible to address this issue in the
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future. The number of suitable fluorescent probes and antibodies is growing at 
great speed as such assays become more widely used. There are now other 
antibodies available, which could be used for this TR-FRET assay. An anti-Flag- 
Eu®  ^ antibody is now available and it would be interesting to confirm these data 
with the anti-Flag antibody as a donor and antl-c-myc antibody as acceptor. This 
would allow further optimization of the TR-FRET assay, investigations into the 
cell-surface presence of kORs would be of interest. The use of fluorescent 
ligands has already been developed for opioid (Arttamangkul et al., 2000, 
Kshirsagar et al., 2001, Maeda et al., 2000) and other GPCRs (Heithier et al. 
1994) and the use of fluorescent ligands has been recently reviewed by McGrath 
et al. (1996). It may be possible to employ TR-FRET assays to look at receptor 
dimerizatlon, and fluorescent ligand binding assays to examine alterations in 
receptor pharmacology in parallel.
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CHAPTER 6
Final Discussion
Final Discussion
GPCR homodimerization, heterodimerization and oligomerization have all been 
suggested. The lack of a robust assay which allows the detection of
receptor:receptor interaction in live cells has hindered the progress of
investigations of such interactions.
Pharmacological data have been presented for heterogeneous receptor
systems, which affect each other both in vivo and in vitro. This however, does 
not demonstrate any physical interaction between the contributing GPCRs. 
Identification of constitutive and agonist-modulated homodimers (Angers et ai., 
1996, Cvejic and Devi, 1997) and hetero-dimers (George et al., 2000, Gomes et 
al., 2000) has been reported. Co-immunoprecipitation experiments of 
differentially tagged GPCRs have been used to determine such interactions 
although care has to be taken while producing cell lysates for co-
immunoprecipitation. The length of time used for film exposure to the ECL has 
to be taken into consideration to ensure each interaction is fully identified.
Co-immunoprecipitation of differentially tagged GPCRs has been used to 
demonstrate dimerizatlon, and indeed oligomerization, of many GPCRs (Hebert 
et al., 1996, Cvejic and Devi, 1997, Pfeiffer et al.,2001). This method may 
generate artifactual results as discussed in Chapter 3. The solubilization of 
proteins from cellular membranes can depend on the detergents used. However, 
with proper controls this method can demonstrate protein-protein interactions. 
One drawback to this system is the lack of information provided on where the 
interactions occur within the cell as all the cellular membranes are assayed and 
not just those of the plasma membrane.
The Yeast Two-Hybrid system has also been used successfully to identify 
protein-protein interactions as discussed by Milligan and White (2001). This 
system has the drawback that the protein-protein interaction has to occur within 
the Yeast nucleus, therefore interactions which involve secondary manipulation
163
(e.g. palmitoylation) or compartmentalisation are unlikely to be identified using 
this system.
In this study the challenge to develop an appropriate technique which would 
allow detection of GPCR homo and heterodimers in intact cells was undertaken. 
Transient transfection of epitope-tagged GPCRs allowed their specific labelling 
at the cell surface with appropriate antibodies that were fluorescently labelled. 
The use of fluorescent molecules has increased in biological applications as new 
fluorophores with high quantum yields and a variety of excitation and emission 
wavelengths have been developed in parallel with the production of sensitive 
and affordable equipment for the detection of fluorescence. In the study of 
GPCRs, fluorescent ligands in place of the more traditional radiolabelled ones 
(Maeda et al., 2000, Arttamangkul et al., 2000, Kshirsagar et al., 1998) have 
been used to make assays safer. GPCRs themselves have also been directly 
labelled with fluorophores (Gether et al., 1995) to identify the conformational 
changes associated with ligand binding.
Fluorescent energy transfer arises as a fluorescent donor transfers excitation 
energy in a non-radiative way, by dipole-dipole interaction, to an acceptor 
molecule. The emission spectrum of the donor molecule must overlap the 
excitation spectrum of the acceptor molecule for the energy transfer to be 
possible. The acceptor molecule does not have to be fluorescent and in this case 
the energy transfer is observed by the quenching of the emission from the donor 
molecule. For successful energy transfer, the donor and acceptor molecules 
have to be in very close proximity 10-100Â, depending on the fluorophores used. 
Lanthanide chelate molecules have a long fluorescence lifetime in comparison to 
more traditional fluorophores allowing their emission signal to be measured after 
a short lag period, by the end of which any autofluorescence from the sample will 
have decayed, increasing the signal to noise ratio for such time-resolved 
fluorescence. TR-FRET is an appropriate technique to study the cell-surface 
expression of N-terminal epitope tagged GPCRs using fluorescently tagged 
antibodies. Eu®  ^ and ARC were the fluorescent tags used in this study as they 
have appropriate spectral overlap and the Eu^^ has a long-lived fluorescence 
emission signal.
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Constitutive homodimerization of 8 0 Rs was demonstrated at the cell surface 
using this technique. As the presence of GPCRs at the cell surface is an 
indication of their correct folding, glycosylation and trafficking, it is advantageous 
to be able to identify the cell-surface receptors only. The related technique of 
BRET also detects constitutive homodimerization of 8 0 Rs although BRET does 
not indicate the site of receptor interaction as this signal is derived from 
receptors within intracellular compartments as well as at the plasma membrane. 
Agonist stimulation of constitutive mouse 8 0 R homodimers has been shown 
previously to increase the monomerization of these receptor homodimers (Cvejic 
and Devi, 1997). This was not the case for the constitutive homodimers detected 
using TR-FRET or BRET (McVey et al., 2001). Agonist activation of GPCRs has 
been demonstrated to vary from having no effect, increasing the levels of 
dimerizatlon or causing monomerization of constitutive homodimers. The lack of 
a consensus of agonist effect may be, in part, the result of the different 
techniques used to study these interactions or may reflect true variations in the 
GPCR signalling.
Heterodimerization between the human 8 0 R and P2AR was demonstrated using 
the co-immunoprecipitation technique however this was not replicated when 
using the TR-FRET assay even in the presence of ligands to either or both 
receptors. The related BRET assay did however, demonstrate a small but 
statistically significant increase in signal in the presence of ligand to either 
receptor (McVey et al., 2001). Subsequently Jordan et al. (2001) have 
demonstrated interactions between these two GPCRs. The lack of consensus 
may be due in part to the different techniques used to identify GPCR 
dimerization and again highlights the care that has to be taken when interpreting 
the data from them.
Heterodimerization between 8 0 R and i^GR has been shown by Gomes et al. 
(2000) and George et al. (2000). Interaction between these receptors on 
transient transfections was indicated but not confirmed in a significantly
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significant manner using the TR-FRET technique. This may be due to the lack of 
cell surface expression of the p,OR as discussed in chapter 5.
Other methods are being developed to look at receptor dimerization within live 
cells. One such method is I CAST where the proteins of interest are tagged with 
p-galactosidase deletion mutants. As the proteins interact the p-galactosidase 
components also interact resulting in p-galactosidase activity, which being 
enzymatically amplified, can be measured in a number of spectrometric, 
fluorescent or chemiluminescent methods (Blakely et al., 2000).
The development of the TR-FRET assay to determine GPCR dimerization has 
been accomplished. There are, however, further challenging aspects for the 
future development of this assay which time did not allow me to address. These 
include stoichiometry of GPCR monomers, homodimers and heterodimers and 
the development of new fluorescent probes.
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